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Introduction 
 
Membrane proteins perform vital functions like import of nutrients, binding site for ligands 
and export of harmful substances out of the cell. 
ABC transporter is one of the largest families of membrane proteins and some ABC exporters 
are known to be involved in efflux of antibiotics. The acquisition and transport mechanism of 
these substrates by the exporters has been a question to address. High resolution X-ray 
structures of ABC exporters showed two extreme conformations: inward facing and outward 
facing conformations. In both structures the interaction between intracellular part of 
transmembrane domain and nucleotide-binding-domains was conserved. X-ray structures 
showed the conformation of exporters in a static manner and using a dynamic technique could 
provide information about the intrinsic flexibility of exporters. This flexibility might be 
essential in order to bind the drug substrates.  
Hydrogen deuterium exchange in combination with mass spectrometry (HDX-MS) has been 
used during last two decades to probe the dynamics of proteins. The technique is now 
expanding its application to membrane proteins dynamics and conformational changes. HDX-
MS requires less sample amount, is tolerant to the presence of solubilizing agents as in the 
case of membrane proteins. Recently it was shown that the technique can be used to probe the 
dynamics of membrane proteins in near physiological condition.  
In the presented study HDX-MS is applied to probe the dynamics of three membrane proteins: 
BmrA, BmrC/BmrD and GLIC, a pentameric channel. 
BmrA is a homodimeric ABC exporter from Bacillus subtilis. Limited proteolysis show that 
the exporter adopts two different conformations: apo form less resistant to protease and an 
ATP bound form which is much more resistant to protease digestion. With limited proteolysis 
but also using global HDX kinetics it was shown that in detergent or in membrane the global 
behavior of BmrA is similar. Using local HDX kinetics we show that ICDs of BmrA are 
highly dynamic in apo conformation but not in the closed form. 
The local HDX kinetics of BmrA Walker ‘A’ mutant, K380R, show that in presence of 
ATP/Mg this mutant is unable to close but adopts a conformation in between apo state and 
closed state.  
 BmrC/BmrD is a heterodimeric ABC exporter from Bacillus subtilis. For BmrC/BmrD again 
HDX-MS kinetics are determined in apo and closed states. The exporter is found dynamic in 
apo state but closed form of the transporter is not as tight as that found for BmrA homodimer. 
GLIC is a ligand gated ion channel recently identified from Gloeobacter violaceus. The effect 
of change in pH on different regions of channel is studied by HDX-MS. Local HDX kinetics 
show five monomers of GLIC are arranged in symmetrical manner. The kinetics difference 
between pH 4 and pH 7 clearly show that the channel adopts different conformation due to its 
closure at physiological pH. The main difference of HDX kinetics is found on the 
transmembrane and extracellular domain interacting regions. 
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Chapter 1. Antibiotics: 
The influence of bacteria and other microorganisms in our daily life is at very large scale. It is 
considered that bacteria are present everywhere in our surroundings and a number of 
biological processes are occurring due to their presence. The number of microbes found on 
the body of a healthy adult is several times more than the total number of its own cells. But 
disease is produced by some specific bacteria which are categorized as pathogenic. These 
pathogenic bacteria normally do not inhabit in host body except when the target is affected. 
Antibiotics were introduced to counteract against these bacteria. 
Antibiotics are chemical compounds, administered to kill pathogenic bacteria. The idea to 
introduce the antibiotic and increase the life expectancy was highlighted in 1940s and 
provided a sense of security which was proved false in the coming years. 
The bacteria came out with unique strategies against these administered antibiotics and 
minimize or in some cases nullify their effectiveness, what we call now antibiotic resistance. 
The hallmark feature of the antibiotic resistance is multidrug resistance (MDR) means that a 
cell resists to the drugs which are structurally and functionally unrelated. Sometimes, this 
resistance is based upon the experiences, cells had already learnt from previous drugs contact.  
Before we go to further details of MDR, let’s recall about antibiotics and their mode of action. 
Antibiotics can be classified into different groups based on their functional group or mode of 
action. Bacteria wherever they are present grow and divide to continue producing more and 
more colonies of their offspring. Hence, antibiotic can be also divided into two types, those 
which stop bacteria growth and those which can kill the bacteria. The first one does not kill 
the bacteria but has proven very effective as they stop the spreading of the infection and 
provide enough ‘time’ to host immune system to react against infection.  
Antibiotics can be further classified into different types based on their mode of action. In 
addition to their mode of action antibiotics are also classified based upon their diversity of 
target.  
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Table 1. Common examples of antibiotics and targeted microorganisms 
Target Diversity Targeted Bacterial Organisms Common Examples 
 
Narrow Spectrum Gram-positives (Actinomyces, Corynebacteria, 
Bacillus, Clostridium, Pyogenic cocci, 
Spirochetes) 
Macrolides (Erythromycin) 
Polypeptides (Polymyxin) 
Moderate Spectrum Gram-positives plus systemic, enteric and urinary 
tract Gram-negatives 
Sulfonamides,Aminoglycosides 
(Streptomycin, Gentamycin, 
Tobramycin) 
Broad Spectrum All prokaryotes except Mycobacteria and 
Pseudomonas 
Chloramphenicol,Tetracycline 
Anti-mycobacterial Mycobacteria Isoniazid,Ethambutol,Streptomycin 
Rifampin 
 
1.1. Antibiotics mode of action: 
The antibiotics used to control bacterial growth are of different types, targeting various sites 
with versatile mode of actions (Figure 1). 
 
1.1.1. Antibiotics altering cytoplasm membrane: 
Cell membrane wraps around the cytoplasm is the hallmark feature of living organisms. It 
keeps the cell protected and unaffected from their surroundings. It is believed that this 
membrane is a complex mixture of lipids carrying protein molecule and these protein 
molecules provide the passage for the substances to cross the membrane. Furthermore there 
are protein molecules covalently linked with carbohydrates and lipids with diverse functions.  
 
 
Some antibiotics destabilize the lipid bilayer, distorting the regular cell structure of bacteria 
leading to their death (Figure 2). The antibiotics affecting the bacterial cytoplasm membrane 
are toxic for mammalian organisms and apparently they can not be used to target the bacteria 
inside the living organism. The action of these compounds are limited to Gram-negative 
Figure 1. Antibiotics mode of actions: 
The different strategies adopted against 
bacterial growth in a nutshell 
(Clatworthy, Pierson et al. 2007).  
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bacteria only, these are high molecular weight positively charged molecules which displace 
the negatively charged phospholipids on the surface of bacteria (Dixon and Chopra 1986). 
 
    
 
Figure 2. A. Colistin is one of the antibiotics effecting cell membrane. The drug is able to 
cross the cell wall and destabilize the lipid bilayer. B. Polymyxin is able to cross the cell wall 
and then destabilize cytoplasmic membrane (Web link: http://quizlet.com/6100231/chc-
micro-150-exam-5-final-redux-flash-cards/). 
 
 
1.1.2. Antibiotics inhibit bacterial cell wall synthesis: 
Bacterial cell wall provides the first line of defense to bacteria in severe conditions; it 
maintains the shape of the cell and keeps the cell alive in case of water loss. The properties of 
bacterial cell wall are mainly attributed to the peptidoglycan. The peptidoglycans are made up 
of carbohydrates chains and these chains are linked by peptides comprising of unusual D-
amino acids (van Heijenoort 2001). Since peptidoglycans are the most important components 
of bacterial cell wall, some antibiotics target peptidoglycan synthesis which eventually leads 
to death of bacteria. 
The synthesis of peptidoglycan takes place in three steps and there are antibiotics targeting 
these particular steps. The first and irreversible step is the transfer of phosphoenolpyruvate to 
the hydroxyl moiety of UDP-N-acetyl glucosamine catalyzed by MurA enzyme (UDP-N-
actetylglucosamine-3-enolpyruvyltransferase) (El Zoeiby, Sanschagrin et al. 2003).  
 
 
A 
B 
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Fosfomycin halts first step of peptidoglycan synthesis by inactivating MurA enzyme. It has a 
broad spectrum of target and it is effective against both Gram-positive and Gram-negative 
bacteria. Since mammalian cell enzymes are not affected by fosfomycin, it has been used as 
potent antibacterial agent to treat infection (Marquardt, Brown et al. 1994).  
 
  Fosfomycin 
 
Once the precursor of peptidoglycan is synthesized, it must be transported outside the 
cytoplasm to the growing peptidoglycan. This transfer of the precursor is catalyzed by 
enzymes linked to the membrane. The enzymes modify the precursor into GlcNAc-ß-(1,4)-
MurNAc-(pentapeptide)-pyrophosphoryl-undecaprenol and transfer this hydrophilic molecule 
across the hydrophobic membrane. It is also believed that this transfer is also accompanied by 
flip flop of lipid molecules but no biochemical evidence ha been obtained so far (Scheffers 
and Pinho 2005).  
 
1.1.3. Protein synthesis and antibiotics: 
Proteins are essential molecules found within living organisms along with lipids, 
carbohydrates and nucleic acids. Production of new proteins transcribed by the mRNA is 
essential for metabolism and growth of organism. Ribosomes are the machines of protein 
production and shutting down these machines will stop protein synthesis. In bacteria, protein 
synthesis is carried out on 70S ribosome (30S and 50S ribosomal subunit) with help of some 
proteins. Hence, any compound that can bind to the ribosomes or protein can be used as 
antibiotic. The protein synthesis is divided into three steps initiation; elongation and 
termination; some antibiotics target initiation and elongation steps (Figure 3). 
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Figure 3. The steps of protein synthesis and antibiotics acting to halt the protein synthesis 
(Web link: pathmicro.med.sc.edu/mayer/antibiot.htm). 
 
 
1.1.3.1. Antibiotics action on 30S ribosomal subunit: 
The antibiotics affecting the 30S ribosomal subunit can be divided into three classes of 
compounds: Aminoglycosides , tetracyclines and spectinomycin.  
  
Aminoglycosides: 
The initiation of protein synthesis requires the 30S ribosomal subunit, mRNA and tRNA. 
Amnioglycosides target the complex of protein synthesis initiation and bind to the 30S 
ribosomal subunit and stop the initiation of protein synthesis. The antibiotic is also affected 
for the blockage of protein chain elongation. Since the binding is irreversible, the effect on 
bacteria is bactericidal (Shakil, Khan et al. 2008; Durante-Mangoni, Grammatikos et al. 
2009). Kanamycin, neomycin, streptomycin and tobramycin are some examples of 
aminoglycosides.  
 
    
Streptomycin    Kanamycin 
 
Streptomycin and Kanamycin target protein synthesis in bacteria. These two antibiotics are 
widely used in molecular biology for screening of resistant strain and for overproduction of 
recombinant proteins.  
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Spectinomycin : 
Spectinomycin share structural similarity with aminoglycosides but its binding to the 30S-
mRNA-tRNA complex is reversible and therefore classified as bacteriostatic. Like other 
aminoglycosides, spectinomycin is also used in combination with penicillin and proved useful 
to overcome the resistance developed by bacteria against the drug (Boslego, Tramont et al. 
1987). 
  Tetracyclines: 
Tetracyclines are another class of compound binding to the 30S ribosomal subunit, they target 
the mRNA and ribosomal unit complex and stop the protein synthesis by inhibiting the 
binding of tRNA. The binding to the 30S subunit is reversible and therefore effect is 
bacteriostatic. This class of antibiotics targets a broad range of target bacteria (Borderie, 
Hernvann et al. 2001), doxycycline and minocycline are examples of tetracyclines. 
 
           
    
         Minocycline 
 
1.1.3.2. Antibiotics Action on 50S ribosomal subunit: 
There are two groups of compounds acting on 50S ribosomal subunit: Lincosamides and 
Macrolides  
 
Lincosamides: 
The 50S ribosomal subunit performs enzymatic function by catalyzing the peptide linkage 
formation between amino acids. This aminoacyl transferase activity of the ribozyme is 
inhibited by the binding of lincomycin or clindamycin to the 50S ribosomal subunit (Spizek 
and Rezanka 2004).  
      
  
   Lincomycin one of the example of Lincosamides 
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Macrolides: 
The 50S ribosomal subunit in addition to enzymatic activity receives tRNA carrying acylated 
amino acid. tRNA binds on position A of the ribosome and after the peptide linkage between 
newly made chain and amino acid, ‘free’ tRNA moves onto position ‘P’ of 50S ribosomal 
unit. Macrolides compounds bind to the ‘P’ position of 50S subunit and inhibits the transfer of 
tRNA from ‘A’ to ‘P’ position. Clarithromycin and azithromycin are common examples of 
macrolides acting on broad spectrum of bacteria.  
      
     Clarithromycin 
 
1.1.4. Antibiotics targeting nucleic acid synthesis: 
The antibiotics targeting nucleic acid synthesis in prokaryotes are the most widely used 
antibiotics in clinical practice. This is due to the fact that the RNA and DNA synthesis 
enzymes in prokaryotes and eukaryotes are different and therefore provide selectivity measure 
for the drug action. 
 
1.1.4.1. RNA synthesis inhibitors: 
Tuberculosis is the leading cause of death due to an infectious disease worldwide and 
rifampicin is widely used for the treatment of tuberculosis (Dye 2006). Rifamapicin binds to 
the -subunit of RNA polymerase which is responsible for initiation of RNA synthesis and 
elongation. Earlier biochemical data showed that the drug inhibits the RNA synthesis 
initiation and once synthesis is began, there is no effect conferred by the drug (Neu and Gootz 
1996). But recent advancement particularly crystal structure of RNA polymerase (RNAP) in 
complex with rifamapicin proved that the agent blocks elongation step of RNA (Campbell, 
Korzheva et al. 2001). Rifamycin and rifampicin are other antibiotics acting on RNAP. The 
binding of the drug is tight and the effect is bactericidal (Yusibov and Streatfield 2010). 
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     Rifampicin 
 
                
 
1.1.4.2. DNA synthesis inhibitors: 
The double stranded structure of DNA is based on the super-coiling of its anti-parallel strands. 
The winding and unwinding of these strands are catalyzed by a group of enzymes called the 
topoisomerases. Only unwound DNA can serve as template for both DNA and RNA 
synthesis. For newly made DNA strand, super-coiling is carried out by gyrase enzyme and 
this enzyme is also the target of antibiotics (Reece and Maxwell 1991). Quinolones are 
compounds acting on gyrase enzyme, they bind to the ‘A’ subunit of the enzyme and halts the 
super-coiling (Drlica and Zhao 1997). 
Nalidixic acid is an example of quinolones. 
 
    
    
Nalidixic acid 
 
1.1.5. Inhibition of metabolic pathways:  
The antibiotics used for targeting metabolic pathways are relatively less in number and in use. 
Most effective antibiotics are those which alter the folic acid synthesis pathway. The end 
product of folic acid synthesis pathway is tetrahydrofolate which has key role in 
peptidoglycan, DNA and RNA synthesis (Maden 2000). The synthesis of tetrahydrofolate 
takes place in three steps catalyzed by different enzymes (Figure 4). 
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Sulfonamides (sulfa drugs) and trimethoprim are two families of compounds acting on 
different steps of tetrahydrofolate synthesis. The sulfa drugs share the structural similarity 
with para-aminobenzoic acid (PABA), the natural substrate of enzyme. There is competitive 
inhibition observed between drug and substrate (Dozzo and Moser). Trimethoprim binds to 
the enzyme dihydrofolate reductase and inhibits the conversion of dihydrofolate to 
tetrahydrofolate. Like sulphonamide, the inhibition by trimethoprin is competitive against the 
natural substrate and results in a dead enzyme-inhibitor complex (Parry 2003; Then 2004). 
Trimethoprim is generally administered in combination with sulfonamide both acting on 
Gram-positive and Gram-negative bacteria (Antoniou and Gough 2005). The enzymes 
required for the synthesis of folic acid are not found in eukaryotes thus bacterial systems are 
specifically targeted by mentioned drugs. 
 
   
 
  Sulfonamides    Trimethoprim 
 
 
 
Figure 4. The biosynthesis of folic acid within bacteria can be inhibited by two different 
antibiotics each affecting on a different step of the synthesis.  
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Chapter 2. Antibiotic resistance: 
The wide use of antibiotic soon after their discovery and/or synthesis led to a problem which 
was not anticipated by the scientists. Bacteria developed some modification in their phenotype 
and started preparing themselves ready to combat with administered antibiotics. The 
modification is not limited to phenotype but also incorporated in the genotype of some species 
making them prepared for long battle. The pace of antibiotic resistance emergence was almost 
same as was of antibiotic introduction (Figure 5). 
Focus of a great deal of biomedical and biochemical research has been to overcome this 
resistance but problem emerges more. Because in most of the cases the mechanism of drug 
resistance is not limited to one strategy, it has diversity, but the result is the same nullifying 
the action of drug.  
 
  
 
Figure 5. Time line of antibiotic administration and resistance emerged showing that the 
resistance was found shortly after the use of antibiotic against bacteria (Clatworthy, Pierson et 
al. 2007). 
 
Different sites are targeted by various antibiotics within the bacteria using different mode of 
actions, in response bacteria has also shown multidimensional strategies not limited to only 
mean of survival. It is possible that many more ways of resistance against antibiotic by 
bacteria will be identified in future but three strategies are investigated in detail yet (Figure 6). 
The resistance of the bacteria towards a drug or compound can be either passive or active 
(acquired). There are number of natural shields provided by the nature to bacteria to survive 
in extreme conditions. These factors are equally distributed among pathogenic or non-
pathogenic bacterial species. While introducing antibiotics these passive ways of resistance 
were in consideration by the scientists and therefore this kind of resistance was overcome 
easily. 
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The second and major mean of resistance is of active type in which bacteria acquire the 
genetic elements and express them in response to antibiotic encounter. 
Although all the means of active resistance are potent and effective, the most important one is 
the active efflux of the drug by integral membrane proteins called exporters. These exporters 
are the main reason behind the multi-drug resistance because of their ability to export diverse 
arrays of compounds which are even unrelated in their structure. 
Each type of active resistance will be discussed in detail: 
• Enzymatic effect on the drug  
• Modification of the drug target protein 
• Reduced drug accumulation by active efflux and less permeability 
 
 
Figure 6. Summary of mechanisms of antibiotic resistance conferred by Gram-negative 
bacteria (Allen, Donato et al. 2010).  
 
2.1. Enzymatic alteration of the drug 
Penicillin is a group of antibiotics which are characterized and widely used around the globe. 
Penicillium is a fungus which serves as source for penicillin compound and many derivatives 
of penicillin are being used as clinical drugs. First proof of the effectiveness of the compound 
against bacteria lies back in 1871 when Sir John Burdon-Sanderson observed difference in 
turbidity of bacteria media in presence or absence of penicillium mold growth (Selwyn 1979). 
The modification of the administered compound (drug) by the bacteria is one of the active 
types of resistance against antibiotics. The resistance is due to expression of broad spectrum 
of enzymes under selective pressure of an antibiotic or group of antibiotics. 
The following table provides the information about different enzymes, their mode of action 
and plausible targeted antibiotics (Wright 2005). 
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Table 2. Enzymatic strategies of antibiotic inactivation (Wright 2005) 
 
Strategy Type Examples of antibiotics 
effected  
Hydrolytic  -lactamses  -Lactams 
 Esterases  Macrolides 
 Epoxidases  Fosfomycin 
Non hydrolytic  Lyases Type B streptogramin 
Group transfer Acyl Aminoglycoside 
  Chloramphenicol 
  Type A streptogramin 
 Phosphoryl Aminoglycoside 
  Macrolide 
  Rifamycin 
  Peptide 
 Thiol Fosfomycin 
 Nucleotidyl Aminoglycoside 
  Lincosamide 
 ADP-ribosyl Rifamycin 
 Glycosyl Macrolide 
  Rifamycin 
Other Redox Tetracycline 
  Rifamycin 
  Type A streptogramin 
 
The enzymatic action imposed by bacteria directly on the antibiotics are specific i.e. 
expression of a particular enzyme in response to one particular antibiotic or a class of 
structural similar compounds. The enzymatic effect on antibiotics can be of two types: 
 
Destruction of the antibiotic 
Chemical modification of antibiotic 
 
There are two types of enzymatic strategies employed: hydrolytic and non-hydrolytic. 
 
In the hydrolytic, enzyme requires no other cofactor except water. Therefore, these hydrolytic 
enzymes present first wall of defense and destroy the antibiotic even outside the cytosol. 
 
-lactamase: 
Penicillin and its derivatives are recognized by the presence of -lactam ring and hydrolysis 
of the ring is the target of -lactamase enzymes. -lactamases encoding genes are present on 
both bacterial chromosomes and transferable DNA content plasmid. There is a wealth of 
literature dedicated for the functional classification of -lactamases including (Bush 1989; 
Antibiotic 
 Destruction 
Antibiotic 
Modification 
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Bush, Jacoby et al. 1995; Arakawa 1999; Bebrone 2007; Bush and Jacoby) but recent 
classification proposed provides an updated and detail classification (Bush and Jacoby 2010). 
The enzymes are classified into four groups from A to D. Briefly there are two main mode of 
action employed by the enzymes i.e. those mimicking serine proteases (Group A, C & D) and 
others like metallo proteases (Group B). With the introduction of new antibiotics the number 
and even the mechanism of the enzymes are evolving (Jacoby and Munoz-Price 2005). 
 
2.2. Modification of the drug target protein: 
In general bacteria lack the enzymes required for hydrolysis and /or modification of synthetic 
(non-natural source) antibiotics therefore alteration of drug target is a way of conferring drug 
resistance (Nikaido 2009). This alteration can be mutation of the target protein or in some 
cases bacteria adopts changes in usual metabolic pathways hence avoiding some intermediates 
which were possible target of the antibiotics (Perichon and Courvalin 2000; Hooper 2002). 
For example, the effect of fluoroquinolones is minimized by mutation of one amino acid of 
DNA replication enzyme however the activity of enzyme is also retained (Hooper 2000). 
 
2.3. Active efflux of the drugs: 
The most active and efficient way adopted by the bacteria to show resistance against 
antibiotics is the active efflux. This active efflux of compounds is carried out by membrane 
transporters. These membrane proteins The substrate can be caught from cytoplasm or 
directly from inner leaflet of phospholipid bilayer The phenomenon of MDR is attributed to 
these transporters as they are able to extrude variety of compounds belonging to different 
families with distinct structures. Since the active efflux is energy dependent process it is not 
surprising that there are energy sources for the functioning of these pumps. In fact basic 
classification is based on the energy source used. 
There are primary type of MDR transporters, some of them belong to the ABC superfamily, 
which use ATP as energy source and secondary type of transporters those rely on other energy 
sources like concentration gradient of proton or sodium ion (Figure 7). 
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Figure 7. The transporters involved in efflux of antibiotics vary in their size and topological 
arrangement within cell membrane (Higgins 2007). Pink border is possible position of lipid 
bilayer. 
 
2.3.1. SMR Transporters: 
Small multidrug resistance or SMR is the family of integral membrane protein conferring 
resistance against particularly (but not exclusively) against positively charged ions such as 
tetraphenylphosphonium (TPP+), cetyltrimethylammonium bromide (CTAB), and 
benzalkonium (Bz) (Bjorland, Sunde et al. 2001; Nishino and Yamaguchi 2001; Ubarretxena-
Belandia, Baldwin et al. 2003). This is the smallest MDR transporter family both in terms of  
 
 
Table 3. Examples of the members of SMR Transporters (Some are homo-dimer like 
EmrE and some form hetero-dimer like EmrA/EmrB) 
Name of Transporter  Organism 
EbrA    Bacillus subtilis 
EbrB   Bacillus subtilis 
EmrE   Escherichia coli 
Mmr   Mycobacterium tuberculosis 
QacE    Gram-negative bacteria 
Smr (Emrb/QacC/QacD)   Staphylococcus aureus 
YkkC   Bacillus subtilis 
YkkD  Bacillus subtilis 
 
protein size with 100-110 residues (12 kDa) and number of its family members (Chung and 
Saier 2001; Sharoni, Steiner-Mordoch et al. 2005). It consists of only transmembrane domain 
without any cytosolic or extracellular domain. The membrane spanning region consists of four 
-helices which traverse the membrane and linked by very short intracellular and extracellular 
loops. The transmembrane helices provide the pathway for the substrate translocation, this  
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Figure 8. EmrE binds TPP as an antiparallel dimer. Stereo view of the EmrE transporter in 
complex with TPP. The two monomers are colored blue and yellow, and the bound TPP is 
pink (Chen, Pornillos et al. 2007). 
 
pathway is achieved by the dimerisation of two monomers in antiparallel fashion (Figure 8) 
(Yin, He et al. 2006). 
Since both monomers are aligned in an antiparallel manner the accessibility of the substrate 
towards the transporter is considered as unchanged. If both sides have equally affinity for 
substrate then how is it translocated against concentration gradient across membrane? 
To answer the question, EmrE is used as a model representative of the SMR family. The 
structure of EmrE was solved at reasonable resolution (Chen, Pornillos et al. 2007) (Figure 8) 
and it remains highly stable and functionally active even in detergent solubilized state 
(Schuldiner 2009). Briefly, it is shown that EmrE requires two protons as energy cross for the 
translocation of one substrate molecule from cytoplasm to periplasmic space. The highly 
conserved glutamate at position 14 is considered as responsible for the binding and uphill 
transport of the substrate (Grinius and Goldberg 1994; Yerushalmi and Schuldiner 2000; 
Sharoni, Steiner-Mordoch et al. 2005).  
 
2.3.2. Resistance-nodulation-division transporters:  
Resistance nodulation division transporters are one of the key factors responsible for 
multidrug resistance in Gram-negative bacteria. The RND transporter such as AcrB (an 
integral membrane protein) acts in combination with AcrA and TolC and extrude the drug 
outer surface of the cell membrane (Figure 9). This mechanism of drug efflux outside the cell 
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membrane explains the intrinsic resistance of Gram-negative bacteria which was first thought 
to be only due to less permeability of the outer membrane for the drug (Vaara 1993; Nikaido, 
Basina et al. 1998; Murakami 2008). In addition to RND transporters, there are other RND 
proteins responsible for diverse cellular functions like regulation of cell cycle and 
organization of cytoskeleton. The RND proteins are equally distributed within prokaryotes 
and eukaryotes (Ko, Gordon et al. 2001; Ma, Erkner et al. 2002). 
 
 
Figure 9. RND transport complex consisting of RND transporter (AcrB) which works in 
coordination with outer membrane pump (TolC). The intermediate role of membrane fusion 
protein (AcrA) in complex between AcrB and TolC is shown in schematic presentation (Blair 
and Piddock 2009). 
 
2.3.2.1. AcrB: 
AcrB is the integral cytoplasmic membrane part of the three member complex, responsible for 
extrusion of the drugs from cytoplasm. AcrB is first harboring point for drug export driven by 
proton motive force. As other multidrug transporters, AcrB recognizes and binds to wide 
array of substrates nevertheless showing priority for lipophilic compounds like ethidium 
bromide, cephalosporins, fusidic acid and even different detergents (Nikaido and Takatsuka 
2009).  
AcrB is first member of secondary type multidrug transporters whose structure became 
available, the structure was solved for first time in year 2002 (Murakami, Nakashima et al. 
2002). In coming years release of more structures helped to explain the mechanism of AcrB 
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functioning (Yu, McDermott et al. 2003; Murakami, Nakashima et al. 2006; Seeger, Schiefner 
et al. 2006; Das, Xu et al. 2007; Tornroth-Horsefield, Gourdon et al. 2007; Drew, Klepsch et 
al. 2008). 
The obtained structural data shows that the AcrB functions as a trimer consisting of three 
similar subunits. Each subunit can be divided into two parts periplasmic domain, which is 
involved in interaction with TolC, and transmembrane domains. The transmembrane domain 
consists of twelve -helices traversing the cytoplasmic membrane (Figure 10). Each subunit 
carries a drug binding site (lower part) to catch the drug from cytoplasm, the captured drug is 
then moved to upper part of AcrB and eventually released to TolC. On any given time, only 
one site of the three monomers can bind with drug and sites on other monomers are 
potentially inaccessible. The energy required for the conformational change to transport is 
driven by the proton downhill concentration movement.  
 
 
Figure 10. AcrB makes a homotrimer giving rise to a functional transporter in cytoplasmic 
membrane. Each monomer can be divided into three domains: Transmembrane domain, porter 
domain and TolC interacting domain (Murakami, Nakashima et al. 2002).  
  
2.3.2.2. TolC: 
The substrate caught by AcrB either from cytoplasm or from cytoplasm lipid bilayer is 
transferred to a huge outer membrane protein called as TolC. TolC interacts with AcrB and 
traverse the outer membrane and release the substrate on the outer surface of the Gram-
negative bacteria. In addition to the drugs captured by AcrB, the drugs present in periplasmic 
space are also effluxed to outer cell membrane by TolC. This activity of TolC has an 
important role in drug efflux system because many integral membrane efflux pumps catch the 
drugs from cytoplasm and release in periplasmic space and target of many antibiotics also 
exist in periplasmic space (Blair and Piddock 2009; Eicher, Brandstatter et al. 2009).  
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The structure of TolC was solved in 2000 followed by another structure of its homologue 
OprM (Koronakis, Sharff et al. 2000; Akama, Kanemaki et al. 2004). The structure shows a 
trimeric arrangement of TolC which give rise to a tube like shape providing the pathway for 
the compounds to be exported. Each monomer of TolC can be divided into two: parts 
periplasmic and transmembrane. The periplasmic part is formed by six coiled-coiled helices, 
the arrangement of these helices give rise to a tubular structure. The transmembrane part 
majorly consists of -barrels which are connected by extracellular loops (Figure11) 
(Koronakis, Sharff et al. 2000). 
   
 
Table 4: RND family multidrug efflux systems in Gram-negative bacteria (Poole 2001). 
 
Figure 11. The x-ray structure of 
TolC consisting of long cyliserical 
shape providing the passage for the 
drugs to be extruded on the outer 
surface of the cell membrane og 
Gram-negative bacteria (Koronakis, 
Sharff et al. 2000). 
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2.3.4. Major facilitator superfamily: 
With more than 15000 protein sequences, major facilitator superfamily (MFS) is one of the 
largest families of membrane proteins characterized so far in living organisms. The members 
of MFS are equally distributed between prokaryotes and eukaryotes. Like many other 
secondary transporter, MFS members function is driven by the use of energy conserved in the 
electrochemical gradient of ions generally protons. Large number of MFS substrates that have 
been identified (e.g. sugars, neurotransmitters, drugs, amino acids, peptides and positive ions 
etc.) These transporters are of special interest because they exhibit three types of substrate 
transport, based on electrochemical gradient i.e. uniport, symport and antiport (Law, Maloney 
et al. 2008). (Uniport term is used for transfer of one substrate downhill the concentration 
gradient across the lipid bilayer. In symport and antiport transfer system, the energy obtained 
from downhill transfer of substrate is utilized for transfer of drug towards uphill concentration 
gradient. In symport and antiport, proton and drug are transferred in same or opposite 
direction of the proton respectively) (Chang, Lin et al. 2004; Ren and Paulsen 2005; 
Lewinson, Adler et al. 2006; Ren and Paulsen 2007; Lam, Lee et al. 2011). 
The number of residues within different members of MFS ranges from 400 to 600. Prior to 
release of structures, the traditional structure prediction tools depicted different number of 
transmembrane helices from 6 TMHs to 24 TMHs (Saier 2003; Law, Maloney et al. 2008). 
Few high resolution structures of the MFS transporters have been solved providing a health of 
knowledge towards our understanding of transport mechanisms (Figure 12) (Abramson, 
Smirnova et al. 2003; Huang, Lemieux et al. 2003; Yin, He et al. 2006; Dang, Sun et al. 2010; 
Newstead, Drew et al. 2011).  
 
   
Figure 12. Top view (right) and side view (left) of a major facilitator super-family member, 
EmrD is shown in ribbon presentation. The transporter consists of 12 transmembrane helices 
each shown with different color. Number of transmembrane helices from 1 to 12 is also 
indicated. The substrate translocation is carried through the hydrophobic central region (Yin, 
He et al. 2006). 
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2.3.5. Multidrug and toxic compound extrusion: 
All secondary type multidrug resistance transporters described so far rely on the 
electrochemical gradient of the protons. But presence of a reasonable amount of Na+ ion in 
cytoplasm prompted scientist to look for the transporter which could use electrochemical 
gradient of Na+ ions concentration and this led to recent discovery of multidrug and toxic 
compound extrusion family (Morita, Kodama et al. 1998; Brown, Paulsen et al. 1999; Chen, 
Morita et al. 2002; Begum, Rahman et al. 2005).   
Members of MATE family are distributed in all forms of life from bacteria to eukaryotes 
including mammals and even in plants conferring multidrug resistance (Kaatz, McAleese et 
al. 2005; Magalhaes, Liu et al. 2007; Tsuda, Terada et al. 2009). Most of the identified 
substrates of the MATEs are positively charged ions like norfloxacin, ciprofloxacin, 
ofloxacin. Like the substrates of other MDR transporters, there is no structural similarity 
found within substrate of MATEs (Kuroda and Tsuchiya 2009).  
The x-ray structure of NorM was very recently determined in outward facing conformation. 
The structure also confirms the previously predicted topology showing that NorM consists of 
twelve transmembrane helices (Figure 13) (He, Szewczyk et al. 2010). 
 
 
 
 
Figure 13. Front view of outward facing three dimensional structure of NorM of Vibrio 
cholerae solved at 3.6 Å (He, Szewczyk et al. 2010). 
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Chapter 3. ATP binding cassette transporter: 
AT binding cassette (ABC) proteins are considered as the largest family of protein found in 
both prokaryotes and eukaryotes. Genomic analysis of E. coli revealed that 5% of its genome 
is constituted of genes potentially coding ABC proteins. The amino acid sequence of ABC 
proteins remains highly conserved among 13 different organisms of kingdom Archea, 
Eubacteria and Eukarya (Higgins 1992; Isenbarger, Carr et al. 2008). The name ABC was 
given due to presence of conserved Walker ‘A’, Walker ‘B’ and signature motif of this 
family, a stretch of few conserved amino acids usually starting on LSGGQ. Based on the 
functions, the ABC proteins can be classified into two classes: DNA binding proteins and 
ABC transporters. DNA binding proteins are soluble, found within cell to perform DNA 
repair functions. ABC transporters are then divided into exporters and importers both are 
integral membrane proteins involved in efflux and influx of substrate from and into the cell, 
respectively. The ABC transporters perform their respective function driven by energy from 
the hydrolysis of ATP. Whereas, the importers are specific to their respective substrates, 
exporters can be poly specific.    
 
3.1. Structural characterization: 
The minimal topology of any ABC transporter consists of four domains: two transmembrane 
domains and two nucleotide-binding domains. The transmembrane domains dimerize and 
provide the pathway for the translocation of substrate through the inner membrane. 
Nucleotide-binding domains bind and hydrolyze ATP molecules working as ‘power engine’ 
(Figure 14). In mammalian cells all four domains are usually expressed as one polypeptide 
(Aller, Yu et al. 2009) whereas in prokaryotes two polypeptides, (Ward, Reyes et al. 2007)to 
four polypeptides are expressed separately and then form a functional transporter as in the 
case of BtuCD (Hvorup, Goetz et al. 2007).  
In addition to minimal subunits, additional domains are also found in ABC transporters such 
as regulatory domain found in Cystic fibrosis transmembrane conductance regulator (CFTR), 
extra N-terminal domains in transporter associated with antigen processing (TAP) 
TAP1/TAP2 and C- terminal domain in maltose importer. In importers substrate binding 
proteins are required for import of substances (Sheppard and Welsh 1999; van der Heide and 
Poolman 2002; Biemans-Oldehinkel, Doeven et al. 2006; Oancea, O'Mara et al. 2009). 
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Figure 14. Core structure of ABC transporters  
 
3.1.1. Transmembrane domains: 
Since the TMDs show translocation specificity towards their respective substrates in case of 
importers, they share less sequence similarity as compare to NBDs within the superfamily of 
ABC transporters. The structural features of TM domain were unknown until the availability 
of first crystal structure of an ABC importer which was solved at 3.2Å resolution in year 2002 
(Locher, Lee et al. 2002). The structure provided the key details characteristic which was not 
possible with traditional sequence based topology prediction tools (Dawson, Hollenstein et al. 
2007). Later, on the basis of structural data various folds of the membrane domain were 
recognized (Rees, Johnson et al. 2009).   
 
3.1.1.1. Exporter transmembrane domain fold: 
The first structure of ABC exporter, Sav1866, which functions as a homodimer showed that 
TMD of the exporter comprises of six transmembrane helices (TMH). These helices traverse 
the cytoplasmic membrane and are joined by extracellular and intracellular loops (Dawson 
and Locher 2006). Extracellular loops are short, connecting the TMHs, whereas the 
intracellular loops protrude deep into the cytoplasm and make the transmission interface with 
NBDs. The intracellular loops are more frequently called as intracellular domains (ICDs). 
ICD1 provides linkage between transmembrane helices TMH2 and TMH3 making an 
interaction with its respective nucleotide-binding domain. ICD2 provides a link between 
TMH4 and TMH5. The key feature revealed by the Sav structure was the interaction of 
(ICD2) of cis- subunit with NBD of trans- subunit. Subsequently, the second intracellular 
loop of trans- unit was found interacting with cis- subunit (Figure 15). The cross over 
interaction of the loops and NBDs was not anticipated, and is not found in any ABC importer 
yet.  
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Figure 15. Ribbon presentation of Sav1866 structure. Two subunits of transporter are colored 
yellow and turquoise. The numbering of transmembrane helices from 1 to 6 is shown on 
turquoise colored subunit (Dawson and Locher 2006). 
 
The Sav1866 structure was solved in the outward facing conform showing that the transporter 
is protected or closed from the cytoplasmic side and opened to the periplasmic space. The 
transmembrane helices group themselves from TMH1 to TMH3 and TMH4 to TMH6 giving 
rise to two wings within the membrane (Figure 15). Another structure of Sav1866 which was 
crystallized in the presence AMP-PNP showed the same structural arrangement (Dawson and 
Locher 2007). 
Soon after the release of Sav1866, the structures of MsbA were corrected and released again 
(Chang, Roth et al. 2006; Petsko 2007; Ward, Reyes et al. 2007). The transporter was 
crystallized in three different conditions: in the presence of 5-adenylyl---imidodiphosphate 
(AMP-PNP) or Adenosine diphosphate/vanadate (ADP·Vi) separately or without any 
nucleotide (apo conformation). The solved structures showed three different conformations: 
closed in presence of (AMP-PNP or ADP-Vi), apo open and apo closed (Figure 16). The 
closed structure was in full accordance with Sav1866 structure for both transmembrane 
domain arrangement and nucleotide-biding domains. Whereas apo form yields two different 
conformations, apo-closed and apo-open, in both structures the NBDs are not interacting with 
one another but in apo-open conformation the distance between the two NBDs is higher as 
compared to the apo-closed. In both structures of apo conformation TMD are shown in inward 
Nucleotide-binding domain (NBD) 
Transmembrane domain (TMD) 
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facing conformation, open towards cytoplasmic side and closed on periplasmic side. A 
possible conformation in which the substrate is acquired form cytoplasm. 
 
 
Figure 16. Two apo conformation of MsbA are shown in ribbon presentation: apo open (left) 
and apo closed (right). One of two subunits is colored white and other one rainbow. The 
transmembrane helices are also numbered from 1 to 6. In both conformation there is opening 
inside and extracellular side is closed. The ICD1 and ICD2 (IH1 and IH2 here) are always in 
contact with NBDs (Ward, Reyes et al. 2007).   
 
Recently solved structure of eukaryotic ABC transporter P-glycoprotein from mouse extended 
the structural information of ABC exporters to the mammals (Aller, Yu et al. 2009). In 
human, P-glycoprotein in is the best characterized ABC exporter yet which has an important 
role in multidrug resistance in chemotherapy (Higgins 2007). P-glycoprotein was crystallized 
in the absence of any nucleotide or in the presence of two stereo isomers of QZ59 (Figure 17). 
The apo form yielded the overall same conformation as observed in the case of apo-open 
MsbA. With the virtue of P-glycoprotein structures solved in presence of inhibitors, the drug-
binding sites were revealed showing that there is large cavity able to acquire the drug from 
cytoplasm or plasma membrane (Figure 17) (Aller, Yu et al. 2009).  
All the ABC exporters structurally characterized so far show a similar topology i.e. six 
transmembrane helices connected by loops. 
          
 
 
 
Nucleotide binding domain 
(NBD) 
Transmembrane domain 
(TMD) 
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Figure 17. Binding sites of QZ59-RRR (green spheres) and QZ59-SSS (blue and cyan) 
inhibitors in the internal cavity of P-glycoprotein are shown in space filling model. 
Transmembrane helices of P-glycoprotein are shown in wire presentation (Aller, Yu et al. 
2009).    
 
3.1.1.2. Importer transmembrane domains fold: 
Unlike ABC exporters the number of ABC importers helices is not constant. Based on the 
fold and topology of TMDs, the importers are divided into two types. 
Type I importer fold and Type II importer fold 
The TMD fold name given to a family is based on the historical characterization of their 
respective members not on the basis of sequence of their structural finding or characteristics. 
 
3.1.1.3. Type I importer fold:  
The number of transmembrane helices is not constant in type I importer fold family. The 
numbers of transmembrane helices vary from five to eight. The fold classification is based on 
the comparatively newly determined structure of MetI of Met transporter (Kadaba, Kaiser et 
al. 2008; Rees, Johnson et al. 2009). There are five transmembrane helices present in each 
monomer traversing the lipid bilayer as in the case of ABC exporters. The translocation 
pathway is mainly provided by the TMH-2 to TMH-5 of each subunit. The other members of 
type I TMD importer fold, ModB which imports molybdate possesses six transmembrane 
helices. MalF and MalG subunits of maltose transporter posses eight and six helices 
respectively (Hollenstein, Frei et al. 2007; Oldham, Khare et al. 2007; Gerber, Comellas-
Bigler et al. 2008). The maltose transporter is the only ABC transporter carrying different 
number of helices in the two TMDs. The accessory helices of MetI or MalF and MalG are 
involved in the interaction between transmembrane subunits (Figure 18) (Oldham, Davidson 
et al. 2008).  
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Figure 18. The arrangement of transmembrane helices within Type I ABC importer fold, the 
number of TMHs in both monomers are not constant but translocation pathway is provided by 
TMH2 to TMH5 (TMH 4 to TMH 7 for MalF subunit of maltose transporter) (Oldham, Khare 
et al. 2007). 
 
3.1.1.4. Type II importer fold: 
There are two homolog ABC importers characterized at structural level showing Type II 
importer fold for their TM domains: BtuC subunits of the vitamin B12 importer BtuCDF and 
HI1471 subunit of HI1470/1 transporter of E. coli and Haemophilus influenzae respectively 
(Locher, Lee et al. 2002; Pinkett, Lee et al. 2007). Alternatively these are also called big ABC 
importers because each transmembrane subunit consists of ten transmembrane helices giving 
rise to a complete transporter of twenty TM helices. The TMH2 is oriented in such a way that 
it is closer to other transmembrane helices of its own subunit. TMH4 and TMH5 of each of 
the subunits provide entrance, the translocation pathway and the exit for the substrate (Figure 
19). The interaction between subunits is additionally maintained by the interaction between 
TMH10 of both subunits (Dawson, Hollenstein et al. 2007; Hollenstein, Dawson et al. 2007). 
 
 
 
Figure 19. The transmembrane fold present within Type II ABC importers fold (Pinkett, Lee 
et al. 2007). 
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3.1.2. Nucleotide-binding-domains: 
Nucleotide-binding-domains or ABC cassettes are the cytosolic subunits of ABC transporter 
providing the energy required for the translocation of the substrate by ATP hydrolysis. 
Whereas TMDs vary in their amino acid sequence; the NBDs share very high sequence 
similarity within ABC superfamily (Holland and Blight 1999; Geourjon, Orelle et al. 2001). 
First high resolution structures of separate NBDs became available in year 1998, and in 
coming years the structure of NBDs alone or with whole transporter showed that NBDs are 
highly conserved in the structural arrangement which is probably due to a common 
mechanism for ATP hydrolysis (Hung, Wang et al. 1998; Jones, O'Mara et al. 2009). At larger 
scale NBD is divided into two sub-domains: Rec-A like domain and helical domain. Within 
each NBD there are specific fold and regions which are critical for ATP binding and 
hydrolysis, interaction with intracellular loops originating from TMD and dimerization of two 
NBDs (see Figure 20). 
 
Walker ‘A’: 
Identified by the presence of a highly conserved stretch of few amino acids residues 
GXXGXGK(S/T) is found in many of nucleotide-binding proteins (Walker, Saraste et al. 
1982). It is established that conserved lysine residue is critical for the interaction with 
phosphate moiety of bound nucleotide, mutating this residue leave the NBD in an 
incompetent state (Chen, Lu et al. 2003; Orelle, Gubellini et al. 2008). 
 
Q loop: 
Q-loop contains a conserved glutamate and found only in ABC transporter. It comprises eight 
residues, that makes the interaction face with ICD1 and ICD2 of cis- and trans- 
transmembrane domains respectively (Dalmas, Orelle et al. 2005; Zolnerciks, Wooding et al. 
2007; Oancea, O'Mara et al. 2009). The Q-loop makes the connection between the ATP 
binding subdomain and helical subdomain of NBD. It has a role in the hydrolysis of bound 
nucleotide. 
 
ABC signature: 
Exclusively present in ABC transporters, the name of the superfamily is partly attributed to 
presence of a conserved LSGGQ motif. In monomer state the role of signature motif is not 
established, in dimeric state the signature motif of the trans- subunits comes in proximity with 
nucleotide bound to this cis- subunit by stabilizing the -phosphate of ATP with the help of 
positively charges residues (Fetsch and Davidson 2002; Jones, O'Mara et al. 2009). 
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Walker ‘B’: 
Identified with a conserved sequence of XXXXD (where X=any aliphatic residue). Conserved 
aspartate is considered as interacting with Mg2+ required for ATP hydrolysis. The interaction 
between aspartate and Mg2+ is also thought to stabilize the ATP hydrolysis complex. The 
catalytic glutamate residue (XXXXDE) present just after the Walker ‘B’ motif has a central 
role in nucleophilic attack on the ATP. The mutation of conserved glutamate into alanine or 
aspartate halts the ATP hydrolysis of transporter (Orelle, Dalmas et al. 2003).  
 
 
Figure 20. X-ray structure of nucleotide-binding domains of transpoter Hly. The highly 
conserved motif present within nucleotide-binding domains are labeled (Zaitseva, Jenewein et 
al. 2005). 
 
Mechanism of ATP hydrolysis: 
The ATP hydrolysis mechanism adopted by nucleotide-binding domain of ABC transporters 
is widely discussed and several models are proposed to explain it e.g. ATP switch model 
(Higgins and Linton 2004; Linton 2007). Briefly, it is described that open conformation of 
ABC exporter is in state of high affinity for ligand with less affinity for ATP. The binding of 
ligand to exporter induces affinity of NBDs for ATP leading to its binding. For ATP 
hydrolysis, the NBDs of two subunits form a closed dimer and this conformational change is 
large enough to close the transmembrane face in intracellular side and open on extracellular 
surface and translocation of ligand takes place. The ATP molecule(s) then hydrolyzed and 
returning the transporter back to its open form. This model also explains that in vivo the ABC 
transporters are not in utilizing the ATP but it’s the binding of ligand which triggers ATP 
hydrolysis. The binding of ATP occurs on Walker ‘A’ motif which is stabilized by the 
signature motif of NBD of other subunit. The hydrolysis is then initiated by catalytic 
glutamate adjacent to Walker ‘B’. 
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3.2. Functional classification of ABC transporters:  
The ABC transporters can be classified into two major types depending on their function in 
vivo: ABC Importers and ABC Exporters. 
 
3.2.1. ABC importers: 
Nutrients are essential for the growth and maintain metabolic process of the cell and these 
nutrients are acquired from the environment by specialized membrane proteins including 
ABC importers.  
The transporter acquires the substrate present within the periplasmic space between inner and 
outer cell membrane of Gram-negative bacteria. Here the acquisition is assisted by the special 
periplasmic proteins ‘substrate binding proteins’ that binds to the substrate and deliver it to 
ABC importer which then transfer the substrate to cytoplasm. In Gram-positive bacteria , 
substrate binding proteins are also found in direct contact with the outer surface of 
cytoplasmic membrane or with ABC importer itself (van der Heide and Poolman 2002). In 
large part the specificity towards the substrates is provided by substrate binding protein as 
SBP first bind to their respective substrate and then transfer it to transporter (Figure 21) 
(Wilkinson 2003; Doeven, Abele et al. 2004; Davidson, Dassa et al. 2008).  
 
 
Figure 21. The mechanism of substrate capture by SBP (MalE in this case) and then import by 
the ABC importer (Mal FGK2) is schematized (Davidson, Dassa et al. 2008). 
 
Large number of substrates imported by these importers belonging to different classes of 
compounds including sugars, metals, peptides and amino acids etc (Davidson, Dassa et al. 
2008; Eitinger, Rodionov et al. 2011). 
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3.2.2. ABC exporters: 
The structural features of the ABC exporters are discussed in previous section; here the 
significance will be discussed. Exporters are found in all forms of life from bacteria to human 
performing their general prescribed natural function of extruding the toxic and waste 
substances out of the cell. In higher organism their function is also to provide the selectivity 
filter against harmful substances. The cytotoxic compounds are efflux out of the cells by the 
virtue of presence of ABC exporters. Usually showing specificity towards their substrate, the 
ABC exporters are also found exhibiting poly specificity towards the different compound of 
absolute irrelevant structural features (Higgins 2007). 
 
3.2.3. ABC exporters and human: 
The analysis of completed genome sequence of homo sapiens revealed the existence of 7 
families of ABC exporters with a total number of 49 exporters (Dean, Rzhetsky et al. 2001). 
But importance of these exporters was realized long ago when it was shown that resistance 
towards different administered compounds is due to the active efflux by these transporters 
(Juliano and Ling 1976).  
 
3.2.3.1. P-glycoprotein: 
P-glycoprotein also known as ABCB1 or MDR1 is one of the best characterized proteins with 
vital significance in the clinical practice. The important role of P-glycoprotein in drug 
resistance was realized some 35 years ago when it was shown that a glycosylated protein is 
responsible for the drug resistance and therefore given the name of P-glycoprotein (Juliano 
and Ling 1976). It is a large membrane protein of 170 kDa, expressed as one polypeptide 
which organizes into two transmembrane and two nucleotide-binding domains, giving rise to 
a ‘full transporter’ (Higgins, Callaghan et al. 1997). In human, P-glycoprotein is present at 
various sites within body and perform extrusion of noxious substances to protect the cells 
from their toxicity effect. But during the development of cancer and then the treatment, P-
glycoprotein becomes curse and start extruding the cytotoxic drug administered to kill the 
affected cells. The situation tends to worse many folds as the transporter is able to efflux wide 
range of structurally unrelated drugs. Owing to exposure to drugs, the cells also start 
overexpression of the transporter (Szakacs, Paterson et al. 2006; Hall, Handley et al. 2009). 
Recently solved structure of the P-glycoprotein shows that it share the structural and 
mechanistic features to its bacterial homologues like Sav1866 (Figure 22)(Aller, Yu et al. 
2009; Gottesman, Ambudkar et al. 2009).  
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Table 5. Clinically relevant and atypical ABC proteins (Linton 2007). 
ABC Protein Psuedonym Ligand(s)/Function Associated Disease(s) 
 
ABC1 ABCA1 Cholesterol Tangier disease 
ABCR ABCA4 Retinal Various eye diseases 
TAP1/2 ABCB2/B3 Peptides Bare lymphocyte syndrome 
ABC7 ABCB7 Iron Anemia and XLSA 
MRP6 ABCC6 ? Pseudoxanthoma elasticum 
ALD ABCD1 vlcFA Adrenoleukodystrophy 
Sterolin1/2 ABCG5/G8 Sterols Sitosterolemia 
PGY3/MDR3 ABCB4 Phosphatidylcholine Liver disease: PFIC3, OC 
BSEP/SPGP ABCB11 Bile acids Liver disease: PFIC2 
MRP2 ABCC2 Conjugated bilirubin Liver disease: D-J syndrome 
MDR1 ABCB1 Hydrophobic drugs Failure of chemotherapy 
BCRP/MXR ABCG2 Hydrophobic drugs  
MRP1 ABCC1 Conjugated drugs  
MRP4 ABCC4 Conjugated nucleosides  
Atypical ABC proteins 
CFTR ABCC7 Chloride ion channel Cystic fibrosis 
SUR ABCC8 Regulation of KIR channel  PHHI 
SMC1-6  Chromosome maintenance  
Rad50  DNA, telomere repair  
Elf1p  mRNA trafficking  
 
 
 
Figure 22. The structure of P-
glycoprotein in apo conformation: 
(A) Front and (B) back stereo views 
of PGP. TMs 1 to 12 are labeled. 
The N- and C-terminal half of the 
molecule is colored yellow and 
blue, respectively. TMs 4 and 5 and 
TMs 10 and 11 crossover to form 
intertwined interfaces that stabilize 
the inward-facing conformation. 
Horizontal bars represent the 
approximate positioning of the lipid 
bilayer. The N- and C-termini are 
labeled in (A). TM domains and 
NBDs are also labeled (Aller, Yu et 
al. 2009). 
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3.2.3.2. Breast cancer resistance protein: 
BCRP or ABCG2 is another human ABC exporter conferring the resistance towards the 
chemotherapeutic drugs in the case of breast cancer. Although the transporter is also found on 
other site like placenta, the name was given due to its resistance properties in cancer cell lines 
of MCF-7 on administration of doxorubicin and verapamil (Doyle, Yang et al. 1998; 
Maliepaard, Scheffer et al. 2001; Doyle and Ross 2003). Unlike P-glycoprotein, BCRP 
consists of only one transmembrane domain and one nucleotide domain and two subunits 
make a homo-dimer and eventually an active transporter (Figure 23). The transmembrane 
domain is considered carrying six transmembrane helices as in the case of all the ABC 
exporters (Wang, Lee et al. 2008). BCRP is found to be active against mitoxantrone, 
methotrexate and irinotecan. 
 
 
 
 
 
Figure 23. ABCB transporters are expressed as one polypeptide whereas ABCG dimerize to 
form a functional transporter (Sarkadi, Homolya et al. 2006). 
 
 
3.2.4. ABC exporters and bacteria: 
Multidrug resistance found in bacteria is in part due to presence of the ABC exporters. They 
are equally distributed in Gram-positive and Gram-negative a. There are various physiological 
functions of the performed by these transporters including excretion of cytotoxic compounds 
or rearrangement of the lipid in lipid bilayer synthesis e.g. MsbA.  
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3.2.5. Bacterial ABC exporter BmrA: 
BmrA is a multidrug ABC exporter characterized from Bacillus subtilis carrying out transport 
of the various drugs. The genomic analysis of Bacillus subtilis reveals the existence of 
seventy eight genes coding for ABC transporters and gene YvcC was identified as ABC 
transporter. BmrA is expressed as half transporter of 66 kDa i.e. as one subunit of 
transmembrane domain and nucleotide-binding domain and two subunits dimerize to form a 
functional homo-dimer both when it is expressed or after solubilization in detergent (Dalmas, 
Do Cao et al. 2005; Ravaud, Do Cao et al. 2006). The half transporter shares high sequence 
similarity with its lactococcus homologue, LmrA, and each halves of P-glycoprotein.  
BmrA is one of the best characterized ABC exporter from bacterial origin and in vitro 
analysis show the transport of 7-aminoactinomycin D, doxorubicin and Hoechst 33342 
(Steinfels, Orelle et al. 2004). The transport activity in vitro was recently confirmed when it 
was found that Bacillus subtilis confers resistance towards Cervimycin C due to presence of 
BmrA gene (Krugel, Licht et al. 2010). The vital role of glutamate in ATP hydrolysis was first 
realized when it was shown that mutation of this glutamate to other amino acid leaves the 
transporter in an inactive form devoid of any ATPase activity. This glutamate is found just 
after the conserved Walker ‘B’ motif in ABC domain of ABC transporters (Figure 24). The 
position and residue is highly conserved throughout ABC super-family (Orelle, Dalmas et al. 
2003) and recent structural evidence has underlined the role of this residue (Oldham and Chen 
2011). The structure of BmrA is still undetermined. Low resolution structure determined with 
cryo-elcetron microscopy showed that the overall topology of BmrA is similar to that of 
Sav1866 or MsbA (Chami, Steinfels et al. 2002). It was also shown that conserved lysine of 
Walker ‘A’ motif essential for closure of two subunits to hydrolyze ATP in BmrA (Figure 
24). 
  
 
Figure 24. The effect of two 
mutations (Wlaker ‘A’ motif, 
K380R and catalytic glutamate) 
in BmrA is summarized in the 
schematic diagram (Orelle, 
Gubellini et al. 2008). 
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3.2.6. Bacterial ABC exporter BmrC/BmrD: 
The further search for the new ABC exporters within Bacillus subtilis resulted in finding of 
another ABC exporter BmrC/BmrD. Both genes coding for this hetero-dimer are found within 
same opern anticipating two different ABC transporters and later characterization showed that 
both half transporters are capable of dimerization and giving rise to hetero-dimeric exporter 
(Figure 25). The over expression of both genes produced high yield of targeted genes. 
Overexpression of both gene showed high protein yield when expressed together or separately 
(Torres, Galian et al. 2009). The association between two monomers remains active during 
the purification and characterization steps. The BmrD subunit is bigger in size than BmrC 
with difference of eighty residues. Topological analysis of BmrC and BmrD based on the 
conventional structure prediction methods showed that each monomer can be divided into 
transmembrane domain and nucleotide-binding domain. In both subunits presence of six 
transmembrane helices in TMD is also predicted and extra eighty residues of BmrD are 
predicted to form a large extracellular loop between transmembrane helix 1 and 2.  
The physiological function of this hetero-dimer remains yet to be determined but in vitro it is 
capable of transporting various antibiotics. The conserved glutamate responsible for the ATP 
hydrolysis is found only in the large subunit i.e. BmrD and mutation of this residue into 
aspartate inactivates the transporter (Carmen Galian’s thesis). 
 
 
Figure 25. Gene organization of the YheI/YheH (Torres, Galian et al. 2009).  
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Question related to structure and function of ABC exporters: 
1. The most critical feature of the ABC exporters is their poly-specificity towards the 
different compounds with versatile structural features. What makes ABC transporter 
capable to acquire these compounds from the cytosol with same transporter? 
2. The mechanism of the ATP hydrolysis and transfer of the substrate by the transporter. 
3. Is the distance between the two nucleotide-binding domains shown in the apo ABC 
exporters real? 
 4. The dynamics of ICDs of ABC transporters in different conformations. 
   
We aimed to answer the third and fourth question with the help of hydrogen/deuterium 
exchange mass spectrometry. 
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Chapter 4: Mass spectrometry: 
Mass spectrometers are instruments used to determine the molecular weight of molecules, 
atoms or isotopes in their ionic form. Once analytes are ionized within ion source their mass-
to-charge ratio (m/z) is analyzed by the mass analyzer and then detected by the detector and, 
based upon this m/z ratio, the molecular weight is deduced (Figure 26). Mass spectrometry is 
one of the most highly used analytical techniques for the characterization of a broad array of 
analytes. The applications of the technique range from the pharmaceutical industries to 
petroleum analyses and from structural biology to dope tests. The effect of a drug can be 
monitored by the metabolites which can be analyzed with a mass spectrometer. With a high 
resolution mass spectrometer it has become possible to distinguish very closely related 
compounds within crude oil sample (Rodgers, White et al. 1998). Recent advancement in the 
technique has made it useful for the structural analysis of biomacromolecules (proteins, 
carbohydrates, etc) with prior sample preparations methods (Sharon and Robinson 2007; 
Harvey 2009; Benesch and Ruotolo 2011; Konermann, Pan et al. 2011). 
 
 
Figure 26. Scheme of a basic mass spectrometer 
 
The principle of MS is based on the m/z determination and therefore the analyte must be 
charged before the analysis. A neutral molecule can be ionized by different ways such as 
addition of proton H+ or Na+ or removal of electron within the ion source. These charged 
species are then transferred through the mass analyzer and separated based upon their m/z 
ratio.  
 
4.1. Ionization source: 
There are two types of methods employed for the ionization of organic molecules:  
hard or soft ionization.  
Hard ionization causes the ionization and the fragmentation of the molecule, it is routinely 
used for compounds of low molecular weight. Electron impact (EI) belongs to this type of 
ionization. In EI the electron beam bombards the vaporized molecule, which causes the loss 
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of electron and as well as the fragmentation of the target molecule. This fragmentation is 
found to be useful to obtain structural information of small organic compounds (Cooks, Howe 
et al. 1969; Yinon and Hwang 1984).The analytes, ionized by hard ionization methods are 
volatile in nature and of low molecular weight. This prompted scientists to look for other 
ways of ionization which could be used for bio-macromolecules such as proteins, nucleic 
acids or carbohydrates.  
Other ionization techniques are called soft because these techniques are generally not strong 
enough to dissociate the covalent bonds within analyte molecule but non covalent interactions 
are not preserved in general. Electrospray and MALDI are examples of soft ionization sources 
and are now widely used for the analysis of biological molecules. Both methods cause the 
ionization of protein molecules in the gas phase conserving their covalent linkage. In 2002 the 
inventors of the techniques John B. Fenn and Koichi Tanaka were awarded with Nobel prize 
in chemistry for the development of ESI and MALDI ionization methods, respectively 
(Tanaka, Waki et al. 1988; Fenn, Mann et al. 1989; Fenn 2003; Tanaka 2003). 
 
4.1.1. Electrospray ionization:  
Electrospray ionization is a soft ionization technique most widely used for the analysis of 
biomolecules such as proteins, peptides, nucleic acids and carbohydrates. The mass of the 
analytes which can be ionized by ESI ranges from some tens of Daltons to several mega 
Daltons (Smith, Loo et al. 1991; Griffiths, Jonsson et al. 2001). The mechanism of the 
technique can be divided in few steps: Nebulizer gas (nitrogen) is applied on flow of the 
solvent in presence of high electric voltage between 2 to 4 kV (Figure 27). The combination 
of nitrogen gas and electric field causes the production of highly charged droplets from the 
solution. The droplets are filled with the solvent of the solution and charged ions. The solvent 
present within droplets is evaporated by heating and/or exposing them to dry gas. The release 
of solvent causes the shrinkage of droplet (Kebarle and Verkerk 2009; Raut, Akella et al. 
2009). The shrinkage of the droplets and repulsion of similar ions eventually leads to rupture 
of droplets and release of the ions (Fenn, Mann et al. 1990; Kebarle and Tang 1993). These 
ions are then guided towards mass analyzer. As the ions are produced directly from solution 
flow it is possible to couple electrospray with liquid chromatography. Normal ESI can handle 
the continuous flow up to 200 µl per minute with conventional capillary source (Tang, Bruce 
et al. 2006). A modified version of ESI, is able to work at nano-liter flow reducing the sample 
amount and solvent required called nano-ESI (Wilm, Shevchenko et al. 1996; Frommberger, 
Schmitt-Kopplin et al. 2004). Since the evaporation of the solvent is crucial to produce good 
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ionization of the samples, mostly but not necessarily organic evaporable solvents are used for 
electrospray ionization. The removal of salts or any other contamination within buffer is 
necessary as it can cause poor ionization of biomolecules (Garcia 2005; Cotte-Rodriguez, 
Zhang et al.).  
In ESI, during the ionization of the analyte molecule, the phenomenon of multiple charging is 
also observed.  
 
 
 
 
Figure 27. Ion producing process from an electrospray source (Kebarle and Verkerk 2009). 
 
Multiple charging: 
Basically, the concept of mass spectrometry is to ionize the molecule to obtain its molecular 
mass. But due to the electrospray ionization it was made possible to produce multiple charges 
on the molecule (Fenn, Mann et al. 1989). For example, for proteins or peptides which are 
generally positively charged at acidic pH, the number of charges on one single molecule can 
be from +1 to more than +100 depending on the size (Figure 28). Since in a mass 
spectrometer m/z is measured, the mass with higher charged states will produce m/z far 
smaller than the molecular weight of analyte. This m/z can then be easily analyzed by a mass 
spectrometer with even limited m/z range. The number of charges produced due to multiple 
charging is varied; the determined m/z of these charged states are then fed to computer-based 
program which calculates the exact molecular weight of the analyte. The phenomenon is 
called as multiple charging but the deduced mass is called as average mass determined 
(McLuckey and Stephenson 1998). Robinson’s group showed that electrospray is tolerant to 
some kinds of detergents (like DDM) and can be used as a tool to study the protein complexes 
while keeping their non-covalent interactions preserved in gaseous phase (Barrera, Di Bartolo 
et al. 2008).  
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Figure 28. A typical ESI spectrum of a 19920 Da protein (YDiB). The charge states from 11 
to 29 are shown.  
 
 
4.1.2. Matrix-assisted laser desorption ionization: 
MALDI is another soft ionization technique commonly used for peptide and protein analysis. 
It is a highly sensitive technique detecting femtomolar concentration and requires small 
sample amount. Though not as accurate as compared to ESI it is a robust technique that can 
be performed rather quickly.  
In routine MALDI-ToF analysis, matrix solution 3,5-dimethoxy-4-hydroxycinnamic acid 
(sinapinic acid) and (a-cyano-4-hydroxycinnamic acid) are used for protein and peptide 
sample respectively in 1: 1 ratio (Beavis and Chait 1989a; Beavis and Chait 1989b). A quick 
sample preparation method is used for the analysis of molecules; 1-2 µl of analyte is mixed 
with the matrices and spot is air dried. The spot is prepared on a metal plate and this plate is 
then inserted into the mass spectrometer inlet source.   
A laser beam is fired on the spot which causes the activation of matrix and subsequently the 
activated matrix ions transfer energy to analyte molecule causing their ionization. These ions 
are then analyzed in a time-of-flight analyzer (described later) and detected by the detector 
(Figure 29). Nowadays the use of MALDI is increased for the molecular imaging in 
combination with high resolution analyzers such as FT-ICR (Koestler, Kirsch et al. 2008). 
The coupling of MALDI with liquid chromatography has been also made available. With the 
direct coupling, the analysis of complex mixture of the peptides from proteome has become 
robust while using MALDI as ion source (Bodnar, Blackburn et al. 2003; Mueller, Voshol et 
al. 2007). 
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Figure 29. Mechanism of ionization of the analyte with a MALDI source.  
 
The above mentioned method is used for soluble proteins and peptides. The presence of 
detergent or higher amount of salt leads frequently to failure of ionizations. Only dilution of 
the sample can be useful for salts but generally not for detergent as it might cause 
precipitation of membrane proteins. Nevertheless for intact membrane protein analysis, 
modified methods have been developed, facilitating the ionization and analysis (Figure 30) 
(Cadene and Chait 2000; Fenyo, Wang et al. 2007; Gabant and Cadene 2008).   
 
Figure 30. The difference between two MALDI-ToF spectra of a membrane protein can be 
appreciated after sample preparation with ultra thin layer method (Gabant and Cadene 2008). 
Single, double, triple and quarterly charged states can be observed with this preparation. 
 
 
 
 
 
 
 
 
 
 65 
4.2. Ion analyzers: 
Ion analyzer can be unarguably called as the heart of the mass spectrometer, the efficiency of 
any mass determining machine depends on the strength of its mass analyzer. The selection of 
the mass analyzer depends on the requirements of the sample to be analyzed and experiments 
to be performed. Since the generated ions carry positive or negative charge, magnetic or 
electric field within analyzer exploits this charge on ion and determine their m/z. 
Three types of mass analyzers were used during this work and are discussed here briefly: 
• 3D Ion Trap 
• ToF 
• FT-ICR 
 
4.2.1. 3D ion trap: 
Trap works as a mass analyzer, the ions generated by ESI are trapped under radio frequency 
(rf) field on constant amplitude, and the constant amplitude keeps the ions in a confined 
trajectory unless the amplitude is varied. The ions are trapped with the help of two electrodes 
of parabolic shape with application of appropriate potential on these electrodes showed as ring 
electrodes in Figure 31. The variation of radio frequency causes the escape of the ions from 
the trap and subsequently their detection by detector. The amount of known varied frequency 
from lower to higher range causes the escape of lower mass ion earlier and higher ions later, 
making their separation possible. For understanding the trap instrument it can be resemble to a 
bowl filled with solvents of different densities. On the tilting of the bowl the solvent with 
lower density will flow earlier as compare to other solvents with higher densities. The radio 
frequency generated by electrodes of the trap work as solvent for the ions in the gas phase 
keeping them “soluble” ( for review (March 1997; March 2009)).  
Trap is also used for MS/MS analysis for fragmentation of trapped ions and then analyzing its 
daughter ions varying the rf voltage again to obtain structure information on peptides.  
Trap is advantageous by providing MS and MS/MS analysis of a peptide to identify. Better 
signal-to-noise can be obtained by keeping the ions for longer time in the space confined by 
two electrodes and following their motion.  
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Figure 31. Schematic presentation of a 3D ion trap (Weblink: 
http://drugstestingbook.com/confirmation-via-contemporary-and-latest-techniques/) 
 
4.2.2. Time-of-Flight:  
The idea of the time-of-flight (ToF) was presented more than a half century ago (Wiley and 
McLaren 1955). This method to analyze the ions in mass spectrometry was highlighted in the 
1960s but the development of the technique remained poor until the advancement of detecting 
and recording techniques in millisecond time scale (Guilhaus 1995). The principle of ToF 
analyzer is based upon the measurement of time taken by ions to travel a known distance. If 
ions carry identical kinetic energy, the measured time will be solely dependent on the m/z of 
ions. 
The ions are highly dynamic species and irregularly dispersed therefore their movement and 
extraction is controlled by electrostatic plates. After emission from ion source, ions are 
focused within electrostatic plates. The function of these plates is more important in case of 
electrospray because electrospray produce continuous flow of ion. The ions are then released 
in packets to the ion analyzer.   
Kinetics energy of any particle is described as: 
  1 
KE =         mv2 
 2 
here, m and v correspond to molecular weight and velocity of the ions after acceleration  
for a charged particle: 
 KE = zeV 
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z is charge state, e is charge on an electron and V corresponds to the amount of electric field 
in volts, on combining both equations: 
 mv2 
       =  zeV 
  2 
  
we know that velocity can be calculated by dividing the distance covered with time required: 
 v = l/t  
 1 
     m(l2/t2) = zeV 
 2 
       
 T =  l (m/2zeV)1/2 
 
distance covered by ions, charge on electron and amount of electric potential are constant 
values: t = (m/z) .½ . constant 
hence  m/z = 2.t.1/constant 
 
In linear mode ToF analyzers, ions are analyzed by their time of flight as discussed above. An 
advancement of the ToF analyzers is the addition of “reflector” on end of time of flight tube 
rather than a detector. The reflectors are the electrostatic mirrors acting in dual way: ToF and 
reflector (Figure 32). 
Theoretically all ions present in the source would absorb similar energy but practically this 
does not happen and ions with varied kinetic energies cause peak broadening, this peak leads 
to decrease in resolution. The electrostatic mirrors provide different energy levels for the ions 
of varied energies. The ions with high energy will protrude deep in the reflectron and after 
focusing will be released back into the time of flight tube and lower energy ion will be 
repelled from the surface, hence making the energy level similar within all ions so that ions 
reach at the same time on detector. Secondly, the presence of these electrostatic mirrors 
provides the longer length for the ions to fly within time of flight and enhancing the resolution 
of the instrument (Cornish and Cotter 1993; Cotter, Gardner et al. 2004). ToF provides good 
resolution and in some cases more than 50,000 depending on the instrument specifications. 
The difference in kinetic energy distribution of same m/z ions leads to peak broadening and 
decreasing the resolution (Brown and Lennon 1995). 
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Figure 32. Main components of an ESI-ToF instrument 
 
4.2.3. Fourier transform ion cyclotron resonance: 
The FTICR mass analyzers are the highest mass resolution analyzers these days. The use of 
increasing magnetic field with a proportional effect on the mass resolving power was realized 
more than 60 years ago (Sommer, Thomas et al. 1951). During last two decades, there is big 
progress in development of the instrument mainly contributed by Alan G. Marshall. However, 
high cost and difficult maintenance of instrument explain its less frequent usage. 
The mechanism of m/z determination within FTICR is different as compared to other mass 
analyzers both for ions analysis and detection. The analyzer operates in very strong magnetic 
field, generated by superconducting magnet. The magnetic field is generated when the high 
current is passed through the coiled electromagnetic wires. We know that ionization source 
like ESI continuously generates the ions, these ions are gathered within an octapole ion trap in 
presence of constant electro potential. The ions are then ejected by varying the potential on 
the ends of the octapole. The ions emitted by first octapole are then again passed through 
another octapole ion trap to focus the ion beam before their exit into the centre of the 
magnetic field. After the emission from second octapole ions enter into the cell, this is the 
place surrounded by constant strong superconducting magnetic field. Within the cell ions 
perform circular motion perpendicular to strong magnetic field and presence of trapping 
plates prevents escape of the ions. The force which causes the circular movement of charged 
particles/ions in presence of magnetic field is called as Lorentz force. The frequency of 
circular motion exhibited by ions depends on their respective m/z ratio. But this frequency is 
not strong enough to be recorded or used for m/z assignment.  The ions are excited by the 
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voltage pulse generated by excitation plates and then their round movement within the 
magnetic field generates the ICR frequencies which are recorded by detector plates. The 
frequencies generate the spectrum in time dependent manner which are then treated according 
to Fourier transformation giving the m/z spectrum (Figure 33). There is no colliding of the 
ions with the detector as in the case of other mass spectrometer rather the generation of varied 
frequencies determines m/z of the ions (Marshall, Hendrickson et al. 1998). 
For mathematical understanding of the mechanism we consider that if Lorentz force is 
denoted by F then it should be equal to: 
 F =   zev * B  (1) 
Here, e is the ion charge, v is velocity of the ion and B is strength of magnetic field. 
                          mv2 
 F =    (2) 
                 r 
 
comparing Equation 1 & 2: 
     mv 
     = ze B 
                 r 
 
After excitation of ions the frequency (c) adopted by ions can be donated as: 
                ezB 
 c =  
                 m 
The applied magnetic B is known and generated frequencies by the ions are recorded, hence 
m/z of ion can be determined: 
      eB 
 m/z =  
    c 
  
Since the principle of FTICR analyzer is based on the magnetic field, stronger the field will 
have better mass resolution. The FTICR mass spectrometers are unique for providing MS/MS 
analysis by an unusual fragmentation method for peptide/protein sequencing. The 
fragmentation method is called as electron capture dissociation (ECD). Though FT-ICR 
analyzers provide high resolution and sensitivity, one of their disadvantages is high cost and 
maintenance of the instrument. In contrast, with orbitrap, high resolution and mass accuracy 
can be achieved with comparatively lower expenses. The principle of orbitrap is to confine the 
ions in presence of electrostatic field in absence of any magnetic field (Hu, Noll et al. 2005).  
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Figure 33. Schematic diagram of an FT-ICR ion analyzer (from Bristol University Website). 
 
4.3. Protein/peptide sequencing by MS: 
The sequencing of peptides or proteins in the mass spectrometer is achieved by their 
fragmentation. Fragmentation methods used for MS/MS sequencing can dissociate all three 
types of bonds within protein/peptide backbone, nevertheless fragmentation of amide/peptide 
bond between carbon of carbonyl and nitrogen of amide is more commonly observed  O=C  
NH. For any sequence the fragmentation produces two products, one charged ion and a 
neutral specie. Decrease in m/z of charged fragmentation due to loss of H2O, NH3 or CO is 
called as neutral loss. The fragmentation of a peptide produces series of ions and the 
nomenclature adopted for these daughter ions is shown in the Figure 34. Depending on the 
bond fragmentation, six type of ions are expected (x, y, z) if identified part of the peptide 
belongs to C terminal or (a, b, c) if identified part matches with N-terminal. With the help of 
mass analyzer the molecular weight of the liberated product ions is determined and possible 
sequence is predicted (see Figure 34 and 35).  
 
Figure 34. Daughter ions (fragments) emerging from N terminal and C terminal are given 
name as x, y, z ions and a, b, c ions respectively. The fragmentation of a peptide produces 
series of ions which are generated and the nomenclature adopted for these daughter ions as 
shown in the figure.  
Z4 X4 X3 X2 X1 Z3 Z2 Z1 
a1 a2 a3 a4 c1 c2 c3 c4 
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For an accurate prediction, the fragmentation pattern is searched or compared throughout the 
sequence database to identify the protein. For sequencing and peptide identification of a 
peptide mixture, arising by the digestion of a protein with known sequence, the dissociation 
pattern of residues is compared to theoretical dissociation database with help of database 
dedicated search engine like Mascot (Perkins, Pappin et al. 1999; Sadygov, Liu et al. 2004; 
Paizs and Suhai 2005; Xu and Ma 2006).   
 
Figure 35. General scheme of MS/MS analysis 
 
4.3.1. Fragmentation methods: 
For the fragmentation of peptide different methods are in use. One possibility is the in-source 
decay which is used with MALDI ion source. When laser beam is fired on the analyte for 
ionization with extra energy, it causes the fragmentation of the analyte. The matrix used for 
this purpose is of particular characteristic capable of absorbing high energy like 2,5-
dihydroxybenzoic acid (Reiber, Grover et al. 1998). The method is used for intact protein and 
as well as mixture of peptides of proteolytic digests of a protein or mixture of proteins. If 
peptide mixture of many proteins is under investigation, it can generate complicated MS/MS 
spectrum as the whole analyte will be ionized at one time. To avoid this complication MALDI 
is also being used in combination with liquid chromatography (Poutanen, Salusjärvi et al. 
2001; Hardouin 2007).  
Within post-source fragmentation there are two strategies in used depending on the time and 
the space: MS/MS in space and MS/MS in time  
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4.3.1.1. MS/MS in space: 
As indicated in the name, the mass analysis and fragmentation takes place at physically 
distinct places. For example in triple quadrupole (QqQ) (Figure 36) or Q-ToF (QqToF) 
instruments first quadrupole acts as a mass filter which analyzes the m/z of the precursor ions, 
in the next quadrupole which acts as a collision cell, the ions are fragmented and then 
analyzed with the main analyzer like Time-of-flight or another quadrupole. Conventionally 
FTMS has been used as one of the time based MS/MS instrument but relatively recently 
developed new generations FT-MS are hybrid with Qq-FTMS (quadrupole mass filter and 
fragmentation cell and FT-MS ion analyzer)(Syka, Marto et al. 2004).  
 
 
 
 
Figure 36. Three sections of a typical triple quadrupole are shown. Peptide arising from 
electrospray is analyzed in first quadrupole, fragmented in second and then product ions are 
analyzed in third quadrupole (Halquist and Thomas Karnes 2010). 
 
4.3.1.2. MS/MS in time: 
Examples of time based MS/MS include FTMS or ion trap where at the same place first the 
mass analysis of the peptides occurs followed by their fragmentation and subsequently mass 
analysis of the product ions. Since all the steps of the sequencing occur at the same physical 
space but in different time, the method is called as MS/MS in time. 
Apart from the strategies there are several ways to fragment the peptides like: 
 
Collision Induced Dissociation (CID) 
Electron capture dissociation (ECD) 
Electron transfer dissociation (ETD) 
Infra red multi-photon dissociation (IRPMD) 
 
 
4.3.2. Collision induced dissociation: 
Employed for both MS/MS in space and MS/MS in time, collision induced dissociation is the 
most widely used method for the peptide fragmentation. The principle of the CID is based on 
the fact that the internal energy of ions in their gaseous phase is induced by colliding them 
 73 
with an inert gas. The kinetic energy of the ions is increased by submitting them to electric 
field. The increased kinetic energy cause fasts movement of ions and their collision with inert 
gas. Due to continuous collision with gas, the kinetic energy tends to transform into internal 
energy. At certain limit the internal energy causes the breakage of the precursor ions 
generating daughter ions. The principle of the CID is used both for the linear triple 
quadrupole and 3D ion trap in presence of argon and helium gas, respectively (Wells and 
McLuckey 2005; Pittenauer and Allmaier 2009; Romanov, Verkerk et al. 2009). Labile post 
translational modifications are not conserved when CID fragmentation method is applied for 
peptide sequencing or for determining exact site of modification (Creese and Cooper 2007).    
 
4.3.3. Electron capture dissociation: 
Recently developed electron capture dissociation technique is based on the use of low energy 
electron to cleave the peptide bond. For electron bombardment, an electron gun is introduced 
within MS instrument. The low energy electrons emitted from the electron gun target the 
peptide bond within protein or peptide generating the fragments. The electron capture 
dissociation is mostly used with FTMS analyzers. The use of high resolution analyzers made 
possible the MS/MS of the intact protein without prior digestion by proteases. Another 
advantage of the ECD is that the fragmentation pattern only dissociates the peptide bond 
thereby conserving any post-translational modification on the protein like phosphorylation, 
glycosylation and the modified peptides are then identified indicating the exact site of the 
modification (Kelleher, Lin et al. 1999; Medzihradszky 2005; Peter-Katalinic 2005; Sweet 
and Cooper 2007; Sweet and Cooper 2009). 
In proteomics the FTMS instruments with ETD are used for protein identification (Mikesh, 
Ueberheide et al. 2006). The use is not limited for protein identification, for HDX-MS, these 
tools are used for peptide mapping as for a typical HDX experiment protocol (HDX section). 
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Table 6. A general comparison of mass analyzers used here modified from (Siuzdak 2006). 
  
  Ion Trap Time-of-Flight 
Reflectron 
FT ICR Orbitrap 
(Perry, 
Cooks et al. 
2008) 
Accuracy 0.01% (100 ppm) 0.001% (10 ppm) <0.00005% 
(<0.5 ppm) ฏ 2 ppm 
Resolution 4,000 15,000 500,000 500,000 
m/z Range 4,000 100,000 >20,000 >150,000 
Scan Speed ~a second milliseconds ~a second 1.8 sec 
Tandem MS MSn MS2 MSn MSn generally 
with LTQ 
Tandem MS 
Comments 
Good accuracy 
Good resolution 
Low-energy 
collisions 
 Excellent 
accuracy and 
resolution of 
product ions 
Advantageous 
as FT  
General 
Comments 
Low cost 
Ease of switching 
pos/neg ions 
Well-suited MSn 
Good accuracy 
Good resolution 
High resolution, 
MSn high 
vacuum, high 
cost, difficult 
expense 
Low cost, 
easy 
maintenance  
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Chapter 5. Hydrogen/deuterium exchange:  
Like other biomolecules proteins are mainly made up of carbon, nitrogen, hydrogen, sulphur 
and oxygen atoms. These elements perform defined roles e.g. hydrogen atoms remain 
constantly engaged in the exchange of hydrogen provided by the solvent keeping the 
molecules soluble (Kwart, Kuiin et al. 1954). In the case of proteins the exchange of the 
hydrogen with the solvent also depends on the global three-dimensional structure, the local 
spatial conformation of the protein and the protein interaction with other ligands or protein-
protein interactions themselves. In protein molecules secondary structural features 
polypeptide are dependent on hydrogen bonding. The hydrogens involved in hydrogen 
bonding to form secondary structure are less susceptible to exchange the hydrogen with 
solvent (Kabsch and Sander 1983; Richards and Kundrot 1988). Therefore, a technique 
capable of measuring this hydrogen exchange can provide significant information regarding 
the solvent accessibility or even the dynamics of the protein. To measure this hydrogen 
exchange, the protein molecules are diluted in the deuteration solutions and the deuterium 
uptake is then monitored by nuclear magnetic resonance or mass spectrometry.  
The role of mass spectrometry to determine hydrogen deuterium exchange (HDX) was first 
time realized by Chait’s group (Katta and Chait 1991) and fundamentals advancement in the 
techniques was brought by David Smith’s group (Zhang and Smith 1993; Yang and Smith 
1997). The role of different acid proteases was used for the HDX MS technique by our group 
as well (Cravello, Lascoux et al. 2003; Marcoux, Thierry et al. 2009; Rey, Man et al. 2009).  
 
5.1. General mechanism: 
For a protein or peptide, three types of hydrogen atoms are found (Figure 37). First, those 
hydrogens which are linked to carbon atoms of main chain or side chain; these exchange very 
slowly with solvent and can not be used for few hours deuteration exchange experiments. 
Second, those hydrogens which are part of the side chains of the residues linked through 
functional group. Since the side chains of the amino acids are highly dynamic the exchange of 
these hydrogen atoms occurs at relatively high speed making it difficult to monitor. Third type 
of hydrogens called as amide hydrogens are considered as best candidates for HDX studies. 
Their exchange rate is neither too slow nor too fast to be monitored. The amide hydrogens are 
directly linked to the backbone of the protein therefore provide the exact information of the 
protein backbone dynamics (see Figure 37)(Rose and Wolfenden 1993).  
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Figure 37: Three kinds of hydrogens found in peptides and site of deuterium exchange in lieu 
of hydrogen. 
 
EX2 and EX1 kinetics: 
In folded proteins, secondary structural elements are made due to hydrogen bonding of amide 
hydrogens. The other amide hydrogens which are not involved in secondary structure and are 
more likely on protein surface mainly contribute for deuterium exchange. The deuterium 
exchange for these regions can be explained according to equation 1. 
      kex 
              F (H)                  F (D)          (1) 
      D20 
where folded state of protein is shown as F, hydrogen and deuterium are shown as H and D. 
The rate constant for this exchange is defined as kex. 
Within the proteins in a particular region or globally unfolding and folding occurs at different 
rates in physiological conditions. The deuterium exchange for this condition is described 
according to equation 2 which shows that deuterium exchange takes place only on unfolded 
state of protein.  
                                                  k1                     k2                                    k-1    
                F (H)                  U (H)           U (D)                 F (D)         (2) 
      k
-1                            D20                      k    
 
where F and U show the folded and unfolded state of protein and/or protein region 
respectively. Hydrogen and deuterium are shown as H and D, respectively. k2 is the rate of 
exchange in unfolded state of protein. k1 and k-1are rate constant of protein unfolding and 
folding respectively. 
 
 
Deuteration 
D D D 
H : Do not exchange  
H : Too fast to be monitored 
H :  Best candidates for deuterium exchange; 
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     k
-1 >>k2 
Now, if rate constant of protein folding k
-1 is higher than the rate constant of exchange k2, low 
deuterium content can be observed for short deuteration times. This model of deuterium 
exchange kinetics is called as EX2. EX2 is the case for most protein in physiological 
conditions.       
     k
-1 <<k2 
But in some cases the unfolded states of protein exist for comparatively longer duration. In 
this case rate constant of exchange in unfolded state k2 is considered higher than the rate 
constant of protein folding k
-1  , this condition is called as EX1 kinetics.    
It is common to observe two species of isotopic envelopes after deuteration in EX1 kinetics, 
Pure EX1 kinetics is identified by progressive decrease in intensity of lowered mass and 
increase in intensity of higher mass envelope (Figure 38)(Deng and Smith 1998; Weis, Wales 
et al. 2006; Kerfoot and Gross 2011). In other words, EX2 and EX1 can also be defined as 
deuterium exchange uncorrelated and correlated to protein unfolding.  
The remaining traces of undeuterated peptides before the deuterated sample run on liquid 
chromatography can sometimes also lead to a false observation of EX1 kinetics as reported by 
Fang et al (Fang, Rand et al. 2011). The determination of the exact rate of folding requires 
precise information of the contribution of each residue exhibiting the EX1 kinetics. 
 
   
 
Figure 38. Exmaple of EX1 and EX2 kinetics 
observed in hydrogen/deuterium exchange (Weis, 
Wales et al. 2006).  
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5.2. H/D exchange is influenced by factors: 
Apart from protein dynamics and conformation, three other major factors influence the 
deuterium exchange: the temperature and the pH of the solution and amino acid composition.  
 
5.2.1. Temperature: 
It is well established that the movement of the molecules within water or any other matter 
depends on the temperature of the matter itself and the surroundings. On heating the 
molecules absorb the energy which leads to increase in their internal energy and fast 
movement.  
In the case of proteins we know that lowering and increasing temperature above a certain limit 
leads to their cold denaturation and denaturation respectively. However, changes in certain 
limits do not affect the protein native state but the movement and their rate of amide hydrogen 
exchange with solvent is affected. The rate of exchange is found to be slowed down the by 3-
fold factor on lowering the temperature by 10 degrees (Zhang and Smith 1993). Most of the 
proteins remain soluble and functionally active at room temperature, therefore HDX 
experiments are performed at ambient temperature in routine. However, in some cases due the 
very highly dynamic nature of the protein the exchange was carried out at 0°C and significant 
difference in HDX was observed in presence or absence of ligand (Brier, Lemaire et al. 2004).  
 
5.2.2. pH: 
The reaction of exchange is initiated by the exchange of proton of the HOH or deuteron of 
DOD in case of deuterated buffer, therefore the pH or pD of the solution plays a major role. In 
nature mostly the protein molecules are found to be active around physiological pH i.e. 
between pH 7 to pH 8. Increase or decrease in the pH affects the stability and structure of the 
protein and as well as rate of hydrogen deuterium exchange. It was also reported that lowering 
the pH by one unit slows down the exchange rate by a factor of 10 (Figure 39). For example a 
protein sample requiring 10 seconds to exchange at pH 7 will require 1000 seconds at pH 5 
and 10000 seconds at pH 4 respectively (Englander and Kallenbach 1983; Bai, Milne et al. 
1993).   
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5.2.3. Peptide sequence: 
Soon after introduction of the technique, the influence of amino acid composition in a 
particular region of protein on HDX was first realized and then monitored by the Englander 
group (Bai, Milne et al. 1993). The HDX was monitored on the group of dipeptide 
considering dipeptide of alanine as reference. The effect of side chain of different residues 
and the absence of amide hydrogen of proline was also considered while calculating the 
percent deuterium exchange. The presence of acidic or basic amino acids has effect on rate of 
exchange depending on pH of the solution but generally not considered. 
 
Figure 40. Steps of a typical HDX experiments are shown. The protein sample is diluted in 
deuterated buffer for different time intervals. The back-exchange of deuterium is avoided by 
decreasing pH and temperature of sample. The deuterated sample is then either proteolysed by 
acid proteases or directly sent to mass spectrometer.  
 
Figure 39. Effect of pH and temperature on 
amide hydrogen exchange (Bai, Milne et al. 
1993). 
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5.3. Hydrogen deuterium exchange experiment: 
Different steps in a typical hydrogen/deuterium experiment are outlined in Figure 40. 
5.3.1. Peptide mapping: 
The protein mapping is initial step of any HDX experiment. To acquire the knowledge about 
conformation change in different regions of a protein, the HDX difference is calculated after 
digestion of protein by acid proteases. The acid proteases are generally not specific for their 
cleavage site on protein and generate mixture of unidentified peptide. These peptides are 
identified by MS/MS and mapped on the sequence of protein. 
 
5.3.2. Protein labeling: 
The hydrogen deuterium exchange experiment starts by exchange of protein amide hydrogen 
with deuterium. This labeling is achieved by diluting 5 to 20 fold the protein solution in 
deuterated buffer. The pD of this deuterated solution is already adjusted to physiological 
value or varied unless required (Man, Montagner et al. 2007). For continuous labeling 
experiments, the concentrated protein sample diluted in deuterated buffer and after different 
time intervals, the aliquots are drawn, ‘quenched’ and frozen. Usually, the labeling is carried 
out at room temperature and quench is performed by lowering the pH to 2.2 and temperature 
to 0°C (Thevenon-Emeric, Kozlowski et al. 1992; Zhang and Smith 1993). 
 
5.3.3. Global deuteration kinetics: 
The deuterated sample of proteins can be directly analyzed by electrospray ionization or 
MALDI mass spectrometry. The mass of undeuterated protein is also determined and the 
difference of the determined mass between deuterated and undeuterated determines the 
percent deuterium intake by the protein. The mass of undeuterated protein can also be 
calculated from the protein sequence but use of mass spectrometer also ensures the target 
protein is unvaried (Maw, Kennedy et al. 1997).  
 
5.3.4. Local deuteration kinetics: 
The local deuteration kinetics is determined to identify the region of interest of the protein. 
Deuterated samples are digested with help of some acid proteases like pepsin, rhizopuspepsin 
and plasmepsin (Marcoux, Thierry et al. 2009; Rey, Man et al. 2009). Since the acid proteases 
are generally non specific to the cleavage site on the protein sequence, therefore the peptides 
are identified with the help of MS/MS. The uptake of deuterium is then followed with 
increasing time. The deuteration level of peptides is determined as function of deuteration 
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time. The deuteration level at any time (t) for example can be calculated by following 
expression: 
                                      m(t)-m0 
Deuteration level (t) =        
                                      m100-m0 
 
where m0 is the molecular weight of undeuterated peptide and m(t) is the weight determined 
after deuteration of protein for duration of time (t). m100 corresponds to the determined 
molecular mass of the fully deuterated amides of the peptide. Another frequent way to 
determine the percentage of deuteration content is to subtract the molecular weight of 
undeuterated peptide from the determined molecular weight after of deuterated peptide after 
deuteration time (t). The value obtained is then divided with the number of amides present in 
the peptide. This method does not require the fully deuterated peptide as reference. 
 
 
Difference of molecular weight “m(d)” = m(t)-m0 
                                              m(d)  
Percent deuteration =                                     X  100 
                                     Number of amides 
 
5.3.5. Data analysis: 
After successful completion of series of experiments, the next step is to analyze the obtained 
MS data. Usually manual data processing of the each peptide was in trend but nowadays 
successful efforts are made to make a computer program enabled of automated data analysis 
like Magtran, HD-Express, Hydra, Deuterator and HD Examinor etc. (Zhang and Marshall 
1998; Weis, Engen et al. 2006; Pascal, Chalmers et al. 2007; Slysz, Baker et al. 2009).  
 
5.3.6. Top-Down HDX: 
Recently introduced “top down” approach in HDX MS which is based on the determination of 
per residue deuterium exchange is carried out by the above mentioned fragmentation method 
and MS instrument. The ‘top down’ approach is unique to the conventional HDX experiments 
because no prior digestion with acid proteases is carried out (Figure 41). The intact protein is 
exchanged with deuterium and subjected to fragmentation with ECD (Hagman, Tsybin et al. 
2006; Pan, Han et al. 2009; Pan, Han et al. 2010). The technique is used for smaller proteins 
in general. There are few examples where CID fragmentation is also applied for Top-Down 
HDX but due to scrambling effect, it is not being applied extensively (Deng, Pan et al. 1999; 
Ferguson, Pan et al. 2006). 
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Figure 41. The conventional HDX MS experiment setup called ‘Bottom-Up HDX MS is 
compared with recently advanced Top-Down HDX-MS (Kaltashov, Bobst et al. 2009). 
 
5.4. HDX-MS applications: 
The applications of HDX-MS are increasing with time as the development of the technique. 
For example, X-ray crystallography is no doubt the main source about the knowledge of any 
protein structure but the dynamics of the protein in solution itself and after binding with 
effectors is difficult to follow with the typical X-ray crystallography generated structures. 
Protein-ligand, protein-protein interactions and the intermediate states of the protein folding 
pathway from its denatured to natured state is possible to be monitored with the HDX-MS. 
The focus of research has been towards the membrane protein characterization during last few 
years by various biophysical methods. HDX-MS is also expanding its role for characterization 
of membrane proteins dynamics.  
 
5.4.1. Protein folding: 
The specific sequence of the amino acids and subsequently structure adopted by the proteins 
dictates the function of protein molecules. In cell the protein molecules are expressed as linear 
chain and then they are folded with help of other factors and special folding machineries 
“chaperones”(Rose, Fleming et al. 2006). It is also reported that misfolding of the protein can 
cause severe dysfunction leading to disease conditions such as Alzheimer's and Parkinson's 
diseases (Selkoe 2003). Therefore, it seems interesting to acquire the knowledge about the 
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different folding stages and protein conformation during these steps. With the help of HDX-
MS it is possible to follow the folding of the protein (Konermann and Simmons 2003).  
Whereas a protein has the capability to conserve its native conformation in the favorable 
conditions which is of course necessary for the function, on the change of pH or temperature 
it tends to lose the structural arrangement and we called this as denatured state. But 
interestingly on providing the good conditions the denatured form adopts back the native one. 
During this denatured to native state there are several short-lived protein conformations which 
are explored by deuteration of the fractions of sample for milliseconds (Figure 42). 
Deuteration kinetics of these fractions carries the information about the intermediate of the 
folding steps. The technique is called as pulse HDX (Miranker, Robinson et al. 1993; 
Konermann and Simmons 2003; Pan, Han et al. 2010).  
 
 
Figure 42. The scheme of the strategy used for the pulse labeling to probe the folding steps of 
a denatured protein (Suchanova and Tuma 2008). 
 
5.4.2. Protein-ligand, protein-protein interaction: 
Within the biological systems the interaction of protein molecules with other protein 
molecules and/or varied molecular weight ligands (drugs, metals, or hormones etc.) is often 
observed. By interacting with the regulators the mechanisms of protein functioning are 
regulated (Schneider, Prosser et al. 2009). The binding of DNA binding proteins to DNA is 
also found to be essential for its replication and super-coiling (Weber, Ashkar et al. 1996; Saiz 
and Vilar 2008; Tarassov, Messier et al. 2008; Schneider, Prosser et al. 2009). Therefore, 
these interactions are of high significance and monitoring them can provide the functional 
basis of these complexes. 
There are few examples of high resolution structures of these complexes but to crystallize 
these assemblies has been challenging for the X-ray crystallographers and due to their large 
size nuclear magnetic resonance has been also a difficult solution (Shi and Wu 2007; Janin, 
Bahadur et al. 2008; Tang, Luo et al. 2010). Nevertheless, the interaction between the 
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subunits of these complexes can be probed by HDX-MS (Marcsisin and Engen 2010) (Figure 
43.) For this purpose the HDX of intact protein in monomeric form or in apo form is 
monitored and compared with protein in multimeric form or after interaction with ligand 
respectively.  
 
 
 
Figure 43. The strategy employed for targeting the interaction regions in case of protein-
protein or protein ligand interaction is illustrated (Marcsisin and Engen 2010). 
 
5.4.3. Membrane proteins and HDX-MS: 
The importance of membrane protein in living organisms is very well established. They 
provide a passage across the lipid bilayer for transportation of hydrophilic substances inside 
and outside of the cell. Many act as receptor, bind the ligand on extracellular surface and 
trigger the response inside the cell. As a receptor on the cell membrane or on nuclear receptor, 
membrane proteins are also target of the administered drugs (Tsuchida, Yamauchi et al. 2005; 
Taylor, Talley et al. 2007). Within the cell their presence in the mitochondria makes sure the 
availability of ATP which is energy coin for the cell e.g. the mitochondrial membrane carries 
high number of ADP/ATP carrier(Nury, Dahout-Gonzalez et al. 2006). In eukaryotes small 
peptides involved in immune response and the peptides results of the protein degradation are 
transported with the help of membrane proteins like ABC transporters (Procko and Gaudet 
2009). 
Due to their presence in lipid bilayer the membrane proteins are largely composed of 
hydrophobic residues and in result their hydrophobic nature makes difficult dissolution in the 
aqueous buffer. Therefore, several agents like detergents are used for the solubilization and 
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extraction of these proteins; in contrast these agents produce hindrance in the analysis of 
target protein molecules. With the development of biophysical techniques the number of 
membrane proteins structures are increasing on daily basis but search within PDB with 
keywords of membrane proteins retrieves only 441 out of 76669 structures making only 0.5% 
of all the deposited entries. Even if structure is solved, it is possible that the protein is 
crystallized in a conformation and in presence of other ligand with other conformation the 
structure is never solved. Another issue frequently encountered with researchers in case of 
membrane proteins is their expression level is poor and therefore less sample availability for 
structure determination techniques. 
After realizing the above mentioned problems and importance of membrane proteins, the 
HDX-MS is now being frequently used for the conformational analysis of membrane proteins. 
Due to several advantages of HDX-MS it is possible to use the technique for exploration of 
the mentioned class of proteins. As compared to other techniques, it requires less sample 
amount, more tolerant to presence of solubilization agents like detergents. Several methods 
have been invented for removals of the detergents before mass spectrometry analysis (Wu and 
Yates 2003; Everberg, Gustavasson et al. 2008; Rey, Mrazek et al. 2010).  
The structure of mitochondrial ADP/ATP carrier from bovine in complex with 
carboxyatractyloside was solved several years ago. The structure of carrier in complex with 
other inhibitors couldn’t be obtained. However, with the use of HDX-MS it was made 
possible to explore the dynamics of the carrier in complex with another inhibitor bongkrekic 
acid. The dynamics obtained in complex with CATR were similar to those obtained with the 
structure and validated the technique. Application on the bongkrekic acid carrier complex 
showed other possible adopted conformation (Rey, Man et al. 2010). 
Another important class of membrane protein G protein-coupled receptor (GPCR) has been 
targeted by the scientists to obtain the information about their functioning and mechanism 
behind the activation of GPCR after binding the ligands (Yao, Velez Ruiz et al. 2009; Wu, 
Chien et al. 2010). Very recently the dynamics of the receptor was explored with the help of 
HDX-MS and information about the conformations in presence of different agonists and 
antagonists is obtained (West, Chien et al. 2011).  
Furthermore, it is also recently shown that technique is suitable to probe the conformational 
changes of membrane proteins embedded in phospholipid bilayer nanodiscs (Hebling, Morgan 
et al. 2010). 
  
  
 
 
 
 
Materials and Methods 
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1. Purification of recombinant BmrA: 
The plasmid pET-23b carrying the gene for BmrA was transformed into competent E. coli 
strain C41 (DE3). 
 
1.1. E. coli StrainC41 (DE3):  
C41 is an expression system used for the overexpression of recombinant proteins both from 
prokaryotic and eukaryotic origin. It is a mutant of BL21(DE3) which is known for producing 
the T7 RNA polymerase after receiving the genetic information from prophage (Miroux and 
Walker 1996). The addition of IPTG induced the expression of cloned gene of recombinant 
protein by acting on lac UV5 promoter region (Studier, Rosenberg et al. 1990). 
 
1.2. Plasmid vector pET-23b: 
pET-23b is a circular DNA molecule which is transformed into the competent bacteria for 
overexpression of targeted protein (Figure 44). The pET-23b has dual functions: first it carries 
the DNA information which helps the bacteria to survive on exposure to ampicilline hence 
providing the selectivity for the bacteria with the transformed vector. The gene of target 
protein with extra His-tag of six histidine is inserted into the plasmid immediately after the 
region for expression by the T7 RNA polymerase. After the induction of IPTG, the bacteria 
tend to overexpress the T7 RNA polymerase and eventually the recombinant protein. 
 
Figure 44. Map of the plasmid pET-23a(+) 
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1.3. Preparation of competent cells: 
E. coli bacteria were grown overnight in a small amount of LB medium. In 50 ml of LB 
medium, 1 ml of the preculture was added and kept for incubation at 25°C. At optical density 
between 0.6-0.8 the cells were taken and centrifuged in a sterile tube at 5000g at 4°C. The 
pellet was slowly dissolved in PIPES buffer (buffer composition, page. 93). After 
solubilization the bacteria were kept on ice for 2-3 hours followed by another centrifugation 
step at 1100g at 4°C. The pallet was dissolved in same buffer with maximum volume of 2 ml. 
The cells were fractionated in 100 µl volume, frozen in liquid nitrogen and stored at -80°C till 
further use.  
 
1.4. Plasmid vector transformation: 
100 µl of the previously prepared competent bacteria strain C41 (DE3) were left on ice for 10 
minutes to thaw them. Then 1 µl of vector plasmid carrying the gene for BmrA was added to 
the competent cells and left on ice for 20 to 30 minutes. The competent bacteria with the 
plasmid were submitted to a thermal shock at 42°C for 1 minute. Immediately after the heat 
shock the bacteria were again left on ice for another 10-15 min. Then 600 µl of autoclaved LB 
medium was added to the tube. The bacteria were then incubated at 37°C for one hour. This 
phase helps the bacteria to become active and start dividing. After one hour, 100 µl of the 
transformed bacteria were spread over a Petri dish. The Petri dish contained LB medium, 35 
g/l of agar and 100µg/ml ampicilline. The Petri dish was then incubated overnight at 37°C.  
 
1.5. Culture Medias: 
Two culture medias; LB and 2YT were used for the transformation and production of BmrA 
respectively. 
 
Composition: 
 
LB Medium 2YT Medium 
Bactotyptone 16g 10g 
Yeast Extract 10g 5g 
Sodium Chloride 5g 10g 
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1.6. BmrA Overexpression: 
While avoiding any satellite colony, three to four colonies of transformed E. coli were 
randomly picked up from the Petri dish and added to one liter of 2YT medium in a flask. The 
medium was autoclaved and then 75µg/ml ampicilline was added before the addition of 
colonies. The flask was then kept at 25°C in a shaking incubator overnight. Next day the 
absorbance of the growing culture was measured at 600 nm. As soon as the optical density 
reached 0.8, 700 µl of IPTG (1 M) was added into culture medium which makes the final 
concentration of IPTG 0.7 mM. Again the flask was incubated in a shaking incubator at 25°C 
for another four hours.     
 
1.7. Preparation of inverted membrane with overexpressed BmrA: 
After the induction of BmrA expression, the bacteria were centrifuged at 7500g for 20 
minutes at 4°C. The pellet of bacteria was solubilized in 10 ml of buffer ‘A’ (see buffer 
composition, page 93) making sure that the entire pellet was well dissolved without leaving 
any solid mass. The cells were then broken with the help of microfluidizer with a pressure 
range between 15000 to 18000 psi. 
 After the breakage of the cells, EDTA was added to cell lysate at 10 mM final concentration. 
Microfluidizer lysis is considered one of the latest and most efficient way to lyse cell. 
Nevertheless, the lysate was centrifuged at 15000g for 30 minutes in order to remove cell 
debris (high molecular weight cytoplasmic content of the cells) and bacteria which were not 
broken. After centrifugation step, the solid residue at the bottom of tube was discarded and 
supernatant was collected. The supernatant was then subjected to ultracentrifugation at 
100,000 g for one hour. This ultracentrifugation step was performed in order to collect the cell 
membranes. This pellet of cell membranes was dissolved in buffer ‘A°’ and subjected to 
another ultracentrifugation step at 100,000 g for one hour. After second centrifugation step, 
the pellet was dissolved in buffer ‘B’ keeping the volume as low as possible. This dissolved 
pellet contained inverted vesicles highly enriched in BmrA (at almost 50% of the all protein 
content). The protein concentration within vesicles was determined by modified Lowry’s 
method. The vesicles were frozen in liquid nitrogen and stored at -80°C. All the steps right 
after the bacteria centrifugation until the preparation of vesicles were performed keeping the 
temperature of the sample at 4°C. 
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1.8. BmrA solubilization: 
The inverted vesicles were thawed at 37°C and then immediately transferred onto ice. The 
vesicles were then diluted in buffer ‘S’ in such a way that final protein amount concentration 
remained between 1-2 mg/ml. Detergent DDM (n-dodecyl -D-maltoside) was added to the 
solution (final concentration of DDM at 1%). The solution was left for mixing at slow speed 
for one hour to solubilize the proteins. In order to separate the membrane after solubilization, 
another ultracentrifugation step was added at 280,000 g for one hour. The supernatant with 
solubilized proteins was kept and the pellet was discarded.  
 
1.9. Affinity chromatography: 
As it is described earlier, BmrA was overexpressed with additional continuous six histidines 
residues at the C-terminal of the protein. The purpose of this His-tag is to facilitate the 
purification of BmrA with the use of Ni affinity chromatography. In Ni affinity 
chromatography the nickel element is fixed on the resin sepharose, and works as chelating 
agent. On the addition of protein solution with His-tag, electrostatic interaction is formed 
between the protein and fixed nickel and hence protein molecules are trapped within the resin. 
Once bound, the interaction can be then reduced by addition of another potential partner (in 
our case imidazole) for nickel and thereby protein is released from the nickel and collected.  
 
Column preparation: 
In an empty plastic column of 20 ml the filter was placed on one end to close it. 20% ethanol 
was used to wash the column followed by another washing step with deionized water. Then 1 
ml of Ni++-agarose resin was poured in the column as supplied by the manufacture. The resin 
was washed with deionized water.  
 
Equilibration of the column: 
Into the column eighteen ml of buffer ‘E’ was added and column was kept on the rotor wheel 
at 4°C for ten minutes. This step is for the equilibration of the column before addition of 
protein solution.  
 
Loading protein solution on the column: 
After the equilibration of the resin, excess buffer ‘E’ was removed. Then the solubilized 
proteins solution was added into the column and left on rotor wheel for 30 min at 4°C. After 
30 min of incubation this solution was allowed to pour through the column leaving the protein 
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bound with the resin. 20 ml of buffer ‘L’ was added into the column and left for incubation 
for 45 minutes followed by overnight incubation of column with buffer ‘L’. The long duration 
washing with buffer ‘L’ is to get rid of any protein contamination. 
  
Elution of BmrA: 
After the washing step, bound protein was released by passing 7 ml of buffer ‘E’. There was a 
high concentration of immidazole within the buffer which helped to dissociate the interaction 
between protein and Ni and hence targeted protein is released and collected in fraction of 1 ml 
each. 1 µl of each fraction was mixed with 5 µl of Bradford and based on visual examination, 
fractions with higher protein amount were pooled together.   
 
1.10. Dialysis: 
The pooled protein fractions were dialyzed against 1 L of buffer ‘D’ for two hour and then for 
overnight. The protein concentration of the dialyzed sample was determined by Bradford 
method. The protein concentration was concentrated up to 1.6 mg/ml with a vivaspin filter 
with a cut off of 100 kDa. 
 
1.11. Composition of buffers: 
Buffer ‘A’ : Buffer ‘E’ : 
  
50 mM Tris-HCl pH 8 50 mM Tris-HCl pH 8 
5 mM MgCl2 Glycerol 15 % 
1 mM DTT 100 mM NaCl 
1 mM PMSF 10 mM Imidazole 
Anti protease  DDM 0.05 % 
  
Buffer ‘A°’ : Buffer ‘L’ : 
  
50 mM Tris-HCl pH 8 50 mM Tris-HCl pH 8 
1.5 mM EDTA Glycerol 15 % 
1 mM DTT 100 mM NaCl 
1 mM PMSF 20 mM Imidazole 
Anti protease  DDM 0.05 % 
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Buffer ‘B’ : Buffer ‘E °’ : 
 50 mM Tris-HCl pH 8 
20 mM Tris-HCl pH 8 Glycerol 15 % 
300 mM Sucrose 100 mM NaCl 
1 mM EDTA 250 mM Imidazole 
 DDM 0.05 % 
  
Buffer ‘S’ : Buffer ‘D’: 
  
50 mM Tris-HCl pH 8 50 mM Tris-HCl pH 8 
Glycerol 15 % Glycerol 10 % 
100 mM NaCl 50 mM NaCl 
10 mM Imidazole DDM 0.05 % 
1 mM PMSF  
  
Buffer PIPES:  
10 mM PIPES   
60 mM CaCl2   
15% Glycerol  
 
2. Purification of recombinant BmrC/BmrD: 
The plasmid pET21 carrying the double gene for BmrC/BmrD was transformed into 
competent E. coli cells BL21 DE3 acrB (Ma, Cook et al. 1995).  
 
2.1. Plasmid vector transformation:  
The plasmid vector was transformed into competent cell following the same protocol as for 
BmrA.  
 
2.2. Overexpression of BmrC/BmrD: 
To one liter autoclaved culture of TB medium ampicilline (75 µg/ml) was added. Then from 
Petri dish around 8 to 9 colonies of BL21 (DE3acrB) carrying the transformed plasmid of 
BmrC/BmrD were added into culture. The culture was incubated at 37 °C for 13 hours in the 
shaking incubator at a speed of 225 rpm. After around 13 hours when optical density reached 
between 1.8-2.0, IPTG was added at final concentration of 0.7 mM and incubated again in 
shaking incubator at 25°C for another16 hours.  
Afterwards bacteria were collected, inverted-membrane vesicles were prepared and 
BmrC/BmrD were purified following the same protocol used for BmrA.   
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3. Biochemical and analytical methods: 
3.1. Protein concentration: 
There are two steps in the protein purification protocol where the exact protein concentration 
determination is required: for the inverted membranes vesicles and at final stage of purified 
protein in detergent. Therefore, two methods were used Lowry method for protein 
concentration determination in inverted membrane vesicles and Bradford method for the 
purified protein solubilized in detergent. Due to the presence of sugar in buffer ‘B’ the Lowry 
method was modified and therefore will be referred to as modified Lowry method. 
 
3.1.1. Modified Lowry method: 
The Lowry method is a biochemical assay used for the determination of total protein 
concentration in a solution. The method can be applied to determine the concentration from 5 
mg/ml to 100 mg/ml (Lowry, Rosebrough et al. 1951). In alkaline medium aromatic residues 
of the protein i.e. tyrosine and tryptophan tend to react with cupric sulfate-tartrate making a 
complex. This complex has tendency to reduce Folin-Ciocalteu reagent. The reduction of 
reagent results in apparent of blue color. The content of blue color could be visually noticed 
and then exact amount is determined by reading at 595 nm against a standard curve using 
BSA.  
 
3.1.2. Bradford method: 
Bradford protein concentration determination method is most frequently used in protein 
purification techniques to accurately determine the protein concentration. It is a short protocol 
requiring only Coomassie Blue G250 dye and can be performed within few minutes. Like 
other spectroscopic technique, the principal is based on the color change of the dye after its 
binding to protein and then can be read at 595 nm (Bradford 1976).   
A standard curve was determined with the help of known concentrations of BSA range of 0 to 
30 µg protein concentration. To determine the protein concentrations, the protein samples 
after the final step of purification were diluted two and five times in buffer ‘D’. 30 µl of both 
sample protein solution and standard BSA solution were mixed with 900 µl of Coomassie 
Plus reagent (provided by Pierce) separately. After five minutes incubation, the absorbance of 
the solutions was read at 595 nm. To measure the exact concentration, the protein samples 
were performed in triplicate and mean protein concentration value was determined. 
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3.2. Protein characterization by polyacrylamide gel electrophoresis (SDS-PAGE): 
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) was used for the 
characterization and separation of protein molecules based on their molecular weight. The 
technique is also helpful for the profiling of proteolytic fragments of a protein originating due 
to the limited proteolysis.  
PAGE principal is based on the movement of charged particles under electric field. 
Acrylamide provide the platform (in form of gel) for the migration of protein molecules and 
addition of SDS causes denaturation and equal charge distribution on all the molecules. 
Therefore, the migration of the proteins is solely based on the number of residues present and 
eventually on molecular weight.  
 
3.2.1. Gel composition: 
The composition of an SDS-PAGE gel consists of acrylamide, Tris-HCl, SDS, ammonium 
persulfate (APS) and N, N, N ', N'-tetramethylethylenediamine (TEMED).  
The acrylamide is provided in solution carrying both acrylamide and bisacrylamide, its 
polymerization is initiated by ammonium persulfate in the presence of TEMED. The tertiary 
amines of the TEMED catalyze the free radical formation from the ammonium persulfate 
which then causes the polymerization of acrylamide. The thickness of the gel is defined by 
percent content of acrylamide in the final solution. In routine analysis ~12% acrylamide gel 
was used for the proteins below 40 kDa and 9-10% was used for the higher molecular weight.  
For BmrA and BmrC/BmrD, the gel was polymerized into two parts, stacking and resolving. 
The stacking gel acrylamide concentration was kept at 4 %, this part of the gel is to 
concentrate the sample before migration on the resolving gel.  
The composition of stacking gel:  
Tris-HCl 100 mM pH 6.5 
Acrylamide 4 % (w / v) 
SDS 0.1 % (w / v) 
Ammonium persulfate 0.1 % (w / v)  
and TEMED 0.001 % (v / v) 
The resolving gel which made the larger part of the gel was 10 % of acrylamide and Tris HCl 
was used at pH 8.0.  
For limited proteolytic samples analysis the concentration of resolving gel was kept at 12 %.  
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Sample Preparation: before loading onto the gel the samples were mixed with Laemmli 4X 
buffer (also known as sample dilution buffer) in 3:1 ratio. The mixture was kept at 37°C for 
five to ten minutes and immediately loaded after the heating step. In addition to samples, 
markers with known molecular weight and prestained with dye were also loaded in the first 
well of the stacking gel. The composition of Laemmli buffer: 
Tris-HCl 250 mM pH 6.8 
Glycerol 40 % (v / v)  
SDS 8 % (w / v) 
-mercaptoethanol 4 % (v / v) 
bromophenol blue 0.001-0.04 % (w / v) 
 
3.2.2. Coloration/decoloration: 
After the samples were separated on the gel by electrophoresis, the acrylamide gel was kept in 
the solution of Coomassie Blue R250 , 0.25 % (w/v) dissolved in ethanol 40 % (v/v) and 
acetic acid 10 % (v/v). This step was performed to color the protein samples in the gel. The 
unrequired staining of the gel which masked the proteins samples was removed by keeping 
the gel in ethanol 10 % (v/v) and acetic acid 5 % (v/v) solution (Diezel, Kopperschlager et al. 
1972).  
 
3.3 Limited proteolysis of BmrA: 
The limited proteolysis of wild-type BmrA was performed in apo and Vi inhibited form in 
detergent solubilized state and BmrA enriched membranes. The protease to substrate ratio was 
kept 1:1000 in both cases.  
Briefly, 10 µl of freshly prepared trypsin at concentration of 10 µg/ml was added to 100 µl of 
concentration protein solution carrying BmrA at 1.0 mg/ml protein concentration. Aliquots of 
10 µl were withdrawn after 5, 15 and 30 min. 1 µl of TFA 0.01% was added in each aliquot 
and quickly frozen in liquid nitrogen. To acquire the inhibited form of BmrA with Vi, 5 µl of 
Mg2+ 100 mM, 5 µl of ATP 100 mM and 2µl of Vi 70 mM were added to the protein solution 
prior to digestion by the protease. The aliquots for BmrA digestion in inverted membranes 
vesicles were withdrawn after 5, 15, 30, 60, 120 and 180 min.  
The samples were then analyzed by electrophesis on a SDS PAGE gel of 12.5%. The gel was 
scanned after the completion of electrophoresis.  
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3.4. ATPase activity: 
To determine the ATPase activity of BmrA, a multienzyme coupled system was used. In this 
system the ADP produced by the hydrolysis of the ATPase (BmrA in this case) is 
continuously regenerated back into ATP by the pyruvate kinase. The pyruvate kinase converts 
phosphoenol pyruvate into pyruvate. Lactate dehydrogenase catalyze a reaction converting 
pyruvate into lactate, this reaction requires NADH as cofactor and its oxidation results into 
NAD+ formation. The NADH absorbs at 340 nm, as the hydrolysis of ATP is increased the 
rate of conversion of NADH to NAD+ is also accelerated which leads to decrease in amount 
of NADH. The lower absorbance at 340 nm provides direction of the ATP hydrolysis rate by 
ATPase (Pullman, Penefsky et al. 1960).  
 
 
Preparation of ATP and ortho vanadate stock solutions: 
100 mM ATP solution was made by dissolving the amorphous ATP (supplied by Sigma) in 
100 mM Tris solution. The pH was adjusted at 8 with HCl. Tris solution protects the sharp 
change in pH on the dissolution of ATP, as ATP tends to hydrolyze quickly itself at acidic 
pH.  
To prepare the saturated solution of orthovanadate, 100 mg of Na3VO4 was dissolved in 3 ml 
of deionize water. Due to low solubility, the solution was heated at 90°C and pH was adjusted 
at 10 with HCl. As the solution turns colorless, the concentration of vanadate is measured at 
265 nm, optical density coefficient of vanadate is 2925M-1cm-1.  
Both solutions of ATP and vanadate were divided into 100 µl aliquots and frozen at -20°C till 
further use.  
 
Formula for rate of ATP hydrolysis:  
How to calculate the activity: OD = ε.l.c   therefore  OD = ε.l.c  
and εNADH340nm = 6220 (l.mol-1.cm-1) 
Lactate Phosphoenol pyruvate Pyruvate 
ADP ATP 
ATPase (BmrA) 
NADH NAD+ 
Pyruvate 
kinase 
Lactate 
dehydrogenase 
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Rate of NADH disappearance (mol/min) = c (mol/l/min) x V(sample volume, in l) 
 
Rate (mol/min)  = OD x V = OD (min-1) x 500.10-6 (if 500 µl) 
                    ε.l    6220 x 1 (cm) 
 
Rate (µmol/min)  = OD x V = OD (min-1) x 500 
                       ε.l      6220 x 1 (cm) 
 
Rate (µmol/min/mg)  = OD (min-1) x 500 x 1000 = OD (min-1) x 5.102 
                     6220 x Protein (in µg)    6.22 x Protein (in µg) 
 
To measure the activity of proteins in detergent, the buffer used was  Tris-HCl 50 mM 
pH 8, NaCl 50 mM, MgCl2 5 mM , glycerol 10 % (v / v), -mercaptoethanol 5 mM, lactate 
dehydrogenase 32 µg/ml (isolated from rabbit muscle, Roche), pyruvate kinase 60 µg/ml 
(isolated from rabbit muscle, Roche), phosphoenol pyruvate 4 mM (Roche), NADH 0.4 mM 
(Roche) and DDM 0.05 % (w / v) (Alexis). While monitoring the inhibitory effect of vanadate 
on ATPase activity of BmrA, orthovanadate 0.2-0.5 mM was added in the reaction buffer 
before the addition of protein. In a quartz cuvette with a thickness of 1 cm and a volume of 
500 µl, 10-20 mg of protein in detergent was incubated in buffer at 30° or 37° C for 5 
minutes. The reaction was triggered by adding 20 µl of ATP 100 mM to a final concentration 
of 4 mM and absorbance at 340 nm was followed for 10 minutes. The slope (OD340nm/t) 
was calculated from 2 to 4 minutes. 
 
3.5. Deuterated sample preparation: 
3.5.1. BmrA deuteration in detergent: 
ABC exporter BmrA, both wild-type and mutant E504A, were purified in dimeric state and 
concentrated up to 1.6 mg/ml in hydrogenated buffer. After concentrating the protein was 
diluted ten times in deuterated buffer. The deuterated buffer was composed of 50 mM NaCl 
and 0.05 % DDM in 99.9% D2O (Sigma).  
Hydrogen deuterium exchange (HDX) reaction was initiated by adding 84 µl of concentrated 
protein in 756 µl of deuterated buffer at 0 s. After 15, 60, 300, 600, 1800 and 3600 s, aliquots 
of 120 µl of deuterated samples were withdrawn and mixed with 26 µl of quench solution. 
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The quench solution was composed of 8 M guanidium hydrochloride (GndCl), 500 mM 
glycine HCl, pH 2.2. This solution was pre-cooled on ice. After mixing with quench buffer 
each aliquot was frozen in liquid nitrogen and kept frozen till further use. 
For inhibited state of wild type BmrA, the concentrated protein solution was incubated with 5 
µl of 100 mM ATP, 5 µl of 100 mM Mg2+ and 2.5 µl of 70 mM Vi for few minutes prior to 
dilution in deuteration buffer. To obtain inhibited state of BmrA mutant E504A similar 
amount of reagents were used as for the wild-type except that Vi was not included.  
The deuterated samples for protein deuteration kinetics and peptide deuteration kinetics were 
prepared in similar way.  
 
3.5.2. Deuteration of BmrA enriched inverted membrane vesicles: 
To deuterate BmrA enriched membranes vesicles, 20 mM Tris HCl (pD 7.6) solution was 
prepared in 99.9% D2O. For both wild-type and mutant E504A, membranes were diluted till 
total protein concentration of 5 mg/ml. Then, as for the experiments in detergent 84 µl 
solution of membranes were diluted in 756 µl of deuteration buffer to initiate the hydrogen 
deuterium exchange and after specific time intervals aliquots were withdrawn and frozen. 
The inhibited state of mutant of BmrA mutant E504A was prepared in a similar way as to the 
detergent sample. 
 
3.5.3. BmrC/BmrD deuteration in detergent: 
BmrC/BmrD, in case of wild-type and mutants, was purified and concentrated up to 5 mg/ml 
in detergent. For wild-type apo state 40 µl of concentrated protein was diluted in 560 µl of 
deuterated buffer. For deuterated buffer of BmrC/BmrD, HCl 50mM pD 7.6, NaCl 300 mM 
and DDM 0.05 % was dissolved in 99.9 % D2O. After 15s of dilution an aliquot of 105 µl 
from dilution tube was withdrawn and transferred into another tube already containing 
precooled 35 µl of quench solution (GndCl 7M in HCl 50 mM) and frozen in liquid nitrogen 
till further use. Similarly, four more aliquots after 1, 10, 30 and 60 min were mixed with 
quench solution and frozen.  
For mutants, E592D (BmrD), E592D/D500E (BmrC/BmrD) and E592A/D500A 
(BmrC/BmrD), 2.5 µl of ATP 100 mM and 2.5 µl of Mg2+ 100 Mm were incubated with 45 µl 
of protein sample for 10 minutes. From incubated solution 40 µl of sample was diluted in 
deuteration buffer, quench mixed and frozen as for the wild type. 
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4. Mass spectrometry: 
Similar solvents and conditions were used for peptide analysis of BmrA and BmrC/BmrD 
unless specified.  
 
4.1. Liquid chromatography: 
Two types of MS instruments were used: electrospray ionization (ESI) and Matrix-assisted 
laser desorption ionization (MALDI). But most of the analyses were performed on 
electrospray ionization coupled with high performance liquid chromatography (HPLC). For 
HPLC two kinds of typical solvent systems were used: solvent ‘A’ and solvent ‘B’. 
The solvent ‘A’ was composed of mass spectrometry grade water 99.97 % (v/v) (LC-MS 
Ultra Chromasov, Sigma Aldrich) and trifluoroacetic acid 0.03% (v/v)(Acros Organics, 
99.9%). The solvent ‘B’ consists of acetonitrile 95 % ( v/v) (LC-MS Ultra Chromasov, Sigma 
Aldrich), water 4.97 % (v/v) and trifluoroacetic acid 0.03% (v/v). For online desalting step of 
protein and peptides, protein macrotrap (Protein Macro TrapTM, Michrom) and peptide 
microtrap (Peptide Micro TrapTM, Michrom) were used, respectively. The peptides were 
separated exploiting hydrophobic interactions on Jupiter C18 (Phenomenex) column of 5 µm 
particle size.   
The peptides either eluting from the immobilized pepsin column or from in solution digestion 
were concentrated and desalted on the peptide microtrap at flow rate of 200 µl/min of solvent 
‘A’. The sample loading, digestion (in case of pepsin column), concentrating and desalting, all 
four steps were performed in two minutes. The C18 analytical column was pre-equilibrated at 
15 % of solvent ‘B’, the peptides eluted from microtrap were separated on analytical with 
help of gradient of solvent ‘B’ from 15% to 45% in 26 minutes. The detergent liberated after 
the elution of last peptide hence did not disturb the LC and MS analyses of peptides. The 
monoisotopic mass of each peptide was confirmed on ToF.  
 
4.2. Mass spectrometry calibration: 
The ESI-ToF was calibrated with ESI Low Concentration Tuning Mix (Agilent Technologies) 
molecular weight range from 118 Da to 2722 Da in positive ion mode. Similarly, ESI-TRAP 
was calibrated with ESI Tuning Mix (Agilent Technologies) in positive ion mode but once a 
month only. The MALDI-ToF instrument was calibrated with protein calibration standard 
(Bruker Daltonics) mass range from 757 Da to 3150 Da and from 22307 Da to 66000 Da for 
peptides and protein analysis respectively. The matrices used for sample preparation in 
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MALDI analyses were sinapinic acid (Sigma Aldrich) and -cyano for protein and peptide 
analyses, respectively.  
 
4.3. LC-MS/MS analyses: 
The LC-MS/MS technique was used for the peptides mapping.  
 
BmrA: 
To identify the proteolytic fragments generated from the pepsin digestion, the MS/MS 
analysis of BmrA was performed on Trap Esquire 3000+ (Bruker Daltonics). The instrument 
was equipped with ESI source directly coupled with a manually operated HPLC (Shimadzu). 
The data acquisition and analysis were done with the programs Esquire Control v5.0 (Bruker) 
and Data Analysis v3.2 (Bruker), respectively. 
 The peptides were loaded and concentrated on peptide microtrap at flow rate of 200 µl/min of 
solvent ‘A’ for three minutes. The gradient 15 % to 45 % solvent ‘B’ in 57 min was run on 
pre-equilibrated C18 analytical column. The mass range was kept between 100 Da to 1500 
Da.  
 
BmrC/D: 
The LC-MS/MS experiments for the peptide mapping of BmrC/BmrD were carried out on 
FT-ICR mass spectrometer (Bruker Daltonics). The instrument was also equipped with ESI 
source and directly coupled with liquid chromatography.  
 
4.4. LC-MS analyses: 
Mass Spectrometer: 
The LC-MS analysis of intact protein and peptides were carried out on ESI-ToF (Time-of-
Flight LC/MS 6210, Agilent Technologies). The ESI source was directly coupled with high 
perfoemance liquid chromatography (HPLC). Both HPLC and MS were administered through 
the online program Data Acquisition (Agilent).  
 
Protein analysis: 
BmrA in both detergent solubilized state and inverted membrane vesicles was loaded on the 
protein macrotrap and desalted at flow rate of 200 µl/min of solvent ‘A’. The protein was then 
eluted from the trap with solvent ‘B’ gradient 40 % to 70 % in 15 minutes and an analytical 
column was used to trap the detergent or lipid so that good signal-to-noise of protein could be 
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achieved. To separate the detergent from protein the analytical column C4 was equilibrated 
40% acetonitrile.  
The mass range for data acquisition was kept between 400 to 1500 m/z. The average mass of 
protein was deconvoluted with Windows based program Qualitative Analysis (Agilent). 
 
Peptide analysis: 
For deuterated samples the average of each peptide was calculated in three steps. First, the 
raw data file of peptide was exported in CSV format from Quantitative Analysis (Agilent). 
Then with the help of script the CSV files were converted into simple text format. This text 
file was then opened in program Magtran 1.03 b2 (Amgen Inc.)(Zhang and Marshall 1998). 
The average mass of the peptide was calculated by calculating the centroid of isotopic 
envelope based on Gaussian curve for deuterated or undeuterated samples.  
 
4.5. MALDI analysis: 
The MALDI ToF analysis of intact protein BmrA was carried out by using a modified sample 
preparation method called ultra thin layer method. This method was shown to be useful to 
analyze membrane proteins in the presence of detergent (Gabant and Cadene 2008).  
Different steps of sample preparation are outlined in Figure 45. 
Sample preparation steps:  
A saturated solution of 4HCCA (a-cyano-4-hydroxycinnamic acid) was prepared in FWI 
matrix solvent (consisting of 3:1:2 formic acid: water: isopropyl alcohol (v/v). 
A thin layer of matrix was spread over the plate, after drying remaining moisture was wiped 
gently not disturbing the layer. 
Protein sample was diluted in the same 4HCCA matrix saturated solution from 5 to 50 times 
and 20 times was found the best condition. A spot of 0.5 and 1.0 µl of the diluted sample was 
made on layer. The spot was then washed by 0.1%TFA and aspirated by vacuum line. 
After complete dryness, the spot was ready for MALDI analysis. 
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Figure 45. Ultra thin layer sample preparation (Gabant and Cadene 2008). 
 
The method is applicable from lower to high molecular weight membrane proteins.  
For peptide analysis, the digested sample was mixed with matrix 4HCCA (a-cyano-4-
hydroxycinnamic acid) in 1:1 ratio. 1 µl of digest and 1 µl of matrix was mixed on the plate 
and left on the bench for drying. After the formation of crystal the plate was manually inserted 
in the MALDI ToF. The MS spectrum of MALDI-ToF was obtained with program Autoflex 
(Bruker Daltonics) and processed with Flex Analysis (Bruker Daltonics), respectively.  
  
 
 
 
Results and Discussion 
 
  
 
 
 
Chapter 1. H/D exchange kinetics of BmrA in 
apo and closed form 
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The initial step of characterization of BmrA by HDX-MS was to obtain peptide mapping after 
digestion with acid proteases pepsin and rhizopuspepsin. In beginning the typical in solution 
digestion of the transporter was employed and the peptides were identified on ESI-Trap mass 
spectrometer. BmrA is a membrane protein and sufficient amount of detergent DDM is 
required to keep the transporter solubilized. The final concentration of the DDM was 0.05% 
in the protein buffer as well as in the deuterated dilution buffer. 
Fortunately, the presence of detergent did not interfere with the peptide separation or the mass 
spectrometric analysis. This was due to the semi hydrophobic nature of the detergent that was 
found to be eluted at about 40-45% of acetonitrile, after the elution of most of the peptides 
(Figure 46). 
However, the peptide mapping obtained in solution digestion was only 34% of the total 
sequence, missing most of the significant regions of the transporter. The prolonged digestion 
time i.e. from two minutes to five minutes did not improve the sequence coverage. The use of 
immobilized enzyme proved to be useful for digestion of the transporter and the use of 
denaturants further improved the digestion and a reasonable 78% sequence coverage was 
obtained in the presence of 1.5 M guanidine hydrochloride (GnCl). As anticipated the 
transmembrane region of the transporter was not well covered as compared to the nucleotide-
binding domain. However, the peptides originating from the regions of interest like ICD1, 
ICD2 and ABC motif were mapped. After careful identification and assignment of all 
peptides with the help of MS/MS data and Mascot server, each peptide was then identified on 
ESI ToF mass spectrometer.  
The global deuteration kinetics of BmrA was determined in a detergent solubilized state or 
BmrA enriched membranes in order to define the effect of detergent on the transporter. The 
overall kinetics showed that in two different conformations the relative deuterium exchange 
of the transporter was found to be similar. Furthermore, limited proteolysis analyses of the 
protein showed that the closed conformation (vanadate inhibited or conserved glutamate 
mutation) is more resistant towards the enzymatic digestion as compared to the open 
conformation (in absence of any nucleotide), in detergent solubilized state and as well as in 
BmrA enriched membranes. 
The influence of the conformation of BmrA on the significant regions of the protein is 
discussed in detail in the manuscript submitted and included within chapter 1 starting at page 
11. Please note that figures’ numbering within paper is in its own order different from global 
numbering of thesis manuscript.  
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Figure 46. Chromatogram showing total ion current of the eluted peptides of BmrA. In-sets 
show the presence of peptides and elution of detergent at the end of the run.  
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SUMMARY 
The study of membrane proteins remains a very challenging task and approaches to unravel the 
dynamics of these proteins are scarce. Here, we applied H/D exchange coupled to mass spectrometry 
to probe the motions of a bacterial multidrug ATP-Binding Cassette transporter, BmrA, in two 
different conformations. The closed state, outward facing conformation, was obtained using either the 
wild-type BmrA trapped in a vanadate-inhibited complex or the ATP-bound E504A inactive mutant, 
while in the resting state BmrA was expected to adopt an open inward-facing conformation. First, 
trypsin digestion and global H/D exchange support the existence of two very different conformations 
of BmrA either in membrane or in detergent. Next, local H/D exchange rates obtained for different 
peptides of BmrA agree with the overall 3D models of the transporter derived from each state. This 
shows that BmrA can cycle between an inward and outward facing conformations. However, in the 
resting state, peptides from the two intracellular domains, ICD1 and especially ICD2, show a much 
higher rate of H/D exchange than in the closed state. This shows that these two sub-domains are much 
more flexible in the resting state than expected from the known 3D structures of related transporters, 
MsbA or ABCB1. Congruent with this, molecular dynamic simulations suggest a large fluctuation of 
C position from ICD2 residues in the inward facing conformation of MsbA. These results highlight 
the unexpected flexibility of a multidrug ABC transporter in a resting state and underline the power of 
H/D exchange coupled to mass spectrometry to explore conformational changes and dynamics of large 
membrane proteins.      
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INTRODUCTION 
 
Transport across membranes to import nutrients or export signaling molecules or noxious 
compounds, toxics or wastes, is an essential process in all kingdom of life, and selectivity of transport 
must therefore be ensured. This task is maintained by transporters, and the ATP-Binding Cassette 
(ABC) is one of the largest families of proteins involved in this ‘checkpoint’ [1, 2]. ABC transporters 
are found in all living species and they are powered by ATP hydrolysis to transport a wide variety of 
substrates. In prokaryotes, they participate in either the uptake of food supplies or the extrusion of 
many different compounds, some being harmful upon accumulation (e.g. antibiotics) while others can 
be incorporated as building block in the cell wall [3]. In man, the dysfunction of several ABC 
transporters causes severe pathologies such as adrenoleukodystrophy, hyperinsulinemic hypoglycemia 
or cystic fibrosis [4]. Other medically important ABC transporters are responsible for multidrug 
resistance (MDR) phenotypes. As opposed to most ABC transporters that are usually specific to one 
class of compounds (e.g. sugar, vitamin, or ions), multidrug transporters are capable to recognize and 
expel many unrelated organic compounds with quite dissimilar chemical scaffold. Thus, although their 
original function is dedicated to a protective role in healthy cells, the occurrence of these transporters 
in malignant tissues, pathogenic microorganisms or parasites confer a resistance towards the drugs 
used to cure the related pathologies [5]. The archetype of multidrug ABC transporters and first to be 
discovered is the human P-glycoprotein (also known as ABCB1); it is responsible for the failure of 
chemotherapeutic treatments in cancerous tissues. In bacteria, the identification of related transporters 
is relatively recent [6], as compared to other families of multidrug transporters that use the proton 
gradient as the energy source [7]. However, growing bodies of evidence support the implication of 
these multidrug ABC transporters in antibiotic resistance in many species [8], including recently in a 
Streptococcus pneumoniae strain isolated from a clinical setting [9]. Thus, given the prevalence of 
putative multidrug transporters in many bacterial genomes [10], they are now considered as a major 
threat jeopardizing a successful therapy.  
 All ABC transporters share a common architecture with two transmembrane domains (TMD) 
responsible for substrate translocation and two nucleotide-binding domains (NBD). In importers, these 
four core domains are usually borne on different polypeptides, up to four, and an additional subunit 
captures the substrate from the extracellular medium and delivers it to the transporter. In most 
exporters, these four domains are either linked into a single polypeptide (e.g. for the majority of 
eukaryotic transporters) or function as dimers with one NBD fused to one TMD (homo- or hetero-
dimers). As opposed to the TMDs which are rather divergent in sequence and topology, the NBDs are 
highly conserved with several distinctive motifs, notably the Walker A and Walker B found in many 
ATPases and the ABC signature specific to this family [11, 12]. Tremendous progresses have been 
made in the past ten years to decipher the molecular mechanisms of ABC transporters by solving high-
resolution 3-D structures of isolated NBDs or full-length transporters in different conformations. 
Hence, NBD structures have shown that during the catalytic cycle, the two NBDs interact together 
transiently to form a sandwich dimer in a head to tail fashion thereby trapping two ATP molecules at 
their interface [13-15]. In this closed conformation, that can be stabilized either by ATPase-inactive 
mutations [16] or by vanadate-induced ADP trapping [17], each composite ATP-binding site is made 
of elements from one NBD (i.e. Walker A and B motifs) while the ABC signature is provided in trans 
by the second NBD. For full-length ABC transporters, the overall structure of importers appears more 
compact than those of exporters with the presence in the latter of two large intracellular domains, 
called ICD1 and ICD2, that protrude from the TMD to interact with the NBD [18]. Importantly, while 
ICD1 from one monomer interacts with its own NBD, ICD2 (or ICD4 for full-length exporters) 
interacts with the NBD of the other monomer (or other moiety for full-length exporters) [19-21], and 
this has been validated by cross-linking experiments [22, 23]. Snapshots of 3-D structures and EPR 
spectroscopy indicate that large motions occur during the catalytic cycle of ABC exporters, with the 
transporter oscillating between an apo open conformation, with its two NBDs lying far apart, and an 
ATP-bound closed conformation with the NBDs engaged in a tight interaction [19-21, 24]. 
Importantly, the contact between ICDs and NBDs are always maintained in these structures, as these 
two domains keep the same overall conformation and interaction. Thus, this suggests that NBDs 
closure operates by a rigid body motion [19, 21]. On the other hand, cross-linking experiments 
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between ICDs and NBDs give support to alternative conformations for these two domains in different 
ABC exporters [22, 23, 25, 26].  
 To shed light on structural modifications that might occur during the mechanism of ABC 
transporters, we used a hydrogen/deuterium exchange (HDX) approach coupled to mass spectrometry. 
It revealed how different domains and sub-domains of an ABC transporter are affected in the resting 
versus the closed states. HDX has been widely used on soluble proteins to probe the accessibility of 
backbone amides, thus highlighting secondary structure modifications at the peptides level [27-29]. 
For membrane proteins, this approach is only beginning to emerge [30-34], but given their importance 
in the living world (i.e. one-third of proteins in each organism and about two-thirds of current medical 
targets), our results strengthen the benefit of using HDX to address fundamental issues about the 
functioning of these proteins in general. Here, it gave us access to the dynamics of BmrA, a bacterial 
multidrug ABC transporter strongly homologous to two related bacterial transporters, MsbA and 
Sav1866, and to the murine P-glycoprotein [35-37]. The results obtained extend our vision of the 
functioning mechanism of ABC exporters and complements the snapshots of high-resolution 3D 
structures. In particular, it showed for the first time that the two ICDs of BmrA behave quite 
differently depending on the conformational state considered. As opposed to the closed state, ICD2 
and to a lower extent ICD1 become highly exchangeable in the resting state (open conformation). 
Therefore, this reveals a much greater flexibility of these two sub-domains than what was foreseen 
from the known 3-D structures of related ABC transporters.  
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Results 
Comparison of the apo and closed conformations of BmrA in membrane and detergent. 
3-D structures of MsbA and murine MDR1 solved in the presence of detergent have suggested 
that large conformational changes might occur during the ATPase cycle of these transporters [19, 21, 
38]. To investigate this, we first checked if the presence of detergent affects the conformational 
changes that take place during the catalytic cycle of BmrA. Thus, global HDX was performed on the 
protein either purified in detergent or in its membrane environment. After overexpression in E. coli 
[36], BmrA-enriched membranes were either frozen in liquid nitrogen and kept at -80°C or solubilized 
in DDM detergent and purified by Ni affinity chromatography as previously described [37]. In 
agreement with our previous results [39], the ATPase activity of BmrA was shown to be conserved in 
a detergent solubilized state and sensitive to vanadate inhibition (Figure S1). Because lipids and 
detergents either give strong signals in mass spectrometry or disturb the protein ionization in the 
electrospray source [40], they must be separated from the protein before reaching the source. Previous 
separations involved gel electrophoresis and electroelution [41], protein precipitation and resuspension 
in concentrated acidic solutions [42], or size exclusion chromatography after dissolution in a 
chloroform/methanol/acid solution [43]. Yet, although efficient, all these methods were hardly 
compatible with the requirement of a fast preparation of the samples to limit as much as possible the 
back exchange reaction after deuterium incorporation into BmrA. Thus, chromatographic parameters 
were first optimized to separate membrane lipids or DDM detergent from the protein using classical 
reversed phase chromatography (see Materials and Methods). The electrospray mass spectra of BmrA 
either embedded in membrane or in a DDM solubilized state are presented in Figure 1 (panels A and 
B). First insets show the deconvoluted mass spectra (with close-up views in the second insets), with 
the mass of the major peak of 66341 ± 2 Da in membranes. Due to the cloning strategy used [37], 
purified BmrA was expected to contain three additional residues on its N-terminus (sequence 
MASMPT…, with the underlined residues corresponding to the beginning of the native protein) and 
15 additional residues on its C-terminus including the Histidine tag (sequence 
…KAGVDKLAAALEHHHHHH, with the underlined residues corresponding to the end of the native 
protein). Thus, the deconvoluted mass obtained is in very good agreement with the calculated mass of 
BmrA possessing only one extra Ser amino acid on its N-terminus (66340 Da). Masses of a second 
peak (66413 Da, in membranes) are also in very good agreement with the calculated mass of BmrA 
with two extra amino acids on its N-terminus, Ala plus Ser (66411 Da). Therefore, the first methionine 
and sometimes also the second amino acids (Ala) of the N-terminus of the proteins were very likely 
cleaved off by proteolysis during the purification process. The other peaks of lower intensity were 
likely due to unidentified non-covalent adducts on both forms of BmrA. The high quality of each 
spectrum reflects the efficiency of the chromatographic separation upstream the electrospray source 
for either samples.  
After incubation of each BmrA preparation in deuterated buffers for times varying from 15 s 
to 1 h the mass of deuterated BmrA was measured. The percentage of deuterated amides was 
calculated taking into account the average total number of amide hydrogens in BmrA (585 for the 
native protein) and the mass increase. Deuteration kinetics are presented in Figure 1C with open 
symbols for BmrA in its resting state in membranes (squares) or in DDM (circles). Both curves show 
the same behavior, the exchange steadily increasing with time. However BmrA in membranes was 
about half less deuterated (13-25%) than in its solubilized state (23-52%). This lower deuteration 
exchange in membrane could possibly reflect a more compact conformation of BmrA dimer. However, 
when the same experiment was performed after a prior incubation of BmrA with vanadate in the 
presence of ATP-Mg (closed symbols), i.e. conditions known to promote the formation of a closed 
dimer [17], a lower deuteration was found for BmrA either in membrane (squares) or in detergent 
(circles). Thus, although HDX occurs about twice faster in detergent as compared to the membrane 
bound BmrA, vanadate inhibition induced a significant decrease in HDX to a similar extent for both 
environments. Therefore, this shows that in either state, membrane bound or solubilized, BmrA can 
switch between two different conformations: an apo one where deuterium exchange readily occurs and 
a closed one more resistant to deuterium exchange.  
To bring further evidence that the conformational changes observed during the catalytic cycle 
of BmrA are similar in detergent and membranes, the apo and closed conformations were subjected to 
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limited proteolysis in both environments. A clear difference of resistance against proteolysis by trypsin 
could be observed using SDS-PAGE (Figure 2). BmrA in the apo conformation was rapidly digested 
by trypsin in membranes (Figure 2A) as well as in DDM (Figure 2C, lanes 3-5). In contrast, in the 
closed conformation triggered by vanadate inhibition, BmrA exhibited a good resistance to this 
protease in both environments (Figures 2B and 2C, lanes 6-8). These results give support that 
regardless of its environment, DDM or membrane, BmrA can adopt two different conformations: an 
apo one quite sensitive to trypsin digestion and a closed one rather resistant to this protease. Because 
(i) a similar behavior of BmrA was seen in detergent and membrane environments (Figures 1C and 2) 
and (ii) a much higher deuteration level was found for the protein in detergent (Figure 1C), the next 
experiments involving HDX at the peptide level were carried out after purification of BmrA in the 
presence of DDM. Indeed, it is suitable to start from a high deuteration level if one wants to achieve a 
sequence coverage of the protein as large as possible. Also, the presence of E. coli native proteins in 
the membrane fraction would likely pollute the peptide signals coming from BmrA, hampering the 
unambiguous identification or the determination of deuterium incorporation for some of them.  
 
 
Peptide mapping of BmrA. 
To localize the difference in deuterium incorporation between the two conformations of 
BmrA, the protein digestion that must occur at low pH and low temperature and the peptides 
separation were optimized. This step is essential to reach a sequence coverage of the protein as large 
as possible with peptides as small as possible [27]. However, the DDM used for BmrA purification 
gave a very strong signal in MS. To enable observation of the MS signals of the peptides, a protocol 
previously developed in our group for another membrane protein and based on the washing off of non-
ionic detergents with dichloromethane was first tried [44], but without success here. Reversed phase 
separation was then adjusted so that all peptides eluted before the detergent, at low temperature to 
limit deuterium back-exchange. For peptides sequencing using tandem mass spectrometry, the 
chromatographic parameters were chosen for a good separation to facilitate their identification, while 
the detergent still eluted after the last peptides. For the analysis of deuterated peptides, the elution 
times were also shortened as much as possible to limit deuterium back-exchange. Pepsin and 
rhizopuspepsin were used independently to digest BmrA [45]. The pepsin digestion in solution yielded 
only 31 peptides covering 45% of the BmrA sequence (Table 1). However the use of immobilized 
pepsin significantly increased the number of peptides (67) and thus the sequence coverage raised to 
78%. These results were obtained in the presence of 1.5 M guanidinium hydrocholride, a denaturant 
concentration which was optimized after different trials between 0.5 and 4 M. The sequence coverage 
was lower in the TMD (60%), the majority of the identified peptides belonging to the hydrophilic intra 
cellular domains, ICD1 and ICD2 (Figure 3). This low coverage of the hydrophobic transmembrane 
helices is presumably due to the presence of the detergent that presumably afforded some protection 
against the protease digestion. We also noticed a similar protection against proteolysis by lipidic 
vesicles for hydrophobic helices in the diphtheria toxin translocation domain [46]. In contrast, the 
NBD sequence was almost fully covered by the pepsin digestion (98%). Immobilized rhizopuspepsin 
was also used for on-line digestion of BmrA. The goal was to obtain complementary sequence 
coverage to improve spatial resolution by the occurrence of overlapping peptides. The number of 
peptides and the sequence coverage were significantly lower in the TMD in comparison with 
immobilized pepsin (Table 1 and Figure 3). In the NBD, the coverage appeared quite complementary 
from the one obtained by pepsin. However, after deuteration a significant number of peptides were lost 
with each protease, a phenomenon that is frequently observed in HDX [47, 48]. This is due to a 
heterogeneous deuteration that induces a broadening of the MS signal and thus a decrease in its 
intensity. The loss was much higher in the case of rhizopuspepsin which was also less efficient than 
pepsin. Therefore, only pepsin was used in the remaining part of the study, giving 45% and 92% 
coverage for TMD and NBD, respectively, with a peptide average size of about 9 amino acids. 
Although the sequence coverage was lower for the TMD, it is noteworthy that most of the two ICDs 
were covered by the HDX because these two sub-domains are known to be essential for the 
transmission of the conformational changes between the NBD and the TMD [20, 49, 50].  
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Comparison of the deuterium incorporation between the apo and closed forms of BmrA for 
three selected peptides. 
Besides the inhibition by vanadate, another way to promote the closed conformation in ABC 
transporter is to use catalytic inactive mutants [7, 14, 15]. For BmrA, we previously showed that the 
conserved glutamate residue E504 adjacent to the Walker-B motif is very likely the catalytic base for 
ATP hydrolysis, because mutation of this residue to Asp, Ala, Gln, Ser or Cys fully abrogated the 
activity [51, 52]. Thus, BmrA mutants could be trapped into a closed conformation in the presence of 
ATP-Mg alone [51]. Therefore, these mutations can be used as a substitute for vanadate to reach a 
stable closed conformation during the ATPase cycle. Deuterium incorporation was monitored as a 
function of time and was compared for each peptide generated from the three following forms of 
BmrA: wild-type in the resting state (apo form), wild-type inhibited by vanadate (in the presence of 
ATP-Mg) and E504A mutant in the presence of ATP-Mg. The mass spectra are presented for three 
selected peptides in Figure 4 after two deuteration times, 15 s and 1 h, and kinetics for all peptides are 
shown in Figure S2. In some cases, as exemplified in Figure 4, peptides mass spectra from the 
vanadate inhibited form showed two envelopes of isotopic peaks, thus giving two different kinetics, 
with the minor envelope corresponding to that of the wild-type. Because the inhibition of ATPase 
activity by vanadate was not total  (~ 80% see Figure S1, and see also [39]), it is very likely that this 
envelope originates from BmrA dimers not inhibited among the whole population; depending on the 
peptide considered and on its initial intensity, this tiny envelope could be detected, or not, on the MS 
spectrum. In other cases, the two envelopes were too close to be deconvoluted with the Magtran 
software and the kinetics could not be drawn (Figure S2). In the apo conformation of wild-type BmrA, 
each of these peptides belonging either to the ICD2 (203-215 and 216-236) or to the NBD (372-383) 
showed a very fast deuterium exchange with a large shift of the isotopic envelope towards higher m/z 
(Figure 4). This shift was already obtained after 15 s with identical exchange after 1 h for peptides 
203-215 and 216-236 while peptide 372-383 exhibited a little further shift increase between 15 s and 1 
h. After vanadate inhibition and 15 s deuteration a first major envelope corresponded to a very limited 
deuteration whereas a second one, much smaller in intensity, corresponded to the highly deuterated 
form observed also for the wild-type in the apo conformation. After 1 h the first envelope shifted 
towards higher masses and the second one still behaved like that of the wild-type in the apo 
conformation. In contrast, the E504A mutant showed practically only one isotopic envelope that was 
always similar to the low isotopic envelope observed in the vanadate inhibited sample.  
An uncommon behavior was found for peptide 501-509 including the E504 amino acid and 
most of the Walker B motif (Figure S3). Like several other peptides in the apo form of BmrA, it 
quickly reached its maximum deuteration level (at about 70%; see Figure S2). Again, the vanadate 
inhibited form showed the same behavior as the three previously described peptides with two isotopic 
envelopes. In the E504A mutant, however, the isotopic envelope shifted much faster than the main one 
in the vanadate inhibited form and evolved with time to HDX values similar to that of the wild-type in 
the apo conformation. This very specific difference between the mutant and the vanadate inhibited 
form could be explained by a rather flexible and accessible region in the mutant (although lower than 
in the apo conformation of the wild-type protein). In the case of the vanadate inhibited form and for 
the main isotopic peaks, there might be some additional protection afforded by the presence of 
vanadate (or the combination of ADP-Mg-Vi in the ATP-binding site). This masking effect would 
contribute to the low isotopic envelope that was not present in the E504A mutant. 
 
Given the propensity of the E504A mutant to readily adopt the closed conformation of BmrA 
in the presence of ATP-Mg and the homogeneity of HDX of its peptides, the remaining part of the 
paper will focus only on differences between this mutant in the closed conformation (ATP-bound 
state) and the wild-type in the apo conformation. It is important to note that addition of ATP-Mg in the 
wild-type BmrA, which triggered ATP hydrolysis, gave HDX patterns for the different peptides 
similar to that found in the apo conformation. This is consistent with many biochemical and structural 
data showing that upon ATP hydrolysis, and thus in an ADP-bound state, ABC transporters reset into 
their resting state (i.e. an open conformation) [53, 54]. Conversely, local deuteration kinetics were also 
determined for the E504A mutant in the absence of any nucleotide (apo conformation) and they were 
found to be similar to those of the wild-type in the same conformation. Therefore, the comparison 
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between the E504A mutant and the wild-type BmrA highlights the two different conformations, open 
and closed, that occur during the catalytic cycle of this ABC transporter.   
  
Visualization of HDX between the open and closed forms on the predicted topology and 
secondary structure of BmrA. 
To pinpoint the local differences of HDX between the open and closed conformations of 
BmrA, the percentage of deuteration was plotted for each peptide at two different times, 15 s and 600 s 
(Figure 5). It is noteworthy that HDX is systematically higher in the wild-type apo conformation (open 
form) than in the mutant (closed form), except in a few cases where it is similar. Very low HDX could 
be observed in THM2 and THM4 for both forms showing likely a strong protection by DDM against 
HDX, similar to that observed against pepsin proteolysis. Interestingly, a high HDX level was quickly 
obtained in the C-terminus part of ICD1 and in all peptides identified from ICD2, for the wild-type in 
the apo conformation. This indicates a high accessibility and/or a low level of structuration of these 
sub-domains. In the closed conformation of the E504A mutant, the corresponding peptides from ICD1 
were much less exchanged on a short time scale, but a longer incubation period allowed to 
substantially increase the exchange. For ICD2, even after a prolonged exchange time, a huge 
difference remained between the peptides from the wild-type and the E504A mutant. The NBD 
generally shows major differences between open and closed forms, particularly in the Walker A, 
Walker B and the ABC signature regions which are known to be involved in nucleotide binding. In 
contrast, some regions of the NBD notably between the Walker A and the ABC signature in the so-
called α helical sub-domain [14] showed no HDX difference. This indicates that they are likely not 
involved in the NBD/NBD interaction triggered by ATP/Mg binding. The major differences in HDX 
between both protein forms can be visualized on the “heat map” presented in Figure S4. The regions in 
red or orange correspond to peptides with still more than 45% and 30% HDX difference, respectively, 
after 1h deuteration. They clearly belong to ICD1, ICD2 and NBD, domains on which we will focus 
below. 
 
Influence of the BmrA conformation on HDX of the ICDs and NBDs. 
To highlight the HDX data, two BmrA models previously constructed [35], and based on the 
X-ray structures of homologous bacterial ABC transporters were used (Figure 6). For the apo 
conformation of BmrA, the open form of EcMsbA was used as a template whereas the closed 
conformation of BmrA (mimicked by the ATP-Mg bound E504A mutant) was modeled upon the 
Sav1866 structure [20, 21]. In agreement with the proposed closed model, the regions participating 
either in NBD/NBD interaction triggered by ATP binding or in direct interaction with ATP/Mg show a 
rather low level of HDX. This is the case, for instance, for the peptide 372-383 that entirely covers the 
Walker A motif and makes direct contact with ATP (HDX of 29%), or with the peptide 479-492 
encompassing the ABC signature and involved in ATP binding in trans upon NBD/NBD dimerization 
(26%). In contrast, the former peptide became much more rapidly deuterated in the apo conformation 
of the wild-type transporter with a high deuteration level of the Walker A motif (82%), consistent with 
the presence of a large accessible loop, while the peptide covering the ABC signature motif showed 
also a substantial increase in its exchange rate (69%). The lowest value of HDX obtained for this 
second peptide suggests that in the open conformation, it likely conserved an α-helical structure less 
prone to HDX than a loop. Thus, the exchange rates for these two peptides are in agreement with the 
open model used to picture the apo conformation (Figure 6, panel B). For other peptides of the NBDs 
known to be involved in ATP/Mg binding or NBD/NBD dimerization, similar trends were observed 
with a faster exchange rate in the apo conformation as compared to the ATP-bound conformation (e.g. 
peptide 501-509 partially encompassing the Walker B motif). Other regions of the NBDs not involved 
in either process (i.e. ATP binding or NBD/NBD dimerization) gave similar HDX in both 
conformations with, for instance, a high deuteration level consistent with a loop structure (84%) for 
peptide 439-447.   
A different picture emerges when one focuses on ICDs. In contrast to the two models 
suggesting that these domains have a similar conformation in the two states, open and closed, peptides 
from both ICDs showed a large difference in the HDX in these two conformations. Thus, ICD2 was 
highly deuterated in the apo conformation, with 82% and 79% for peptides 203-215 and 216-236, 
respectively, whereas in the closed conformation the HDX rate significantly decreased for both 
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regions to 33 % and 34 %, respectively. Likewise, but to a lower extent, regions 104-114 and 115-132 
from ICD1 were also fairly deuterated in the apo conformation, showing a rather high accessibility (66 
and 81%, respectively) whereas this value dropped in the closed state to 27% for the former peptide, 
while it remained highly deuterated for the latter peptide (69%).  
This difference is not simply due to a greater accessibility of the peptides from either ICDs in 
the resting state versus the closed state because based on the two BmrA models used here, the 
accessibility of these two domains is essentially unaffected upon the tight dimerization of the two 
NBDs (i.e. in the closed state, see Figure S5). For instance, peptides 104-114 from ICD1 and 203-215 
from ICD2 are predicted to be equally accessible in either state, whereas their HDX is far greater, 
especially for the ICD2 peptide, in the apo conformation. Therefore, the conformation and/or 
flexibility of both ICDs is somehow modified to account for the faster rate of deuterium exchange 
observed in the resting state.  
To further assess the flexibility of these two sub-domains in the 3D structures of the related 
transporters used to model BmrA, molecular dynamic simulations were performed on EcMsbA and 
Sav1866 along with that of StMsbA which was included for comparison. After reaching a plateau for 
the root mean square deviation of the C for each conformation, the fluctuation of the position of these 
atoms were calculated for the last 20 ns of the simulations and the results are shown in Figure 7. 
Clearly, a minor fluctuation was observed in the closed conformations of either Sav1866 or StMsbA 
whatever the C considered (always below 2.5 Å). In contrast, some basal fluctuations occurred 
throughout the sequence of EcMsbA and were much more pronounced (above 4 Å) for four areas 
including in particular ICD2. This suggests that this latter sub-domain must be quite flexible in this 
apo conformation. 
 
   
Discussion 
 
 The goal of this study was to get some insights into the dynamics of a multidrug ABC 
transporter in two different conformations, i.e. the resting state where the transporter might adopt an 
open conformation and the closed state where the two NBDs interact together in a transient, ATP-
bound, conformation. Overall, global H/D exchange and trypsin digestion show that either in 
membrane or in detergent BmrA can switch between two very different conformations during its 
catalytic cycle: a closed conformation rather resistant to trypsin digestion and H/D exchange and 
another one in the resting state quite sensitive to trypsin and more susceptible to H/D exchange. Thus, 
our results give support to the postulate that multidrug ABC transporters can cycle between an open, 
inward facing, conformation in the resting state and a closed, outward facing, ATP-bound 
conformation. Similar conclusions were drawn recently for the catalytic cycle of MsbA from cross-
linking experiments [55] or from EPR spectroscopy [24, 56, 57]. Based on 3-D structures of ABC 
exporters, the transition between these two opposite conformations was proposed to operate according 
to a rigid body motion [21]. This entails that the same overall structure of the two monomers (or 
moieties) of the transporter would be maintained throughout the catalytic cycle. However, local H/D 
exchange obtained for BmrA clearly challenges this assumption. In fact, our results strongly suggest 
that in the resting state, BmrA samples different conformations. Yet, these different conformations 
appear to be restricted to both ICDs, mostly to ICD2 but also to ICD1 although to a lower extent. 
Indeed, apart for the peptides involved either in the interaction between the two NBDs or with ATP, 
no major changes are observed for the other peptides from either the NBD or the transmembrane 
helices, although limited information is available for this latter part. Therefore, the interaction between 
the TMD and the NBD that is secured by the two ICDs in the closed state, must become loosen in the 
resting state due to a greater flexibility of these ICDs. This would allow some reorientation of the 
whole NBD as compared to the TMD and would explain some unexpected cross-links previously 
observed for BmrA. Indeed, it was found that disulfide bonds were formed between ICD1 and the Q-
loop of the NBD in the resting state only [25]. However, in all structures of exporters, either closed or 
open, ICD2 appears firmly sandwiched between ICD1 and the Q-loop thereby impeding the possible 
interaction between these two protein segments [19-21]. Hence, some reorganization of BmrA 
domains presumably occurred to allow the cross-link between ICD1 and the Q-loop [25]. Other 
unpredicted cross-links questioning the conformation observed in 3D structures were also reported for 
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two other ABC transporters, TAP1/TAP2, and Yor1p [22, 26]. These results lend support to additional 
conformations of these transporters with different orientations of the NBD relative to ICDs or of the 
two ICDs with respect to each other. It is worth mentioning that two other studies performed on 
homodimeric ABC transporters, LmrA and MsbA, and using either solid state NMR or EPR 
spectroscopy reached similar conclusions of alternative conformations (or greater flexibility) of the 
NBD in the resting state, as opposed to the TMD [56, 58]. In addition, to the NBD flexibility, EPR 
experiments also support a large conformational entropy of residues from ICD1 in the resting state of 
MsbA as evidenced by the large distance distribution of the spin label probe tethered to residue 115 
[56]. For CFTR, although cross-link patterns support a global architecture similar to that found in 
Sav1866 or MDR1, Riordan and colleagues proposed that a considerable flexibility must exist at the 
interface of NBDs and ICDs to account for the formation of the cross-link between these two domains 
regardless of the length of the cross-linking reagent (from 3.9 to 24.7 Å) [23]. In addition, a recent 
report using a genetic screen with the yeast ABC multidrug transporter, PDR5, support the idea of a 
non-canonical coupling between the NBD and the TMD as being mainly achieved through ICD1 and 
not through ICD2 [59]. Whether this is a peculiar property of PDR5 or reflects an alternative 
conformation of the ICDs in this transporter remains to be investigated. Related to the former 
hypothesis, the ICDs of PDR5 are predicted to be shorter than those of Sav1866 or MDR [60], and this 
might lead to a different interaction of these domains with the NBDs. Interestingly, a molecular 
dynamic study of Sav1866 has revealed that in a closed conformation and among residues whose C 
show the largest displacement between the ATP and ADP+Pi bound states, some belong to ICD2 
(residues 221-222) and to ICD1 (residues 110-113) [61]. Here, molecular dynamic simulations suggest 
that in the open-apo conformation of EcMsbA, and in contrast to the closed conformations of StMsbA 
or Sav1866, a large fluctuation in the position of C residues from ICD2 is likely to take place.  
H/D exchange coupled to mass spectrometry is commonly used to probe the dynamics of 
soluble proteins but this technique remains trickier in the case of membrane proteins especially 
because detergent often reduces the sequence coverage. Up to now, the only ABC transporter for 
which this technique was employed was the soluble NBD1 of CFTR [62]. However, our results on 
BmrA emphasize how useful this technique might be especially to study membrane proteins with large 
extramembranous domains like the ABC family. Other membrane proteins containing large soluble 
domains include for instance the secondary transporter of the Resistance-Nodulation-cell Division 
(RND) family such as the multidrug AcrB transporter [63]. Also, primary transporter of the P-type 
family contains several extramembranous domains and the transport mechanism are supposed to 
required large conformational changes among these domains as exemplified in different structures of 
the archetype of this family, the Ca2+-ATPase [64-66]. The use of H/D exchange coupled to mass 
spectrometry to unravel different conformations of these membrane proteins should shed new light on 
their transport mechanism.   
Materials and Methods 
Materials 
Unless specified, chemicals and pepsin were purchased from Sigma-Aldrich. n-Dodecyl-ß-D-
maltoside (DDM) was purchased from Anatrace. Recombinant protease rhizopuspepsin (Rp) was 
purified as previously described [45]. 
 
Site-directed mutagenesis and purification of BmrA 
The E504A BmrA mutant was constructed as previously described [51]. The E504A mutant and wild-
type BmrA were overexpressed as described [36] and BmrA-enriched membranes were either frozen 
in liquid nitrogen and kept at -80°C until used or solubilized in 1% DDM. After solubilization of the 
membranes, BmrA was purified by Ni affinity chromatography as previously described [37]. Protein 
concentrations were estimated by using a modified Lowry method [67] for BmrA-enriched membranes 
or the Bradford method [68] after purification. The accurate masses of the purified mutant and wild-
type proteins were checked using electrospray mass spectrometry. 
 
Limited proteolysis of BmrA 
BmrA was proteolysed with trypsin at a protease/substrate ratio of 1:1000 (w/w). For BmrA 
solubilized in detergent a reaction mixture of 100 µl was prepared and aliquots of 10 µl were 
120 
 
withdrawn after 5, 15 and 30 min. To reach the vanadate-inhibited state 5 mM ATP, 5 mM MgCl2 and 
3 mM vanadate were added to the protein solution and incubated for 15 min at room temperature 
before adding trypsin. For digestion of BmrA-enriched membranes, a reaction mixture of 100 µl was 
prepared and aliquots of 10 µl were withdrawn after 5, 15, 30 min, 1 h, 2 h and 3 h. Each aliquot was 
acidified with 1 µl of 5% trifluoro acetic acid (TFA) and immediately frozen in liquid nitrogen. 12.5% 
SDS PAGE were run followed by Coomassie blue staining.  
 
Pepsin digestion 
The vanadate-inhibited state was prepared in the same way as for limited proteolysis experiments. The 
E504A mutant was incubated with 5 mM ATP and 5 mM MgCl2. All protein digestions in solution 
were performed in an ice bath at 0 °C. Protease solutions were prepared in 500 mM glycine, pH 2.2, 
and cooled to 0 °C. BmrA was digested in the same buffer for 2-5 min using a protease/substrate ratio 
of 1:1 or 1:10 (w/w) for pepsin and recombinant type XVIII, respectively. Increase in digestion time 
did not have any effect on the proteolysis. On-line digestions in the presence of 0.5-4 M guanidinium 
chloride (GndCl) (final concentration) were also performed in an ice-bath at 0 °C using columns 
packed with Rp or pepsin immobilized on POROS-AL resin [45].  
 
H/D exchange of BmrA 
The vanadate-inhibited state of wild-type BmrA was prepared in the same way as for limited 
proteolysis experiments. The E504A mutant was first incubated for 10 min with 5 mM ATP and 5 mM 
MgCl2. The HDX reaction was initiated by a 10 times dilution into deuterated buffer containing 50 
mM NaCl and 0.05 % DDM. Time course of the HDX was followed over a 1 h period of time by 
sequential withdrawing of 120 µL deuterated samples which were immediately added to 26 µL of 
quenching buffer (8 M guanidium chloride, 500 mM glycine HCl, pH 2.2), rapidly mixed and flash-
freezed in liquid nitrogen. Samples were stored in liquid nitrogen until they were analyzed. 
 
HPLC peptide separation 
Peptides obtained by in-solution or on-line digestion were loaded onto a peptide MicroTrap (Michrom 
Bioresources, Auburn, CA) column and desalted by washing with 0.03% TFA in water (HPLC 
solution A). The peptides were then separated on a reversed phase C12 column (1 X 50 mm, Jupiter; 
Phenomenex) using a linear gradient of 15–45% (v/v) solution B (CH3CN 95% and TFA 0.03%) 
during 26 min, followed by 100 % (v/v) solution B during 20 min at a flow rate of 50 µL/min. For 
peptide mapping the gradient lasted 55 min instead of 26 min to improve the separation of the 
peptides. The column was connected to the electrospray source of mass spectrometers until 30% (v/v) 
B and then disconnected to avoid pollution of the electrospray source by the detergent. The column 
was pre-equilibrated with 15% (v/v) solution B. The valves, trap cartridge and column were cooled to 
0°C by immersion in an ice-bath. 
 
Mass spectrometric analyses of peptides 
The tandem mass spectrometry (mapping) analyses were performed on an ion trap mass spectrometer 
(Esquire 3000+, Bruker Daltonics). The HPLC system was connected directly through a splitting T-
piece to the electrospray ionization (ESI) source of the mass spectrometer. Data were processed using 
DataAnalysis 3.0. Tandem mass spectra were searched using Mascot, and the assignments were 
verified manually and by accurate mass measurements. Accurate mass measurements and the analysis 
of the local kinetics of deuteration were done on a time-of-flight (TOF) mass spectrometer (6210, 
Agilent Technologies, Santa Clara, CA) equipped with an electrospray source. Data were processed 
with MassHunter Qualitative Analysis, and the deconvolution and calculation of the average masses 
were carried out in Magtran [69]. 
 
Electrospray mass spectrometry of the full-length proteins 
The molecular mass of the intact protein was measured with the same electrospray TOF mass 
spectrometer coupled with HPLC. Protein was loaded onto a protein MicroTrap (Michrom 
Bioresources, Auburn, CA) column and desalted by washing with 0.03% TFA in water (HPLC 
solution A). The protein and detergent were then separated on a reversed phase C18 column (1 X 50 
mm, Jupiter; Phenomenex) using a linear gradient of 5-60% (v/v) solution B (95% CH3CN and 0.03% 
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TFA) during 3 min, followed by 100% (v/v) solution B during 12 min at a flow rate of 50 µL/min. 
Protein eluted after 13 min and HPLC was quickly disconnected from the source to avoid pollution 
with the detergent. The deconvoluted mass was calculated with the Agilent MassHunter Qualitative 
Analysis software. To simplify the processing of the global deuteration data, a non deuterated average 
mass of 66 440 Da was calculated, taking into account the different forms of BmrA and of its adducts. 
 
ATPase activity 
To measure the ATPase activity of BmrA in detergent, an enzymatic coupled assay system was used 
[70], in the presence of 0.05% DDM and as described previously [71]. The activity was measured in 
the presence of 10-20 µg of BmrA and followed at 37°C for 10 min. When vanadate was present, it 
was added at a final concentration of 3 mM from a 100 mM stock solution (see [71]).  
 
Calculation of accessibility areas of peptides 
The accessibility area of BmrA peptides was calculated with the help of naccess. This software 
calculates the accessible area of a protein structure in a PDB format then, based on accessibility of 
each atom, the total access area of a residue is determined. The program is based on the calculation 
method of Lee and Richardson [72]. In order to compare the accessibility values with HDX MS data 
the mean accessibility area of individual peptides was determined. Taking into account that region 
from residue 325 to residue 332 is the most accessible in both models, the values of other peptides 
were normalized considering the peptide 325-332 as a 100% accessible region. 
 
Molecular Dynamics simulations 
MD trajectories were simulated with the version 2.7 of NAMD [73], using the CHARMM27 force 
field with CMAP corrections [74], and the TIP3 (Transferable Intermolecular 3-point) model for water 
molecules [75]. All the simulations were performed in the NpT ensemble. The pressure was 
maintained at 1 atm using a Nose-Hoover Langevin piston control [76], with period of 100 fs and 
damping time constant of 50 fs. Temperature was maintained at 300 K by coupling to a Langevin 
thermostat, with damping coefficient of 5 ps-1. Electrostatic interactions were treated by the Particle 
Mesh Ewald algorithm [77], with grid spacing lower than 1 Å. Smoothed cut-off (10-12 Å) was used 
for the van der Waals interactions. Equations of motion were integrated with a time step of 2 fs. The 
SETTLE algorithm was used to restraint hydrogen atoms [78]. 
Three systems were considered: (i) the Sav1866 multidrug transporter from S. aureus at 3.0 Å in an 
outward-facing conformation reflecting the ATP-bound state [20], (ii) the MsbA lipid ‘flippase’ either 
from E. coli in the open apo-conformation at 5.3 Å, or (iii) from S. typhimurium in the outward-facing 
conformation at 3.7 Å [21]. The structures were defined according to PDB files 2HYD, 3B5W and 
3B60 respectively together with the crystallographic water molecules. Only the C-trace structure is 
available in 3B5W. Missing backbone and side-chain atoms were predicted using MAXSPROUT [79] 
and SCWRL [80]. An acetyl group was attached to the N-terminus residue to mimic the preceding 
peptide bond and the C-terminal carboxylate was protonated. Default ionization states at pH 7 were 
set, except for buried residues whose ionization states were determined using WHATIF [81] and 
visual inspection. The proteins were centred in the x-y plane with the permeation pathway aligned to 
the z-axis, and embedded in a pre-equilibrated bilayer of 569 DOPC molecules. The upper layer of the 
lipid membrane was aligned to the centre of mass along z of the aromatic residues of the extracellular 
side (Phe158, Phe157, Tyr39, Tyr268 in Sav1866, and Trp165, Trp66, Tyr162, Tyr168, Phe157, 
Phe265, Phe272 in MsbA). Lipid molecules closer than 1.2 Å to protein atoms were removed. Sodium 
and chloride ions were added to neutralize the system (up to a final concentration of 150 mM). The 
final systems contain ~195,000 atoms in the Sav1866 simulation (~41800 TIP3P water molecules, 360 
DMPC lipids, 61Cl- and 59Na+), ~202,000 atoms in the simulation of MsbA PDB 3B60 (~42,800 
TIP3P water molecules, 402 DMPC lipids, 55Cl- and 63Na+), and ~244 atoms in the simulation of 
MsbA PBD 3B5W (~53500 TIP3P water molecules, 472 DMPC lipids, 71Cl- and 79Na+). 
In order to equilibrate the atoms around the transporters, 2000 steps of energy minimization and 1 ns 
of MD were performed with restraints applied to the backbone atoms of the protein. Restraints were 
initially set to 10 kcal*mol-1*Å-2, and gradually reduced to zero. Unrestrained MD simulation followed 
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for ~82 ns (MsbA 3B5W), ~88 ns (MsbA 3B60), and ~93 ns (Sav1866). The atomic systems used for 
the analyses were from the last 20 ns of the unrestrained MD. A significant drift that stabilizes at 
6.7±0.2 Å after 60 ns and remains constant until the end of the simulation is observed in the RMSD of 
MsbA (3B5W). The RMSD values of the MsbA (3B60) and Sav1866 simulations reached a plateau in 
less than 3 ns with average values of 2.4±0.1 Å and 1.9±0.1 respectively. 
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Figure 1. Raw mass spectra and global H/D exchange of BmrA-enriched membranes or 
BmrA purified in detergent. Raw mass spectrum of BmrA in membranes (A) or BmrA 
purified in DDM (B). Deconvoluted mass spectra are presented in first insets with a close-up 
view in the second insets. (C) Global deuteration kinetics of apo BmrA in membranes (open 
square) or purified in DDM (open circle), or of vanadate-inhibited BmrA in membrane (full 
square) or purified in DDM (full circle). Standard deviations for two separate experiments are 
shown by vertical bars.  
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Figure 2Figure 2. SDS-PAGE of BmrA-enriched membranes or BmrA purified in DDM and after 
limited proteolysis with trypsin. BmrA in membranes in the apo conformation (A) or in the 
vanadate-inhibited conformation (B) and after incubation with trypsin for 5 min, 15 min, 30 
min, 1 h, 2 h and 3 h (from left to right lanes); (C) BmrA purified in detergent in the apo 
conformation (lanes 3-5), and in the vanadate-inhibited conformation (lanes 6-8) and after 
incubation with trypsin for 5, 15 and 30 min (from left to right lanes). C is the control lane 
with no trypsin added with the black arrowhead showing the position of the full-length 
BmrA. The masses of the molecular weight markers (MW) are indicated in kDa.  
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Figure 3. Peptide mapping of BmrA using immobilized pepsin (blue) or 
immobilized rhizopuspepsin (red). The predicted secondary structure (cylinders for 
α-helices and arrows for β-strands) and topology of BmrA based on the Sav1866 3-
D structure is shown above the sequence with the specific regions: Walker A (WA) 
and B (WB) motifs and the ABC signature.  The transmembrane helices 1 to 6 
(TMH1 to 6) are shown in green colour and the position of the intracellular domains 
1 and 2 (ICD1 and ICD2, respectively) are indicated. The extracellular parts of 
BmrA are shown in grey colour. The boundary between the TMD and the NBD is 
shown by a vertical dotted line.   
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Figure 4. Isotopic profiles of three selected peptides at different deuteration times.  The 
mass spectra of three peptides, two from ICD2 (203-215 and 216-236) or one from the NBD 
(372-383) are shown before (black line) or after 15 s (blue line) and 3600 s (red line) 
deuteration of BmrA. These peptides were from the wild-type BmrA in the apo (wt apo) or 
vanadate-inhibited states (wt + ATP/Vi) or from the E504A mutant incubated in the 
presence of ATP (E504A + ATP).  
 
127 
 
100
75
50
25
0
0 100 200 300 400 500 600
%
 
de
u
te
ra
tio
n
TMD NBD
ABC WBWATMH6TMH5TMH4TMH2 TMH3TMH1 ICD1 ICD2
A WT
E504A
100
75
50
25
0
0 100 200 300 400 500 600
%
 
de
u
te
ra
tio
n
residue number 
B WT
E504A
Figure 5
Figure 5. HDX profile of wild-type BmrA and the E504A mutant. The wild-type BmrA in 
the apo state (blue bars) and the E504A mutant in the ATP-bound state (red bars) were 
submitted to HDX, and the results obtained after 15 s (A) and 600 s of deuteration (B) are 
shown. The topology prediction and specific motifs in the NBD of BmrA are displayed 
above the graphs (see legend to Figure 3). 
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Figure 6. HDX of different peptides from the ICDs and the NBD of BmrA depicted 
on BmrA 3-D models. The inserts show BmrA modelled in the open apo 
conformation (A) or in the closed ATP-bound conformation (B) and the close-up 
views are restricted to the ICD1 and the NBD from one monomer together with 
ICD2 from the second monomer. One subunit was drawn in wheat colour and the 
other in light gray. In each conformation, specific regions are drawn with rainbow 
colours determined by their percentage of deuterium exchange after 600 s of 
deuteration (scale of deuterium exchange shown as insert). Selected regions are also 
shown with arrows. 
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Figure 7. Root mean square fluctuation of the C of Sav1866, StMsbA and 
EcMsbA. Molecular dymanics simulations were performed on each structure and, 
once equilibrium was reached, the Root Mean Square (RMS) fluctuation in Å was 
calculated for the last 20ns, and is shown as a function of the residue number. The 
predicted topology of BmrA is also shown on top of the figure for comparison using 
the same color-coding as in Figure 3.     
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Figure S1. ATPase activity of the wild-type BmrA. 10-20 µg of BmrA were injected 
into an ATPase assay medium in the absence (blue bar, WT) or presence of 3 mM 
vanadate (purple bar, WT + Vi).  
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Figure S2
Figure S2. HDX kinetics of all BmrA peptides identified after digestion with 
immobilized pepsin. The percentage of deuteration is plotted against different 
deuteration times for the wild-type BmrA in the apo state (blue circles), in the 
vanadate-inhibited state (green circles) or in the mutated (E504A) form (red circles). 
Standard deviations (for two experiments) are shown by vertical bars ; in many 
cases, bars are so small that they are hidden by the symbols. 
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Figure S2 (following part)
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Figure S3. Evolution of the isotopic envelope of peptide 501-509 at different 
deuteration times for the wild-type BmrA in the apo state (WT Apo) or in the 
vanadate-inhibited state (WT + ATP/Vi) or for the E504A mutant (E504A + ATP). 
Please note that this peptide contains the mutated residue in the mutant form 
accounting for the mass difference observed.  
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Figure S4. Heat map showing the difference in deuterium incorporation between the 
apo conformation (wild-type in the resting state) and the closed conformation 
(E504A in the presence of ATP) after 1 h deuteration. The predicted secondary 
structure and topology of BmrA (see legend to Figure 3) is indicated above the 
sequence with the colour legend shown as an insert.  
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Figure S5. Comparison of deuterium incorporation and accessibility areas in both 
conformations of BmrA, open (A) or closed (B). The left panels are identical to 
those shown in Figure 6 for the HDX except that only the selected peptides are 
coloured according to the deuterium exchange scale. The right panels show the 
accessibility of the corresponding peptides deduced from each BmrA model. 
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 BmrA TMD NBD 
%Coverage 78 60 98 
Peptides 67 24 43 
Pepsin 
Column 
Average 7.0 8.0 6.4 
%Coverage 45 11 82 
Peptides 31 3 28 
Pepsin 
Solution 
Average 8.7 12.6 8.3 
%Coverage 50 10 84 
Peptides 52 8 44 
XVIII 
Column 
Average 5.8 8.0 5.4 
%Coverage 67.5 45 92 
Peptides 44 15 29 
HDX 
Average 9.3 9.0 9.3 
 
Table 1. Sequence coverage, number of peptides and average size of the peptides for BmrA 
and for its domains TMD and NBD obtained in different digestion conditions and after 
deuteration and digestion with immobilized pepsin. 
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Chapter 2. H/D exchange kinetics of BmrA 
mutant K380R 
 
145 
 
Comparative HDX analysis between wild-type apo and closed form of BmrA due to inactive 
catalytic glutamate next to the Walker ‘B’ motif clearly highlighted the difference of the 
conformation of transporter and as well as the dynamics of intracellular domains which was 
not anticipated with static X-ray structures. We extended our investigations with the 
mentioned technique to monitor the effect of the inactivation of the Walker ‘A’ critical lysine 
residue on the dynamics of the transporter. The lysine residue was shown to be required for 
the hydrolysis of ATP in presence of Mg2+. The significance of this residue in BmrA was 
earlier realized showing that the mutation of lysine into alanine or arginine makes the 
transporter unable to hydrolyze ATP. However, the effect of these mutations was different 
from conserved glutamate which is next to Walker ‘B’ motif. As described in introduction, 
BmrA wild-type or mutants are able to form a regular ring shape structures. It was shown that 
addition of ATP/Mg2+ to wild-type BmrA leads to a large conformational change distorting 
regular ring shaped structure. In case of Walker ‘A’ motif mutant (K380R or K380A) the 
addition of ATP/Mg2+ did not affect the rings (Orelle, Gubellini et al. 2008). 
The purpose of applying HDX kinetics to K380R mutant was primarily to monitor the 
dynamics of ICD1 and ICD2 and compare it to wild-type and/or with the closed state of 
transporter. 
 
2.1. Conformation of BmrA mutant K380R in 0.5 mM ATP/Mg2+: 
As it was discussed for wild-type apo or mutant E504A, the protein was deuterated at time 
intervals from 15 s to 3600 s. The deuteration exchange was performed after incubation of 
transporter in 5 mM ATP and 5 mM Mg2+ for 5 min. The protein was diluted ten times in 
deuterated buffer making final concentration of ATP and Mg2+ 0.5 mM in deuterated buffer. 
For apo conformation the peptides from ICDs e.g. 203-215, got highly deuterated as it was 
discussed earlier. In the case of K380R mutant in the presence of ATP and Mg2+, two 
populations of the peptide were observed at 15 s deuteration time: one undeuterated and 
another highly deuterated exactly mimicking the closed and apo form of BmrA deuteration, 
respectively (Figure. 47). The undeuterated population of peptide tends to disappear with 
increasing deuteration time and after 10 min the peptide was more than 80 % deuterated. 
The deuteration kinetics of ICDs and particularly ICD2 led us to conclude that initial 5 mM 
(0.5 mM in deuteration buffer) concentration of ATP/Mg2+ was not enough to limit the 
dynamics of the transporter. Therefore, the mutant K380R was incubated in the presence of 
50 mM ATP/Mg2+ for 5 min and then labeled by diluting ten fold in deuterated buffer (5 mM 
in deuteration buffer). 
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The deuteration kinetics was followed from 15 s to 300 s. To underline the effect of initial 
high concentration of ATP/Mg2+, wild type of BmrA was also incubated with 50 mM 
ATP/Mg2+ and deuterated (5 mM in deuteration buffer). However, peptides of wild-type 
BmrA in presence of 5 mM ATP/Mg2+ showed similar kinetics as it was found for the closed 
form BmrA mutant E504A. The closed form mimicking behavior of wild-type in presence of 
5 mM ATP/Mg2+ might be due to the fact that most of the wild-type BmrA molecules were in 
a closed state in the presence of high nucleotide concentration. Since the mutant K380R lacks 
ATPase activity therefore to compare the difference due to nucleotide, the wild-type BmrA 
was incubated with 50 mM ADP/Mg2+ (5 mM in deuteration buffer).  
The HDX kinetics of different regions of wild-type BmrA and mutant BmrA K380R in the 
presence of 5 mM ADP/Mg2+ and 5 mM ATP/Mg2+ respectively, are discussed.  
 
2.2. Conformation of BmrA wild - type + 5 mM ADP/Mg2+ and mutant K380R + 5 mM 
ATP/Mg2+: 
Figure 48 shows the deuterium exchange level of different regions of BmrA on its sequence in 
mapped form for three conditions wild-type apo, wild - type + 5 mM ADP/Mg2+ and mutant 
K380R + 5 mM ATP/Mg2+. Figure 49 shows the raw kinetics data for all three mentioned 
conditions. The results described in the following sections are based on these figures unless 
otherwise specified. 
 
2.2.1. Transmembrane region: 
The peptides originating from transmembrane region (peptides 70-74 and 73-80) showed low 
deuterium exchange even after one hour of deuteration as it was shown for WT apo or E504A 
due to the protection of the region by detergent. Another peptide, 172-179 from 
transmembrane helix 4 showed low deuterium exchange as it was found for peptide 70-74 or 
73-80. 
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Figure 47. The HDX kinetics of peptide 203-215 of BmrA is shown. Left panel shows the 
wild-type apo, central panel shows the mutant K380R at incubation in 0.5 mM ATP/Mg2+ and 
right panel shows mutant E504A at 0.5 mM ATP/Mg2+.  
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Figure 48. The deuteration kinetics results obtained after incubation of BmrA wild-type apo, 
K380R mutant + 5 mM ATP/Mg2+ and wild-type BmrA + 5 mM ADP/Mg2+ in deuterated 
buffer for 15, 60 and 300s are mapped as heat map on sequence of BmrA. Predicted 
secondary structure elements are also shown. 
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Figure 49. HDX plots of the all identified peptides of BmrA. Hydrogen/deuterium exchange 
of WT-apo, WT + 5 mM ADPMg2+ and mutant K380R + 5 mM ATP/Mg2+ kinetics are 
plotted against time (Part I). Two series of experiments were performed and average value is 
plotted here.   
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Figure 49. HDX plots of the all identified peptides of BmrA. Hydrogen/deuterium exchange 
of WT-apo, WT + 5 mM ADPMg2+ and mutant K380R + 5 mM ATP/Mg2+ kinetics are 
plotted against time (Part II). 
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Figure 49. HDX plots of the all identified peptides of BmrA. Hydrogen/deuterium exchange 
of WT-apo, WT + 5 mM ADPMg2+ and mutant K380R + 5 mM ATP/Mg2+ kinetics are 
plotted against time (Part III). 
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Figure 49. HDX plots of the all identified peptides of BmrA. Hydrogen/deuterium exchange 
of WT-apo, WT + 5 mM ADPMg2+ and mutant K380R + 5 mM ATP/Mg2+ kinetics are 
plotted against time (Part IV). 
 
 
2.2.2. Intracellular domains: 
To investigate the difference between the dynamics of ICD1 of wild-type/mutant apo and 
K380R mutant in presence of ATP/Mg2+, peptides 104-114 and peptides 115-132 were 
analyzed. In peptide 115-132, after 15 s of deuteration, 16% higher exchange was found for 
wild-type+5 mM ADP/Mg2+ as compared to mutant K380R+5 mM ATP/Mg2. The deuteration 
difference was constant after one min and five min of deuteration. The second peptide of 
ICD1 i.e. 104-114 showed lower deuteration exchange in both cases. The minimum exchange 
was found 7 % and 6 % in wild-type+5 mM ADP/Mg2+ and K380R+5 mM ADP/Mg2+ 
respectively and after 5 min, the maximum deuteration found was 20 % and 15 %. Although 
difference of deuteration level of both peptides of ICD1 in two conditions (wild-type + ADP 5 
mM and K380R + 5mM ADP) was not large, in comparison with wild-type apo, both forms 
were significantly less deuterated, showing that dynamics of ICD1 was decreased (Figure 50).  
The significant and unusual trans- interaction of ICD2 was described in detail earlier. The 
domain was well covered with peptide 203-215 and peptide 216-236 from N-terminal to C-
terminal end respectively. The peptide 203-215 was found one to be of the most intense and 
very nicely separated peptide eluting at almost the end of the chromatographic run. Peptide 
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203-215 showed slight difference between two conditions, the overall exchange rate and 
difference in exchange rate was low at the beginning i.e. 10% in WT+5 mM ADP/Mg2+ and 
11% in K380R+5 mM ATP/Mg2+ so the difference was not significant at 15 s. However, with 
the increasing time, the difference of exchange was also found to be increased reaching 7% 
and 18% after 1 min and 5 min, respectively. But in wild-type apo form, the level of 
deuteration was very high more than 70% even after 15 s. This indicated that for the above 
mentioned peptides the movement of ICD2 was restricted in presence of nucleotide both for 
mutant and wild-type. Whereas peptide 203-215 showed some significant difference of the 
deuteration levels in both conditions for two deuteration times, the other peptide, 216-236, 
showed large difference for first deuteration point only. But in comparison to wild-type, 
kinetics of peptide 216-236, the deuteration level was much lower for all three time points in 
two conditions.   
 
2.2.3. Nucleotide-binding domain: 
 
Three significant regions of nucleotide-binding domains which are directly involved in ATP 
binding and hydrolysis were analyzed by HDX: Walker ‘A’, Walker ‘B’ and signature motif.  
Walker ‘A’: 
Walker ‘A’ consists of conserved GPSGGGKTT sequence and peptide 372-383 comprises on 
IVGPSGGGKTTL sequence in BmrA. Therefore, it precisely shows changes taking place on 
Walker ‘A’ motif. The HDX occurs at moderate pace and with increase of time, the deuterium 
exchange content and the difference between wild-type + 5 mM ADP/Mg2+ and K380R + 5 
mM ATP/Mg2+ was also increased slightly.  
The difference of deuterium exchange was very high between wild-type apo and mutant 
K380R in presence of 5 mM ATP/Mg2+.  
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Figure 50. HDX kinetics of ICD1, ICD2 and x-loop are shown on BmrA 3D model based on 
Sav1866. The interaction of ICD1 and ICD2 of cis- subunit with NBD of trans- subunit is 
focused. Part of the ICDs of cis- subunit are shown in green color and ribbon view, part of 
ICDs of trans- subunit are show as wire in cyan color. Part of NBD of trans- subunit is shown 
as ribbon in carton. The NBD of cis- subunit is not shown. 
20
30
40
50
60
70
80
90
10 100 1000
Mutant_K380R + ATP
WT_apo
WT + ADP
0
10
20
30
40
50
60
70
10 100 1000
Mutant_K380R + ATP
WT_apo
WT + ADP
Mutant_K380R + ATP
0
10
20
30
40
50
60
70
80
90
10 100 1000
WT_apo
WT + ADP
20
30
40
50
60
70
80
10 100 1000
Mutant_K380R + ATP
WT_apo
WT + ADP
ICD2 
ICD1 
X-loop 
Peptide 
203-215 
Peptide 
115-132 
Peptide 
104-114 
Peptide 
469-478 
155 
 
X-loop: 
The interaction site of ICD1 and ICD2, on nucleotide-binding domain was identified for the 
first time in Sav1866 and named as X-loop (Dawson and Locher 2006). It is a short stretch of 
few amino acids (TEVGERG in Sav1866) with conserved glutamate (underlined). This 
conserved glutamate is found in nucleotide-binding domains of ABC exporters only. Peptide 
469-478 in BmrA spans the region of X-loop. In apo form of wild-type BmrA, the deuteration 
level was found 71 % and 77 % at 15 s and 300 s, respectively. The deuterium content of the 
mutant K380R + 5 mM ATP/Mg2+and wild-type + 5 mM ADP/Mg2+ was less compared to 
wild-type form. This peptide is one of the fewer examples where the deuteration level of 
mutant K380R + 5 mM ATP/Mg2+ was found higher compared with WT+5 mM ADP/Mg2 
(Figure 50). 
 
Signature motif: 
Highly conserved within nucleotide-binding domain of ABC transporters, signature motif is 
identified by the presence of LSGGQ residues. Peptide 479-492 covers the entire motif. In 
wild-type apo, the deuterium exchange of peptide was found moderate in comparison with 
other peptides. In the K380R mutant and wild-type in the presence of ATP/Mg2+ and 
ADP/Mg2+ respectively, showed less exchange compared with wild-type apo form. No 
difference was observed between mutant K380R+ATP/Mg2+ and wild-type/ADP+Mg2+ at 15 
s and 60 s. At 300 s, the mutant was found more deuterated.  
 
Walker ‘B’ motif: 
Peptide 501-509 covers part of Walker ‘B’ motif and catalytic glutamate. Again the difference 
between mutant K380R+ATP/Mg2+ and wild-type/ADP+Mg2+ was not high but when 
compared with wild-type apo form, both were significantly less deuterated at 15 s, 60 s and 
300 s. But this difference is smaller than the one found for Walker ‘A’ motif. 
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2.3. Conclusion: 
Our results on BmrA mutant K380R showed that the overall dynamics of this transporter was 
restricted in presence of moderate concentration of nucleotide. It has been previously shown 
that this mutant is unable to adopt a closed conformation in presence of nucleotide. Therefore, 
the hydrogen–deuterium exchange kinetics coupled with mass spectrometry of this BmrA 
mutant in presence of ATP/Mg2+, shows the dynamics of BmrA in open conformation but not 
freely moving state. The high deuteration of ICD1 and ICD2 in BmrA apo form was also 
possibly due to disengagement from the nucleotide-binding as we found in closed form of 
BmrA both ICDs and x-loop were less deuterated . A similar kind of behavior of ICDs and x-
loop in mutant K380R +ATP/Mg2+ indicated that due to the presence of nucleotide, the 
mentioned regions are much more folded than in the apo/open conformation. 
Lower deuteration on Walker ‘A’ motif of mutant showed that mutant is still able to bind to 
ATP. Higher deuteration level on Walker ‘A’ motif of wild-type in the presence of ADP 
might be due to a lower affinity comparatively to that of the wild-type for ADP. 
There are two possible reasons of lower deuteration level on signature motif: first the ATP 
binding to Walker ‘A’ motif introduced local conformational rearrangement of signature 
motif. Secondly, in the closed form of ABC transporters, signature motif provides the 
complement site during ATP hydrolysis which indicates that it has some affinity for ATP and 
therefore it was less deuterated in open form in presence of ATP.  
The mechanisms proposed for ATP hydrolysis by ABC exporters describe that binding of 
ATP to Walker ‘A’ motif of NBD acts as a platform and then Walker ‘B’ and catalytic 
glutamate mainly contributes to ATP hydrolysis. Our results on open state of BmrA mutant in 
presence of ATP showed less deuterium exchange on Walker ‘B’ motif compared to apo state. 
The difference of deuterium exchange in two conditions for Walker ‘B’ motif was lower than 
the difference found for Walker ‘A’ motif in same conditions. This is in accordance with the 
proposed mechanism of ATP hydrolysis and that Walker ‘A’ has higher affinity for ATP 
compared to Walker ‘B’ motif. 
 
 
  
 
 
 
Chapter 3. H/D exchange kinetics of ABC 
hetero-dimer BmrC/BmrD 
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The results obtained on the dynamics of BmrA led us to continue following the HDX kinetics 
of another ABC transporter identified by our group. The hetero-dimeric ABC exporter 
BmrC/BmrD shares many features with BmrA. The same detergent DDM is required to 
solubilize hetero-dimer and the concentration of detergent also remains similar i.e. 0.05 %. In 
contrast being a hetero-dimer it contains two different subunits BmrC and BmrD with 
molecular weight of 67 kDa and 77 kDa, respectively.  
 
3.1. Peptide mapping: 
To optimize the peptide mapping of the BmrC/BmrD, four strategies were applied to digest 
the hetero-dimer: immobilized pepsin, immobilized pepsin in the presence of 1.5 M 
guanidinium hydrochloride, immobilized rhizopuspepsin and pepsin in solution. In all cases 
typical HDX digestion conditions were followed. The MS/MS analyses of the peptides, 
obtained with any digestion enzymes, were performed on FT-ICR mass spectrometer coupled 
with LC. The high mass accuracy, due to high resolution of FT-MS, made possible quick 
identification and assignment of the eluted peptides. Peptide mapping MS/MS experiments on 
FT-MS were performed by Petr Man in Prague.  
The immobilized pepsin digestion in the presence of 1.5 M guanidinium hydrochloride was 
found to be the best condition both for BmrC and BmrD. In the case of BmrC 68 peptides 
were identified providing coverage of 73 % sequence. Among these 68 peptides, 22 peptides 
(50 % sequence coverage) were from the transmembrane domain; in contrast the coverage for 
NBD region was 98 % with 46 peptides. Consistent with digestion condition for BmrC, the 
best digestion condition was found when BmrD was digested with immobilized pepsin in 
presence of 1.5 M guanidinium hydrochloride. 68 peptides were identified from BmrD 
covering 66% of the protein sequence: 58 % of the transmembrane region and 91 % of the 
nucleotide-binding domain. The number of peptides identified from transmembrane domain 
and nucleotide-binding domain were 25 and 43, respectively. It is noteworthy that for both 
BmrC and BmrD subunits, the coverage was found better in the nucleotide-binding region and 
poor in the transmembrane domain owing presumably to protection by detergent. The peptide 
mapping obtained for both subunits with the FT-ICR mass spectrometer was required to be 
checked on in-house available Time-of-Flight (ToF) mass spectrometer. As the digestion with 
immobilized pepsin in the presence of guanidinium hydrochloride was found to be the best 
condition, therefore only this condition was used for ToF and for subsequent HDX 
experiments. Few peptides were unrecognized with the ToF mass spectrometer compared 
with FT-MS and signal intensity for some other peptides was not strong enough to be used for 
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HDX experiments. Thus, 50 peptides (67 % sequence coverage) from BmrC and 53 peptides 
(63 % sequence coverage) from BmrD were indentified on ToF (Figures 51 & 52). Tables 7 & 
8 show the summary of number of peptides and sequence coverage identified with both FT-
MS and ToF-MS.  
Table 7. Sequence coverage in percent, number of peptides and average size of peptide 
obtained from BmrC in different conditions on FT-ICR. Last three lines show the peptides 
recognized on ToF. 
 
 BmrC TMD NBD 
% Coverage 73 55 97 
Peptides 68 23 45 
Pepsin 
Column+(GndCl) 
Average 6.5 8.1 5.2 
% Coverage 66 42 97 
Peptides 64 14 50 
Pepsin 
Column 
Average 6.2 10.8 5 
% Coverage 57 19 85 
Peptides 53 11 42 
Rhizopuspepesin 
Column 
Average 6.5 6.2 5 
% Coverage 57 33 85 
Peptides 62 18 44 
Pepsin in solution  
Average 5.5 6.5 4.8 
% Coverage 67 50 88 
Peptides 50 20 30 
ToF MS (pepsin 
column + GndCl) 
Average 8.1 9 7.2 
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Table 8. Sequence coverage in percent, number of peptides and average size of peptide 
obtained from BmrD in different conditions on FT-ICR. Last three lines show the peptides 
recognized on ToF. 
 
 BmrD TMD NBD 
% Coverage 65 58 91 
Peptides 71 25 46 
Pepsin 
Column+(GndCl) 
Average 6.3 10 5.1 
% Coverage 64 47 81 
Peptides 66 20 46 
Pepsin 
Column 
Average 6.7 10.1 4.5 
% Coverage 58 41 89 
Peptides 63 20 43 
Rhizopuspepesin 
Column 
Average 6.3 8.8 5.3 
% Coverage 58 42 88 
Peptides 61 14 47 
Pepsin in solution  
Average 6.5 9.6 4.8 
% Coverage 63 49 88 
Peptides 53 21 32 
ToF MS (pepsin 
column + GndCl) 
Average 8.1 10 7 
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Figure 51. Peptide mapping of BmrC. Peptides recognized after on-column digestion by 
pepsin on ToF (after MS/MS assignment) and peptides used for HDX-MS studies are shown 
in blue and red color, respectively. Predicted secondary structural elements and conserved 
motifs are also indicated on sequence.  
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Figure 52. Peptide mapping of BmrD subunit. Peptides recognized on ToF (after MS/MS 
assignment) are shown in red color and peptides used for HDX-MS are shown in blue color. 
The predicted region of transmembrane helices and conserved motifs are also indicated 
according to Gallian et al (Galian, Manon et al. 2011).  
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3.2. H/D exchange kinetics of BmrC/BmrD apo form: 
Here it is noteworthy that BmrC/BmrD is a high molecular weight complex made up of two 
proteins of 66 kDa and 77 kDa. It was expected that the presence of a large number of 
peptides would hinder the analysis of kinetics data due to some overlapping.    
We, therefore, limited the analysis for the peptides to interesting regions only rather than 
screening all the peptides irrespective of their origin (Figures 51 & 52). 
 
3.2.1. The intracellular domains of wild-type BmrC/BmrD are highly dynamic: 
To determine the kinetics of BmrC/BmrD, the transporter complex was deuterated for five 
time intervals ranging from 15 s to 3600 s. The intracellular domain (ICD1) of BmrC which is 
predicted to connect the transmembrane helix 2 with transmembrane helix 3 was well covered 
with three peptides: 111-123, 124-139 and 140-149 (Figure 51). In beginning, all three 
peptides show similar deuterium exchange level i.e. ~70 % deuteration at 15 s. Peptides 124-
139 and 140-149 did not show any significant change after longer time of deuteration 
incubation, in contrast peptide 111-123 showed a progressive increase in deuteration level 
reaching more than 90 % after 3600 s (Figure 53). Peptides 201-221, 222-235 and 250-262 
are predicted to belong to the intracellular domain two (ICD2) of BmrC subunit. Both 
peptides 222-235 and 250-262 showed EX1 HDX kinetics (Part: Introduction, Chapter 5. H/D 
Exchange) explained later in detail. EX1 also indicates high dynamic nature of a protein 
region. Comparatively, lower deuteration exchange was observed for peptide 201-221 at the 
beginning and a slight increase in deuterium exchange was found with increase in deuteration 
time (Figure 53).  
 
 
 
 
 
 
 
 
Figure 53. H/D exchange kinetics of peptides from ICD1 and ICD2 of BmrC.  
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According to predicted topology of BmrD, ICD1 would be between amino acids 170 and 220. 
Two peptides were identified from the mentioned region but due to low signal-to-noise ratio, 
it was difficult to follow the deuterium exchange kinetics except for peptide 179-190. This 
peptide showed very high deuterium level right from the beginning of deuteration and, 
exceeding 90 % after 3600 s. Part of predicted ICD2 of BmrD was covered by two short 
peptides, 315-323 and 324-332. In C-terminal part of ICD2, very high deuteration level was 
observed ranging between 70 – 80 %. The N-terminal part of ICD2, peptide 315-323 retained 
deuterium exchanged level from 15 to 3600 s but it was lesser than compared to peptide 324-
332.  
 
 
 
 
Figure 54. EX1 and EX2 kinetics examples are shown for the peptide 250-262 and peptide 
589-602, respectively.  
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3.2.2. ICD2 of BmrC showed EX1 kinetics: 
The use of EX1 kinetics can be helpful to determine the folding/unfolding events of the 
interested protein in physiological conditions (Weis, Wales et al. 2006). Two peptides of 
BmrC were identified showing EX1 kinetics, both from ICD2, one example peptide 250-262, 
is shown in Figure 54. The EX1 kinetics for mentioned region of BmrC indicated that there is 
local unfolding takes place in apo state of transporter. For the same region in BmrA (apo 
form), very high deuterium level was observed. Most of the amide hydrogens of ICD2 of 
BmrA were exchange for deuterium in short time showing possible unstructured form of 
mention domain. In the case of ICD2 of BmrC, the local unfolding indicates that ICDs of 
ABC exporters in solution might exist in irregular secondary structure fashion.  
 
3.3. H/D exchange kinetics difference between apo and closed form of BmrC/BmrD: 
From HDX kinetics studies of BmrA apo/closed form, we learnt that a significant difference 
of kinetics is present for NBDs interacting regions i.e. Walker ‘A’, signature motif, etc. and 
for ICDs which was not anticipated from the high resolution structures of ABC exporters. 
After characterizing the HDX kinetics of BmrC/BmrD complex in its apo form, the next step 
was to determine the kinetics of BmrC/BmrD in its closed form.  
As described for BmrA, the closed form can be obtained by inhibiting with vanadate or 
mutation of catalytic glutamate residue after the Walker ‘B’ motif. Within ABC hetero-
dimers, the mentioned catalytic residue is found only in BmrD. In the smaller subunit the, 
BmrC, corresponding residue is an aspartic acid residue. 
The inhibition of BmrC/BmrD by vanadate was incomplete as it was found for BmrA. Earlier, 
in the course of BmrC/BmrD characterization, it was found that mutation of conserved 
glutamate at position 592 of BmrD subunit into aspartate abolished the ATPase activity of 
transporter. To verify that conserved E592 is responsible for ATPase activity, the 
corresponding aspartate of BmrC subunit at position 500 was mutated into glutamate. This 
new double mutant, E592D in BmrD subunit / D500E in BmrC, did not show any ATPase 
activity as well confirming that glutamate of BmrD is exclusively responsible for hydrolytic 
activity of transporter (Carmen Galian’s thesis). Mutations of the corresponding residues in 
hetero-dimer TmrA/TmrB also ended up with similar conclusion (Zutz, Hoffmann et al. 
2011).  
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Table 9. Different mutants used for HDX analyses of BmrC/BmrD are shown. The HDX 
kinetics results obtained for the wild-type BmrC/BmrD apo form and mutant E592A/D500A 
+ 5 mM ATP/Mg2+ are described. To indicate the number of aspartate the sequence of BmrC 
was considered without the N-ter His-tag. 
 
 Conserved glutamate in BmrD 
ILILDE 
 
Conserved aspartate in BmrC 
ILILDD 
Single mutation ILILDD 
E592D 
ILILDD 
 
Double 
mutation 
ILILDD 
E592D 
 
ILILDE 
D500E 
 
Double drastic 
mutation 
 
ILILDA 
E592A 
 
ILILDA 
D500A 
 
 
Therefore, we expected that closed form of BmrC/BmrD could be obtained by addition of 
ATP/Mg2+ in mutants. Preliminary HDX kinetic analyses of BmrC/BmrD single (E592D) or 
double mutants (E592D/D500E) in the presence of 5 mM ATP/Mg2+ (0.5 mM in deuterated 
buffer) showed two populations for the peptides from important regions like ICD1, ICD2 and 
NBDs interacting regions, one example is shown in Figure 55. This is important to mention 
here, that these two populations were due to incomplete inhibition exhibiting EX2 kinetics 
different from EX1. This led us to the conclusion that two species of mass envelopes were 
possibly arising from some residual ATPase activity of these mutants as previously used 
ATPase activity analyses technique was not sensitive enough to measure very low ATPase 
activity.  
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Figure 55. H/D exchange kinetics for peptide 124-139, an example of significant peptides 
from BmrC subunit. Whereas, the peptide showed fast deuterium exchange in wild-type apo, 
in mutant (single mutation in BmrD subunit: E592D) addition of ATP/Mg2+ resulted in two 
populations after deuterium showing that inhibition was not complete.  
 
3.3.1. The closed form of BmrC/BmrD is not as tight as that found with BmrA: 
 Based on the conclusion of single (E592) or double mutant (E592D/D500A) HDX kinetics, 
the conserved glutamate of BmrD and aspartate of BmrC were mutated into alanine. It was 
anticipated that mutation of catalytic residue(s) into alanine would totally abolished any 
residual ATPase activity if any activity was still present in previous mutants. The ATPase 
activity of this newly made double mutant is undetermined yet. 
The double alanine mutant (E592A/D500A) transporter complex was incubated with 5 mM 
ATP/Mg2+ for five minutes and then diluted in D2O for several time intervals ranging from 15 
s to 3600 s and local HDX kinetics were determined. With this mutant again two populations 
of deuterated masses were found. The very similar kinetics behavior obtained with this mutant 
confirmed that the closed form of BmrC/BmrD is not as tight as compared to BmrA and two 
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populations found in earlier mutants were also due to loose closure of the complex in this 
inhibited state. Determination of ATPase with radiolabeled 8-azido-ATP, where very low 
level ATPase activity can be monitored, it can confirm that it is still capable to hydrolyze 
ATP. 
Though two isotopic envelopes due to presence of two populations induced more 
complication for data analysis, it was overcome by determination of average mass based on 
both envelopes.  
 
3.3.2. Dynamics of closed form/inhibited state of BmrC/BmrD mutant (E592A/D500A): 
As for the previous BmrC/BmrD mutants and BmrA mutant E504A mutant, this newly 
prepared BmrC/BmrD double alanine mutant (E592A/E500D) was incubated with 5 mM 
ATP/Mg2+ and ten fold diluted in deuterated buffer (0.5 mM ATP/Mg2+ in deuterated buffer). 
The overall local kinetics data showed that closed form of BmrC/BmrD is less dynamic 
compared to its open form. The difference of kinetics exchange between two conformations 
(apo and closed) in significant regions is smaller compared to the difference that were 
observed in two forms (apo and closed) of BmrA but this might be due to the presence of two 
populations. There are some regions e.g. C-terminal part of both subunits which did not show 
any difference in exchange kinetics. The following described results refer to Figures 56A and 
B.  
 
3.3.2.1. Intracellular domains: 
Both intracellular domains (ICD1 and ICD2) of BmrC showed less exchange in closed form. 
Among three peptides of ICD1, peptide 111-123 was the least deuterated i.e. ~35 % at 15 s 
and ~45 % after 3600 s. When compared with apo/open form mentioned peptide showed the 
highest difference in comparison with two other peptides. Two other peptides 124-139 and 
140-149 were almost equally deuterated in apo/open state (about 70 % at any time) in closed 
form and these peptides maintained their similar deuterium exchange pattern but deuterium 
content was ~20 % less at any time. Peptide 201-221 of ICD2 of BmrC showed ~25 % 
deuteration at 15 s, which is 25 % less compared to apo/open state of same peptide, however 
with the increased time deuteration, difference between the two forms was significantly 
decreased to only 10 %. Two more peptides from ICD2 of BmrC, 222-235 and 250-262, are 
not discussed for their closed form because no difference could be observed in two states due 
to presence of EX1 kinetics of their apo form.  
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A large decrease in deuterium level was found for peptide 179-190 in closed form in 
comparison with apo/open. This is the only peptide from BmrD ICD1, therefore the 
information on this region exclusively rely on it. Two peptides identified from ICD2 also 
showed less deuterium level. Peptide 315-323 was 30 % deuterated which is half of the 
deuterium content compared with apo/open state at 15 s. Both level of deuteration of this 
peptide and its difference with apo/open state was unchanged after 3600 s. The other peptide 
of ICD, 324-332, showed high difference in deuterium level compared to apo/open state 
which was reduced with the time increasing. The H/D exchange kinetics data of ICDs from 
both monomers show that the close or inhibited state of protein had decreased their dynamics 
compared to apo state and overall behavior of ICDs in apo or closed form in ABC homo-
dimer and hetero-dimer is similar.  
 
3.2.2.2. Predicted large extracellular loop of BmrD: 
Pairwise sequence alignment and secondary structure prediction tools showed that the 
additional 94 residues found in BmrD form an extracellular loop (ECL1) connecting TMH1 
and TMH2 of transmembrane domain (Galian, Manon et al. 2011) (Figure 52). Although 
there is no 3D structure of ABC hetero-dimer exporter available, Cysteine cross-linking and 
homology model of TAP1/TAP2 based on Sav1866 also indicated the presence of additional 
residues between TMH1 and TMH2 of both TAP1 and TAP2(Oancea, O'Mara et al. 2009). 
The role of this loop is not identified in functioning of ABC transporters yet. In BmrD, the 
loop was partially covered by two peptides: 72-94 and 107-127. In case of peptide 107-127 
high deuterium level was found form the beginning of deuteration and a progressive increase 
was observed for longer time of deuteration reaching 80 % (Figure 56 B). The other peptide 
identified from ECL1 was 72-94. This peptide also showed high deuterium level at 15 s 
reaching ~70 % after 3600 s of deuteration. The kinetics of both peptides did not vary in 
apo/open or close state of transporter.  
 
3.2.2.3. Nucleotide-binding domain: 
The different regions of nucleotide-binding domain of BmrC and BmrD double alanine 
mutant were investigated by H/D exchange in the presence of ATP/Mg2+ and the deuterium 
level of mentioned regions was compared with the H/D exchange kinetics of apo 
conformation of the wild-type. Though two populations (EX2 kinetics) were observed due to 
incomplete inhibition as discussed earlier, the average of two envelopes was calculated which 
showed less deuterium level for both subunits BmrC and BmrD.  
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Peptide 382-407 which covers the Walker ‘A’ motif of BmrC, in apo conformation showed 
moderate deuterium exchange which was reduced in closed form. The deuterium level was 
~15 % and ~35 % at 15 and 3600 s, respectively showing the decrease of ~35 % and ~25 % 
less deuteration compared to apo conformation. The conserved ABC motif ‘LSGGQ’ begins 
at residue 497 in BmrC. A long peptide 490-518 covers the mentioned conserved region, but 
due to presence of an overlapping peptide 509-518, the deuterium exchange kinetics of 490-
508 could be calculated. The region showed fast deuterium exchange ~80 % at 15 s in apo 
conformation and remained constant with increasing time. In closed state the deuterium level 
was found around ~50 % which was ~30 % less compared to apo conformation. Like apo 
conformation, the level of deuterium remained constant after one hour of deuteration, thus the 
difference was also ~30 % after the mentioned time of deuteration.  
Walker ‘A’ motif of BmrD was covered by peptide 462-475. In apo conformation the 
deuterium exchange was found to be ~45 % at 15 s and slow progress was observed reaching 
55 % after 3600 s. In closed form the deuterium exchange was reduced to~25 % at 15 s and 
~35 % after 3600 s, thus throughout the course of exchange the difference in two conditions 
was constant and as 20 %. Peptide 559-577 covered the conserved ABC signature motif of 
BmrD subunit, the peptide showed ~50 % deuterium exchange at 15 s and with increasing 
time the deuterium level was also found to be increasing reaching ~75 % after 3600 s of 
deuteration. The difference in deuterium level of closed and apo stat for same peptide was less 
in beginning of deuteration but gradual increase in difference was observed at higher 
deuteration times. Peptide 589-602 covering C-terminal part of Walker ‘B’ motif including 
catalytic glutamate showed ~60 % deuterium exchange at 15 s. The level of deuterium uptake 
was not changed throughout the deuteration experiment. In closed state, the same peptide 
showed less deuterium level which could be quantified as ~24 % and ~15 % after 15 s and 
3600 s of deuteration.  
Both NBDs of ABC transporters take part in ATP hydrolysis. In hetero-dimers, the catalytic 
activity is retained within one subunit but complementary interactions with other subunit 
provide efficient hydrolysis activity. Low H/D exchange kinetics of most of the regions of 
both NBDs in closed confirm the active involvement of both subunits in hetero-dimer, 
BmrC/BmrD.  
Some C-terminal peptides of NBDs of BmrC and BmrD did not show any difference in 
deuterium exchange in two states. The level of difference was not changed in the mentioned 
regions validating their no contribution in ATP hydrolysis.  
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3.4. Conclusion: 
Our results on ABC hetero-dimer BmrC/BmrD show that intracellular domains of both 
domains are highly dynamic in the resting. The dynamics of mentioned domain reduces on the 
closure/interaction of the nucleotide-binding domains. The predicted extracellular loop of 
BmrD is also dynamic in the resting state and closure of nucleotide-binding domains did not 
have effect on its movement. The interaction between two subunits in inhibited state is not 
strong might be due to asymmetry founding hetero-dimer in comparison with homo-dimeric 
ABC exporters. Though in wild-type BmrC/BmrD, the BmrD acts as catalytic subunit, the 
hydrolysis of ATP is contributed by both subunits by interacting together because lowered 
deuterium exchange was observed for ATP binding regions of both subunits. The dynamics of 
C-terminal end of both NBDs remained unchanged in apo/open or closed states. 
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Figure 56-A. Kinetics plots of selected peptides of BmrC wild-type apo (WT) are presented in 
blue and double mutant (E592A and D500A)(DM) in red color. The double mutant was 
deuterated in presence of 0.5 mM ATP/Mg2+. For peptide 222-235 and 250-262 the average 
of two envelopes are shown in apo form (Part I).  
ICD1 ICD1
ICD1
ICD2 ICD2
ICD2 
Walker ‘A’
Signature motif
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Figure 56-A. Kinetics plots of selected peptides of BmrC wild-type apo (WT) in are presented 
in blue and double mutant (E592A and D500A)(DM) in red color. The double mutant was 
deuterated in presence of 0.5 mM ATP/Mg2+ (Part II). 
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Figure 56-B. Kinetics plots of selected peptides of BmrD wild-type apo (WT) in are presented 
in blue and double mutant (E592A and D500A)(DM) in red color. The double mutant was 
deuterated in presence of 0.5 mM ATP/Mg2+. 
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Chapter 4. H/D exchange kinetics  
of a prokaryotic homologue of ligand-gated 
ion channel GLIC 
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4.1. Introduction  
4.1.1. Ligand-gated ion channel superfamily: 
In higher organisms, the activities of the body are controlled by brain. The orders from the 
brain are carried to the target organ with the help of different kinds of intermediates. Nerve 
cells are one of the mean of this transport of information. The transmission of information 
across nerve cells is mediated by neurotransmitters, stored in synaptic vesicles (Figure 57). 
With the change in active potential of nerve cell, these vesicles are ruptured releasing 
neurotransmitters. The neurotransmitters bind with the receptors (these receptors are linked 
with intrinsic channels) present on post synaptic end. The neurotransmitters act as ligand for 
the postsynaptic receptor and their binding causes the opening or closing of intrinsic channel. 
Therefore, these are also called as ligand-gated ion channels (LGIC) or receptor-coupled ion 
channels. The opening/closing of channel causes the initiation/blockage of ions transfer. The 
binding sites of neurotransmitter and ion conductance channel are distant, therefore the 
binding of neurotransmitter allosterically controls the passage of ions.   
The mean of selectivity to ions and ligand is provided by ion channels and receptor, 
respectively.  
 
 
 
Figure 57. A schematic presentation of LGIC within a synapse between neuron (Web 
link:http://www.niaaa.nih.gov/Resources/GraphicsGallery/Neuroscience/PublishingImages/sy
napsebetween_neurons.gif) 
 
The LGICs organize themselves in polymeric form within the membrane. The number of 
subunits is not constant and minimal three subunits are joined with one another, forming a 
pore. The topology of individual subunit is shown in Figure 58. Based on the number of 
components, LGICs are divided into three superfamilies (Le Novere and Changeux 1999; 
Collingridge, Olsen et al. 2009).  
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• Cys-loop receptor superfamily  
• Glutamate cationic receptor superfamily 
• ATP gated channel superfamily 
 
Cys-loop receptor superfamily: 
The channels of Cys-loop receptor superfamily are composed of five subunits arranged in 
homo or hetero-pentameric fashion.  
This is the largest family of receptor-coupled ion channels identified by the presence of a 
stretch of conserved residues in each monomer. The conserved motif generally carries 
cysteine residues on both its C-ter and N-ter side. These two cysteine residues form a 
disulfide bridge in addition to a loop formed by conserved residues therefore giving the Cys-
loop receptor superfamily name (Sine and Engel 2006). 
The members of Cys-loop receptor superfamily consists of both positive and negative ions 
conducting channels. The ligands acting on the receptor part of Cys-loop super-family include 
acetylcholine, 5-HT3 (5-hydroxytryptamine; 5-HT3 receptors), glycine and GABA (gamma-
aminobutyric acid; GABAA receptors). Both excitatory and inhibitory functions are mediated 
by these channels (Bocquet, Prado de Carvalho et al. 2007).  
The binding of ligand to the receptor and transmission of information to channel for passage 
of ions through LGICs show that these are highly organized complex transmembrane protein 
assemblies. The mechanism of their functioning and ligand binding site can be understood by 
obtaining the data on structural information of these receptors. Once the mechanism is 
understood, putative drugs can be synthesize and used to target these receptors as they are 
related to several chronic diseases like Alzheimers and Parkinson’s (Connolly and Wafford 
2004; Cederholm, Schofield et al. 2009). One of the examples of Cys-loop ligand gated ion 
channels, the nicotinic acetylcholine receptor from the electric organ of the Torpedo was 
obtained at low resolution by electro microscopy (Miyazawa, Fujiyoshi et al. 2003).  
 
Glutamate cationic receptor superfamily: 
The members of Glutamate cationic receptor superfamily possess four subunits giving rise to 
homo-tetramer or hetero-tetramer. The available structure of receptor shows that two dimers, 
dimerize together giving rise to a tetramer(Tichelaar, Safferling et al. 2004). Unlike Cys-loop 
receptor superfamily, Glutamate cationic receptor superfamily perform only excitatory 
synaptic transmission. The channels linked to Glutamate cationic receptors can mediate the 
transport of cations only (Traynelis, Wollmuth et al. 2010).  
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Figure 58. The topology of individual subunit of different ligand-gated ion channels (Khakh 
2001). 
 
ATP gated ion channel: 
ATP gated ion channel receptors possess three subunits. Each subunit can be divided into 
three parts: two transmembranes and one extracellular domain. The extracellular domain links 
the two transmembrane domains. Extracellular ATP and protons act as ligand for the receptor 
and channels generally show selectivity towards monovalent cation like Na+, K+ (Khakh 2001; 
North 2002).  
 
4.1.2. Ligand-gated ion channels in bacteria: 
The completion of prokaryotic and eukaryotic genome sequencing projects prompted 
scientists to identify the prokaryotic homologues of the proteins already characterized in 
higher organisms. With careful sequence analysis, Tasneem et al showed the presence of 
ligand-gated ion channel homologues in several bacterial species and more than 20 proteins 
have been identified as homologous to Cys-loop ligand gated ion channels in prokaryotes 
(Tasneem, Iyer et al. 2005; Corringer, Baaden et al. 2010).   
After identification of eukaryotic ligand-gated ion channels genes in prokaryotes, attempts 
were made to clone and overexpress the identified genes and determine the functional 
properties of expressed proteins. Bocquet et al showed for the first time that the proteins from 
Gloeobacter violaceus are able to form a channel which is cation-selective. They also showed 
that channel is activated at low pH concluding that protons act as ligand for channel (Bocquet, 
Prado de Carvalho et al. 2007).  
ATP gated channel  Glutamate cationic receptor 
 superfamily 
Cys-loop receptor  
superfamily  
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With the characterization of homologous proteins in bacteria, the next step was to study the 
structure of these complex machines at high resolution (Miyazawa, Fujiyoshi et al. 2003; Hilf 
and Dutzler 2009b).  
4.1.3. Structures of prokaryotic homologues of cys-loop ion channels: 
Recently high resolution structures of two pentameric ligand-gated ion channel (pLGIC) from 
Erwinia chrysanthemi (ELIC) and Gloeobacter violaceus (GLIC) have been solved. Whereas, 
ELIC was crystallized at physiological pH, GLIC could be crystallized at pH 4.6 only. There 
are two structures of GLIC published back to back, solved in similar conditions and showing 
same structural arrangement. Both, GLIC and ELIC structures show similar quaternary 
structural arrangement of pentamers but ELIC and GLIC showed apparently the so-called 
closed and open conformations, respectively (Hilf and Dutzler 2008; Bocquet, Nury et al. 
2009; Hilf and Dutzler 2009a). The difference found within two structures can explain the 
mechanism of receptor functioning. 
 
4.1.3.1 GLIC structure: 
The prokaryotic homologue of Cys-loop ligand-gated ion channel, GLIC, is constituted of 
five identical subunits giving rise to a homo-pentameric complex. Each subunit can be 
divided into two main parts: extracellular domain and transmembrane domain 
 
Extracellular domain: 
The extracellular domain which is responsible for the binding of ligand mainly consists of -
structural elements. There are two -sheets comprising five inner and three outer  strands 
connected by loops of varied length. The two -sheets tightly interact together giving rise to a 
-sandwich (Figure 59). The overall structure of extracellular domain was found in 
correlation with nicotine acetylcholine-binding protein whose structure was solved in year 
2001(Brejc, van Dijk et al. 2001).   
 
Transmembrane domain: 
Like other membrane proteins, transmembrane domain traverses the lipid bilayer. Each 
domain consists of four -helices which are numbered from M1 to M4. M2 helix of each of 
the five subunits forms pore region of the channel. Whereas, M1 and M3 stabilize the pore by 
making strong interaction with corresponding helix of adjacent subunit, M4 is the outer most 
helix. The helices are connected by short loops and arranged in a presumably round shape 
(Figure 59).  
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Figure 59. Left: Ribbon representation of GLIC from the plane of lipid bilayer. The structure 
was solved at 2.9Å. Detergent (dodecyl-D-maltoside, DDM) bound molecules are shown in 
space filling presentation of yellow color. Right: Topological presentation of extracellular 
domain (ECD) and transmembrane domain. ECD consists of three outer and five inner 
strands. The regions which are common in GLIC and ELIC are shown in yellow 
color(Bocquet, Nury et al. 2009).     
 
4.1.3.2. Difference between ELIC and GLIC structures: 
As described earlier both GLIC and ELIC share similar structural features but structural 
arrangement of specific regions is different. Within the two strands of extracellular domain a 
twist is observed when viewed from the plane crossing between the strands. When viewed 
from the membrane plan this twist is made and increases this proximity between strands of 
other subunits. 
The different orientation of M2 in two structures is a major contributing factor for their open 
and closed states. The M2 helix with other helices forms the pore region, a way for 
translocation of ions. M2 helix is shown as twisted out of the plan of central axis of channel in 
GLIC on its C-terminal side and ELIC M2 helix does not change its orientation throughout its 
length, showing apparent closed conformation.  
The region involved in making the interface between transmembrane and extracellular domain 
was previously shown as the binding site of the ligands (Grutter, de Carvalho et al. 2005; Lee 
and Sine 2005). At structural level, this region lies between conserved 1-2 and 6-7 loops 
from the ECD and M2-M3 loop of TMD. In GLIC structure, 1- 2 loop of ECD is in more 
open or freely existing away from the M2-M3 loop of TMD. M2-M3 loop itself adopts a 
position away from the central core (Figure 60). Similar behavior observed for 6- 7 of 
ECD, the famous cys-loop, known for binding ligands and named the superfamily, so 
providing a larger space compared with ELIC structure. 
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4.2. Materials and Methods: 
 
4.2.1. Peptide mapping: 
GLIC protein was expressed and purified as previously described (Bocquet, Prado de 
Carvalho et al. 2007; Bocquet, Nury et al. 2009). The purified protein was concentrated up to 
8.5 mg/ml. The peptide mapping was obtained either with online pepsin digestion with 
pepsin, rhizopuspepsin or in-solution pepsin. For in-solution pepsin digestion, 1:2 protein to 
enzyme ratio was. Briefly 2 µl of GLIC protein solution (300 mM NaCl, 20 mM Tris HCl pH 
7.2, 0.02% DDM) was diluted in 80 µl of cold hydrogenated buffer (300 mM NaCl and 0.02% 
DDM) and kept on ice. 10 µl of 3.4 mg/ml pepsin solution in 50 mM HCl was added to 
diluted protein sample. After addition, the mixture was left on ice for 2 minutes and then 
loaded on the peptide micro-trap.  
Varied protein to enzyme ratio, longer incubation time or digestion at ambient temperature 
did not improve peptide digestion.    
 
4.2.2. Deuterated sample preparation: 
Deuteration at pH 7.0: 
The pH of protein solution was adjusted to 7.0. In 200 µl of deuterated buffer, 10 µl of 
concentrated protein (8.5 mg/ml) was diluted. For GLIC deuteration buffer 300 mM NaCl and 
DDM 0.02 % was dissolved in 99.9 % D2O. After 15 s of dilution an aliquot of 40 µl from 
dilution tube was withdrawn and transferred into another tube already containing precooled 
10 µl of quench solution (pepsin 3 mg/ml in 50 mM HCl) and frozen in liquid nitrogen till 
further use. Similarly, four more aliquots after 60, 180 and 270 s were mixed with quench 
solution and frozen.  
 
 
Figure 60. Side view of GLIC and 
ELIC superimposition in green 
and red color, respectively 
(Bocquet, Nury et al. 2009).  
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Deuteration at pH 4.6: 
The pH of protein solution was adjusted to 4.6. In 200 µl of deuterated buffer (50 mM sodium 
acetate, 300 mM NaCl and DDM 0.02 % in 99.9 % D2O), 10 µl of concentrated protein (8.5 
mg/ml) was diluted. After 63 min, 4 h and 12 min, 12 h and 33 min and after 18 h and 50 min, 
aliquots of 7 µl of quench solution (pepsin 4.5 mg/ml in 50 mM HCl). The longer incubation 
time at pH 4.6 was for the correction of amide exchange as it was found slower with decrease 
in pH, one order of magnitude per pH unit (Zhang and Smith 1993). The ratio between 
incubation times of two conditions was 251 calculated by taking antilog of pH difference.  
pH difference between two conditions: 7.0 – 4.6 = 2.4 
Antilog of 2.4 = 251 
Time at pH 7.0: 15 s 
Required time at pH 4.6 equivalent to 15 s at pH 7.0: 15 X 251 = 3765 s or 63 min 
 
The MS and MS/MS conditions and peptide analyses were performed as described in 
Materials and Methods section for BmrC/BmrD. 
 
4.3. Results: 
 
4.3.1. The transmembrane region of GLIC is strongly protected: 
Several acid proteases were used for GLIC hydrolysis including pepsin, and rhizopuspepsin. 
The purpose of using multiple enzymes is to improve the sequence coverage and precise 
information of region of interest (Cravello, Lascoux et al. 2003; Marcoux, Man et al. 2010). 
We have previously shown that immobilization of these acid protease (Rey, Man et al. 2009) 
is another strategy for optimized digestion of membrane proteins (Rey, Man et al. 2010).  
GLIC complex was digested as described in Materials and Methods section. The peptides 
eluted from hydrolysate were analyzed by tandem mass spectrometry. The tandem mass 
spectrometry allowed the identification of peptides on protein sequence. The separated or 
combined use of enzymes pepsin, enzyme XVIII and rhizopuspepsin generated 107 unique 
peptides exclusively covering extracellular domain. The in-solution digestion by pepsin was 
found the best digestion condition generating 83 peptides (59 % sequence coverage) and was 
followed in all the experiments. The transmembrane domain was very poorly covered; only 
one peptide was identified maybe due to strong protection of transmembrane helices offered 
by detergent. Another reason is probably given by the very strong interaction between  
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Figure 61. The peptides eluting from pepsin in-solution digestion are mapped in red and 
peptides used for HDX-MS are shown in blue color on GLIC sequence. Peptide mapping was 
obtained on FT-MS. 
 
transmembrane helices. After identification of peptides on MS and due to low signal-to-noise 
ratio of deuterated samples, only 24 peptides were used for HDX-MS studies covering 54% 
sequence (Figure 61). 
The HDX kinetics of some other peptides was possible to monitor at pH 7.0 but impossible at 
pH 4.6 may be due to longer incubation time in deuterated buffer which caused protein 
precipitation. Peptide mapping MS/MS experiments on FT-MS were performed by Petr Man 
in Prague.   
 
4.3.2. The dynamics of GLIC at pH 4.6 and pH 7.0: 
The conformational dynamics of GLIC at pH 4.6 and pH 7.0 was probed by HDX-MS. To 
analyze the behavior of precise regions of channel at different pH, local deuteration kinetics 
were determined. For pH 4.6, the protein was incubated in deuterated buffer (pH 4.6) between 
63 min and 19 h and then digested by pepsin. Likewise for pH 7.0, the deuterated buffer at pH 
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7.0 was used and incubation from 15 to 270 s was performed. For all the peptides except one 
the HDX kinetics curves were found higher at pH 4.6 as compared to pH 7.0; however in 
most cases the difference was decreased with increasing deuteration incubation time (Figures 
62 & 63).   
4.3.3. The outer surface of ECD is highly exchangeable at pH 4.6 & pH 7.0: 
The outer surface of each ECD is mainly composed of three -strands made up of 7, 9, 9	 
and 10, connected by short loops. 7 is covered by two peptides, 120-134 and 135-146 on N-
terminal and C-terminal ends, respectively. Peptide 135-146 showed higher exchange of 
deuterium reaching 60% after 270 s at pH 4.6. At pH 7.0, exchange was slightly lower at 
shorter time as compared to pH 4.6 but at the final point of deuteration, no difference was 
found between both conditions. This is consistent with structure of GLIC showing 7 as part 
of outer sheet. Other two outer strands of ECD, 9	 and 10 showed higher deuteration 
exchange level from the least to maximum time of deuteration. Peptide 169-177, partially 
contributing both to 9 and 9	, is the only example where at final deuteration point, 
exchange was found slightly higher at pH 7.0 as compared to pH 4.6. Thus, change in pH had 
affected the deuterium exchange behavior of ECD outer surface. 
 
4.3.4. The interface between ECD and TMD showed the highest exchange difference: 
The TMD and ECD interaction region are one of the examples where structures of GLIC and 
ELIC showed difference in arrangement in high resolution structures. The N-terminal part of 
6- 7 loop and 6 itself was covered by two peptides: 106-112 and 113-120. Peptide 113-
120 showed low deuterium exchange (15 %) at first point of deuterium incubation at pH 7.0. 
After 270 s, the deuterium level was not changed significantly (~20 %). At pH 4.6, the same 
peptide was highly deuterated after first incubation time with ~70 % deuterium exchange; the 
content of exchange was unchanged for other time points. Thus peptide 113-120 showed a 
large difference in deuterium exchange between at pH 4.6 and pH 7.0 for all deuteration 
points from 15 s to 270 s. The other peptide 106-112 which is not part of interaction region 
loop rather showed similar deuterium exchange behavior as it was found for peptide 113-120 
except it showed moderate exchange at first point of deuteration i.e. ~40% and with the 
increase of time, a progressive increase was observed reaching to ~70%. The progressive 
increase in peptide 106-112, might be due to the presence of a regular secondary structure. 
The difference in deuterium content for two peptides between two conditions was ~60 % after 
longest time of deuterium incubation.  
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Figure 62. Heap map showing the deuterium exchange kinetics on GLIC sequence, secondary 
structure elements are also shown. Two separate wide lines show the deuterium exchange at 
pH 7.0 and pH 4.6. Within each line the deuterium content is colored from 15 s to 270 s.  
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Another part of ECD involved in interaction interface between ECD and TMD, is a loop 
connecting 1 with 2. The region was covered precisely with a short peptide 32-40 exactly  
showing the information of this region. As observed for peptide of 6- 7 loop, this peptide 
also showed higher deuterium exchange (~60 %) at first point of incubation at pH 4.6 which 
was slightly increased with the deuterium incubation time. For the same peptide, at pH 7.0, 
~20 % of deuterium exchange was observed that increased to ~35 % at maximum deuteration 
time. Therefore, difference of deuterium content between two conditions was always about 
~35%.  
1- 2 loop is followed by 2 sheet, the difference of deuterium content was also higher in 
this sheet. Though owing to specific secondary structure the deuterium content was not high 
even though difference could be observed.   
 
4.4. Conclusion: 
The X-ray crystallography is unarguably the best mean to provide the structural information 
of proteins which has extended its role in membrane proteins as well. However, due to 
specific experimental conditions and large sample requirement etc. sometimes the protein 
structure in varied condition is never obtained. 
 The x-ray structure of GLIC was solved after crystallization the protein at pH 4.6 but at 
physiological pH no structural data is available for GLIC. The structure of closely related 
protein ELIC was possible to obtain at pH7.0 which showed different arrangement of M2 
helix of pore region and loops of the ECD and TMD interface, as compared to GLIC. 
We applied HDX-MS technique on GLIC at pH 4.6 and pH 7.0. First, quick information was 
obtained that the transmembrane region of protein is strongly resistant against acid proteases. 
This is probably due to protection of TMD by detergent and/or strong interaction of subunits. 
In our experience the protein is not very stable at pH 4.6 for long time at room temperature. 
The signal-to-noise ratio of deuterated protein samples at this pH for long time was very poor 
which resulted in loss of many peptides.  
The HDX-MS results obtained at pH 4.6 were verified by its correlation with three 
dimensional structure at pH 4.6. The comparison of HDX kinetics results obtained at pH 4.6 
and pH 7.0 indicated that at pH 7.0 GLIC also adopts the so-called closed conformation 
similar to that one observed for ELIC structure. 
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Figure 63. H/D exchange kinetics plots of GLIC peptides (Part I). 
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Figure 63. H/D exchange kinetics plots of GLIC peptides (Part II). 
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Figure 63. H/D exchange kinetics plots of GLIC peptides (Part III). 
 
 
  
 
 
 
General Conclusion  
and  
Outlook  
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The investigation of conformational changes in proteins requires use of different biophysical 
techniques. In this PhD thesis work, for the first time, hydrogen-deuterium exchange coupled 
to mass spectrometry was applied to study ABC transporters and pentameric ligand-gated ion 
channel (pLGIC). The major emphasis was on two different ABC transporters: BmrA and 
BmrC/BmrD. In addition a pLGIC, GLIC, was also characterized at two different pH. 
The ABC transporters are present in all form of life in varying number, involved in vital 
functions. Their dysfunction is known to be associated with several diseases like cystic 
fibrosis in humans. Some ABC exporters are involved in multidrug transport and show poly-
specificity to substrates. They are overexpressed in response to chemotherapy treatment of 
cancer. In bacteria they are one of the causes of antibiotic resistance. 
A question directly related to membrane protein is the effect of detergent on their stability and 
conformation. For BmrA we showed both with help of HDX - MS and limited proteolysis 
experiments that protein is more dynamic in detergent as compared to lipid bilayer in apo 
form. But at the same time it is protected in similar extent in both conditions in its closed 
form.  
The structures of other ABC exporters solved at high resolution in presence or absence of 
nucleotides showed different conformations. But in all cases the trans- interaction of ICD2 is 
kept. Our H/D exchange kinetics results on apo conformation of BmrA raised the question of 
this interaction and showed their highly dynamic nature in solution. We also suggested that 
possibly ICDs exist in unstructured conformation for transporter in its apo form. The kinetics 
of ICD2 obtained in the presumably closed form were in agreement with the BmrA models 
based on closed structure of homologue ABC exporter thus validating our results.  
Another aspect of ABC transporter related to our study is physiological existing state of 
NBDs in apo form. We clearly showed that the NBDs of two subunits are highly dynamic and 
are possibly not associated with one another in absence of nucleotide. The addition of 
different drugs which are known to be transported by ABC transporters did not affect 
dynamics of NBDs. We also confirmed that dynamics of NBDs were reduced on addition of 
ATP/Mg2+ due to their tight interaction in mutant lacking ATPase activity.  
The dynamics of different regions of BmrA was also reduced in its resting state but not freely 
moving due to mutation on Walker ‘A’ motif.  
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ABC hetero-dimer showed, BmrC/BmrD, similar H/D exchange kinetics results as found for 
BmrA in apo conformation: highly dynamic nature of predicted ICDs and well non-
interacting NBDs. But closed form of hetero-dimer mutant on addition of ATP/Mg2+ was not 
as stable as found for homo-dimer BmrA. The predicted extracellular loop of BmrD was not 
found to be affected in presence or absence of nucleotide. 
The structures of ligand-gated ion channels at high resolution have been emerging recently 
like GLIC or ELIC. The H/D exchange kinetics of GLIC obtained at pH 4.6 were in 
correlation with its apparently open conformation. For the same protein, results obtained at 
pH 7.0 showed less deuteration for particular region confirming a possible closed form. The 
kinetics at pH 7.0 was found to be in accordance with the structure of homologue protein 
ELIC.  
The HDX-MS technique is expanding its application on membrane protein characterization 
like recent example of ADP/ATP carrier and GPCR receptors. The work performed during 
this thesis showed possible application of mentioned technique on ABC proteins and ligand-
gated ion channels as well. For ABC hetero-dimer BmrC/BmrD, the analogue of ATP (for 
example AMP-PNP) could be used to verify the proposed mechanism of cooperative binding 
of ATP in two subunits. Since both subunits are different in their amino acid sequence, the 
AMP-PNP concentration required for binding on one subunit can be determined by its H/D-
exchange kinetics in varied AMP-PNP concentrations.  
In this study the coverage of peptide mapping was good but not optimum for characterized 
protein. This problem can be overcome by different digestion techniques and new acid 
proteases. Especially good coverage of transmembrane region can provide information about 
drug binding site in case of ABC exporters. In GLIC this can be helpful to determine the 
differential kinetics of pore region particularly M2 helix.  
The finding of different acid proteases can be helpful for characterization of proteins with 
better resolution at short peptide size level. The time required for the HDX experiment can be 
reduced by development of automatically controlled robotic methods (under construction in 
our group). The robotic methods will be helpful for reproducibility of data. The further 
reduction of time, required for the processing of large data generated by HDX-MS 
experiments can be achieved by developing more precise computer based programs.
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Abstract 
Some ATP-Binding Cassette exporters are known to be responsible for resistance against a 
broad spectrum of antibiotics and chemotherapeutic drugs in bacteria and mammalian cells.  
Amide hydrogen deuterium exchange coupled to mass spectrometry (HDX-MS) was applied 
to investigate the conformational changes in two different bacterial ABC exporters, BmrA and 
BmrC/BmrD, in the presence and absence of nucleotide. Local H/D exchange kinetics showed 
highly dynamic nature of ICDs in apo form which was not anticipated from X-ray structure of 
the homologue proteins. In outward facing (closed form) conformation the movement of ICDs 
were largely reduced for both transporters. The H/D exchange kinetics of closed form were 
determined by applying H/D exchange on mutants unable to hydrolyze nucleotides or on 
wild-type inhibited by vanadate. The dynamics of NBDs particularly for those regions which 
interact during ATP hydrolysis were also reduced in closed form as compared to open one. 
The addition of different drugs which are known to be transported by ABC transporters did 
not affect dynamics of NBDs. 
We further applied H/D exchange kinetics on a prokaryotic homologue of pentameric ligand-
gated ion channel (pLGIC) GLIC. Local H/D exchange kinetics were in full agreement with 
the available structure and change in pH showed differences in deuterium level for interacting 
regions of the subunits. 
 
 
Des exporteurs « ATP-Binding Cassette » (ABC) sont connus pour être responsables de la 
résistance contre un large spectre d’agents antibiotiques ou chimiothérapeutiques chez les 
bactéries et les cellules de mammifères. 
L’échange hydrogène / deutérium associé à la spectrométrie de masse (HDX-MS) a été utilisé 
pour caractériser les changements conformationnels de deux exporteurs ABC bactériens, 
BmrA et BmrC/BmrD, en présence et en absence de nucléotide. Les cinétiques locales 
d’HDX ont montré la nature hautement dynamique des domaines intra-cellulaires (ICDs) dans 
la forme apo, ce qui n’était pas attendu d’après les structures cristallographiques aux rayons X 
des protéines homologues. Dans la conformation ouverte vers l’extérieur (« outward 
facing »), domaines fixant les nucléotides (NBDs) interagissant, le mouvement des ICDs sont 
largement réduits pour les deux transporteurs. Les cinétiques d’HDX MS dans la 
conformation « outward facing » ont été déterminées en appliquant cette technique sur des 
mutants incapables d’hydrolyser les nucléotides et sur la forme sauvage inhibée au vanadate. 
La dynamique des NBDs, en particulier pour les régions qui interagissent au cours de 
l’hydrolyse de l’ATP, a été aussi diminuée dans la conformation « outward facing » 
comparativement à celle ouverte vers l’intérieur. L’ajout de différents agents connus pour être 
transportés par des transporteurs ABC n’a pas affecté la dynamique des NBDs. 
Par ailleurs, nous avons aussi appliqué l’HDX MS à la protéine GLIC, un homologue 
procaryote d’un « ligand-gated ion channel » pentamérique (pLGIC). Les cinétiques locales 
d’HDX sont en plein accord avec la structure cristallographique disponible et le changement 
de pH révèle des différences de deutération dans les régions d’interaction des sous-unités. 
 
